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Natural killer (NK) cells are cytotoxic effectors providing a first line of defence against 
viruses and tumours. NK cells can be isolated from peripheral blood (PB) or cord blood 
(CB) for cancer immunotherapy. However, it was shown by our group and others, that 
CB NK cells express higher NKG2A and less killer immunoglobulin like receptors 
(KIRs) than PB NK cells indicating an immature phenotype. Also, CB NK cells require 
high doses of interleukin (IL)-2 for proliferation and activation. It was also shown that 
resting CB NK cells are poorly cytotoxic and produce less IFN-! than PB NK cells after 
stimulation with IL-2.  
Hypothesis and aims 
CB NK cells have an immature phenotype and could mediate different role in neonatal 
immunity than adult PB NK cells. Hence, the aim of this study was to explore whether 
differential mechanisms of activation exist between PB and CB NK cells.  
Methods 
PB samples from healthy volunteers and CB samples were obtained with prior written 
consent and ethical approval from Anthony Nolan. Purified PB and CB NK cells were 
stimulated with cytokines including IL-2, IL-12, IL-15, IL-18, individually or in 
combination. Thereafter, comparative analysis was performed on their phenotype, 
signalling, proliferation, cytotoxicity, cytokine secretion and chemotaxis post-cytokine 
stimulation.  
Results 
My results show that CB NK cells responded less to IL-2 activation than PB NK cells, 
which correlated with lower levels of IL-2 receptors and decreased phosphorylation of 
STAT5 pathway. CB NK cells activated with IL-15+IL-2 showed enhanced 
cytotoxicity while activation with IL-15+IL-18 promoted maximal proliferation, higher 
IFN-! and TNF-" secretion. In contrast, optimal activation of PB NK cells was 
achieved by IL-2 stimulation. Interestingly, CB NK cells secreted substantial IL-8 
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concentrations following cytokine stimulation. IL-12 or IL-18 stimulation induced L-
selectin expression on CB NK cells and promoted NK cell migration towards 
chemokines that induce homing to lymph nodes. I also generated long-lived memory-
like NK cells from PB and CB using cytokines whereby IL-12+IL-15+IL-18 pre-
activation led to substantial IFN-! production.  
Conclusions 
CB NK cells are fully functional upon activation with IL-15+IL-2 or IL-15+IL-18 
rather than IL-2 thereby providing a basis for activation of NK cells derived from 
different sources that may be utilised for future NK cell-based therapeutic purposes. In 
addition, CB NK cell cytokine secretion profile is suggestive for a role of neonatal NK 
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PMA Phorbol 12-myristate 13-acetate 
PPRs Antigen-specific pattern recognition receptors 
PVR Poliovirus 
SCF Stem cell factor 
Sec Second 
Scid Severe combined immunodeficiency 
SLAM Signaling lymphocyte activation molecule 
STAT Signal transducer and activator transcript 
TBI Total body irradiation 
TCR T cell receptor 
TH T helper 
TLRs Toll-like receptors 
TNF Tumour necrosis factor 
TRAF2 TNF-receptor-associated factor 2  
TRAIL TNF-related apoptosis induced ligand  
Tregs Regulatory T cells 
UBC Ubiquitin 
V-D-J Variable-Diversity-Joining  
VEGF Vascular endothelial growth factor  
#-ME #-Mercaptoethanol 
#2M Beta-2 microglobulin 






Chapter 1: Introduction 
1.1 The immune system 
The immune system is a complex system composed of immune cells, tissues and 
molecules that work cooperatively to eradicate infection and compromised host cells. 
The immune system is divided into two main categories, innate immunity and adaptive 
immunity. 
 
1.1.1 The innate immune system 
The innate immune system is the first line of defence against pathogens. The 
components of the innate immune system include epithelial barriers, phagocytes, 
dendritic cells (DCs), natural killer (NK) cells, the complement system and cytokines. 
Importantly, there is no specific memory in the innate immune system. Innate immune 
cells respond to microbes in a non-specific manner and are able to discriminate between 
self and non-self using pattern recognition receptors (PRR). Innate immune cells 
recognise molecular patterns shared by specific groups of microbes that are not found 
on host cells via germ-line encoded PRRs such as Toll-like receptors (TLRs). These 
receptors have limited diversity, as they do not undergo somatic rearrangement 
(Medzhitov and Janeway, 2002). In response to pathogens, innate immune cells release 
inflammatory cytokines such as interleukin (IL)-12 and tumour necrosis factor (TNF) 
that provide activation signals for cells of the innate and adaptive immune systems 
(Table 1.1) (Abbas and Lichtman, 2009). As NK cells are the focus of this study, they 




Table 1.1 List of cytokines and their effects 
Cytokine (s) Source (s) Effect (s) Reference(s) 
IFN-" DCs and macrophages NK cell activation (Costa et al., 2009) 
    Promotes anti-viral effects and increases MHC class I expression 
 
IFN-# Fibroblasts NK cell activation (Iversen et al., 2005) 
    Promotes anti-viral effects and increases MHC class I expression 
 
IFN-! NK cells  Macrophage activation Anti-viral protection 
(Schroder et al., 
2004) 
    Tumour growth inhibition  
IL-1 Macrophages, endothelial cells 
Production by endothelial cells 




  Some epithelial cells Synthesis of acute phase proteins by the liver 
 
IL-6 Macrophages, endothelial cells 
Synthesis of acute phase proteins by 
the liver 
(Eto et al., 2011, 
Hall et al., 2010) 
  T cells Proliferation of antibody-producing cells 
 
IL-8 Macrophages, endothelial cells Chemotaxis, angiogenesis  




  Some epithelial cells  Neutrophil migration towards the inflammatory sites 
 
IL-10 Macrophages and DCs Inhibition of IL-12 production  
  Treg and TH2 




IL-12 Macrophages and DCs 
Promotes the production of IFN-! by 




(Smyth et al., 
2000) 
    
Mediates T cell differentiation into 
TH1 cells 
 
IL-15 Thymus and BM stromal         cells     
NK cell development and 
proliferation 
(Liu et al., 2000, 




  Macrophages and DCs  T cell proliferation  
IL-18 Macrophages  Induces IFN-! production by NK cells and T cells 
(Agaugue et al., 
2008, Mailliard 
et al., 2005) 
    NK cell migration  
TNF Macrophages and T cells Endothelial cell inflammation and coagulation, neutrophil activation 
(Sethi et al., 
2009) 
  NK cells Synthesis of acute phase proteins, apoptosis 
 
BM (bone marrow), IFN (interferon), IL (interleukin), T helper 1 (TH1), TNF (tumour 





1.1.2 The adaptive immune system 
If the innate immune response fails to eliminate the pathogen or transformed cells, a 
highly specific immune response needs to be mounted by the adaptive immune system. 
An adaptive immune response is elicited when an antigen crosses the epithelial barrier 
and is presented within lymphoid organs. This response is antigen specific, systemic 
and is characterised by immunological memory, which is the ability of the immune 
system to respond more rapidly and effectively to pathogens if re-encountered. The 
adaptive immune system comprises T and B lymphocytes as well as their products. 
Furthermore, adaptive immunity is further subdivided into humoral or cell-mediated 
immunity. Antibodies produced by activated B cells, which are also called plasma cells, 
mediate humoral immunity. Antibodies function by blocking and neutralising 
extracellular microbes and toxins whereas intracellular microbes such as bacteria and 
viruses can proliferate inside host cells and need to be destroyed by cell-mediated 
immunity. This type of response involves antigen specific cytotoxic T cells that leads to 
the destruction of infected cells (Abbas and Lichtman, 2009, Parkin and Cohen, 2001) 
 
1.1.2.1 Humoral immunity 
Antibodies released by B cells mediate the humoral immune response. There are 
different antibody classes categorised according to their heavy chain type including 
immunoglobulin (Ig) A, IgD, IgE, IgG and IgM. Each one has different functions and 
distribution within the body. Antibodies released into the circulation mediate several 
functions including neutralisation of extracellular microbes and microbial toxins, 
activation of the complement system and opsonisation of target cells that will be 
eliminated by antibody-dependent cell-mediated cytotoxicity (ADCC). Humoral 
immune responses are characterised by the generation of high-affinity, class-switched 
antibodies against specific antigens and long-lived antibody-secreting cells with 
specific memory and the ability to respond rapidly to subsequent antigen exposure 
(Janeway et al., 2001).  
 
Circulating naïve B cells express membrane-bound IgG and IgM that help mediate 
immune surveillance. A peptide-specific humoral response is elicited when B cells that 
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reside in the follicles of lymphoid organs interact with T cells. In this context, B cells 
act as antigen presenting cells (APC) via MHC class II molecules presenting antigens to 
T cells. This results in B cell activation and proliferation of antigen-specific B cells that 
further differentiate into specific plasma cells that secrete antibodies. The specific 
cytokines present in the milieu dictate the nature of heavy chain class switching. The 
presence of IFN-! leads to the generation of IgG (mediating complement activation and 
phagocytosis), whereas the presence of IL-4 leads to the generation of IgE (mediating 
activation of hypersensitivity or helminthic immunity) (Mosmann and Sad, 1996). 
 
1.1.2.2 Cell-mediated immunity 
T cells are the primary mediators of cell-mediated immunity. T cells are divided into 
two main types: T helper cells (TH or CD4) and cytotoxic T cells (CTL or CD8). T cells 
are important for the clearance of pathogens that are ingested by phagocytic cells or that 
are living within infected cells. T cell responses require the recognition of cell-
associated antigens, which results in the proliferation of antigen-specific clones and 
differentiation of effector and memory cells (Abbas and Lichtman, 2009).  
 
T cell activation is MHC-restricted where T cells are only able to recognise and respond 
to specific antigens displayed by MHC molecules. MHC molecules are polymorphic 
and are composed of two main classes; MHC class I which is expressed by all nucleated 
cells and MHC class II which is expressed by macrophages, DCs and B cells. Both 
classes contain a peptide binding cleft on their outer surface allowing presentation of 
antigens to T cells. T cells express a T cell receptor (TCR) that recognises peptides 
bound to MHC molecules on APCs. B cells, macrophages and DCs are known as 
professional APCs as they capture antigens with high efficiency for presentation to T 
cells. CD4 T cells recognise peptides presented via MHC class II molecules whereas 
CD8 T cells recognise peptides presented by MHC class I molecules (Parkin and 
Cohen, 2001). Upon activation, naïve CD4 T cells differentiate into specialised TH1 
cells (important for the response to intracellular microbes), TH2 cells (important for the 
response to extracellular microbes) (Mosmann and Sad, 1996), TH17 cells (that produce 
IL-17 which is involved in inflammation and autoimmune diseases) (Ouyang et al., 
2008), or regulatory T cells (key in immunosuppression and self-tolerance) (Yamaguchi 
and Sakaguchi, 2006). The presentation of peptides by MHC class I molecules to CD8 
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T cells results in differentiation of CTLs and elimination of infected cells. Both 
processes are regulated by a requirement for a second signal to be delivered via the T 
cell receptor (TCR) and co-stimulatory molecules, in particular B7 binding to CD28 on 
naïve T cells (Abbas and Lichtman, 2009). In addition, a third signal delivered by 
cytokines produced by innate immune cells is required to drive T cell polarisation such 
as IFN-! being produced by NK cells (Corthay, 2006). 
 
Within two days post-antigen exposure, antigen-specific effector cells proliferate and 
undergo clonal expansion. After clearance, a fraction of T cells survive and differentiate 
into long-lived memory T cells. These cells are quiescent in steady state but rapidly 
respond to subsequent exposure to the same antigen. There are two types of memory T 
cells: central memory T cells (TCM) and effector memory T cells (TEM). TCM produce 
high levels of IL-2 and are characterised by the expression of CCR7, L-selectin and 
CD45RO, hence this phenotype allows them to reside in lymphoid organs and mediate 
clonal expansion upon secondary exposure. Conversely, TEM do not express CCR7 but 
express other chemokine receptors such as CCR4, CCR5 and CXCR3 that are involved 
in homing to inflamed tissues. As such, TEM are present in mucosal tissues and are 
responsible for rapid effector function upon restimulation and production of 
inflammatory cytokines such as IFN-! or IL-4 (Sallusto et al., 2004). 
 
1.2 Natural killer cells 
Natural killer (NK) cells were first described in mice in 1975 as granular lymphoid cells 
with cytotoxic function against Moloney leukaemia cells (Kiessling et al., 1975). The 
same year, Herberman et al. confirmed the existence of effector cells that were cytolytic 
against tumour cells and were not T cells using athymic nude mice (Herberman et al., 
1975). Subsequently, these cells were identified as NK cells due to their ability to 
induce natural cytotoxicity without prior sensitisation. Unlike T and B cells, NK cells 
do not undergo germ-line Variable-Diverse-Joining (V-D-J) receptor rearrangement, 
and hence, are classified as a component of the innate immune system (Lanier et al., 
1986b). NK cells are currently defined as large granular lymphocytes, comprising about 





1.2.1 NK cell subsets 
NK cells are characterised by the expression of CD56 and absence of CD3 (Ritz et al., 
1988). Circulating NK cells are divided into two major subsets based on the intensity of 
CD56 expression: CD56bright and CD56dim NK cells (Fig 1.1); each of which has distinct 
phenotypic characteristics and functions (Lanier et al., 1986a). In addition, an aberrant 
NK cell population, which is CD56neg, can be found in small percentages in healthy 
individuals, but expand as a result of chronic viral infections such as human 
immunodeficiency virus (HIV) and hepatitis C virus (HCV) (Björkström et al., 2010). 
 
1.2.1.1 CD56bright NK cells 
CD56bright NK cells comprise about 10 % of total circulating NK cells. CD56bright NK 
cells are cytokine producers, releasing various cytokines including IFN-!, TNF-", TNF-
# and granulocyte-macrophage colony-stimulating factor (GM-CSF) (Fig 1.1 A). These 
pro-inflammatory cytokines play key roles in recruiting and priming other immune 
cells. CD56bright NK cells do not express CD16 or express low levels of this receptor 
(Cooper et al., 2001c). CD56bright NK cells express negligible amounts of killer 
immunoglobulin like receptors (KIR) (Andre et al., 2000). However, CD56bright NK 
cells exhibit high expression of the lectin-like inhibitory receptor CD94/NKG2A (Voss 
et al., 1998) and also express high levels of L-selectin, CCR7 and CXCR3, which are 
chemokine receptors associated with homing to lymph nodes (LN) (Campbell et al., 
2001). Moreover, CD56bright NK cells express the high affinity IL-2 receptor complex, 
IL-2R"#! (Caligiuri et al., 1990). As a result, this subset is responsive to very low doses 
of IL-2, thereby displaying higher proliferative capacity in vitro and in vivo compared 
to CD56dim NK cells.  
 
1.2.1.2 CD56dim NK cells 
CD56dim NK cells constitute up to 90 % of total NK cells in the periphery. These cells 
are characterised by the abundant expression of the CD16 (Fc!III) receptor, a receptor 
that mediates antibody-dependent cell-mediated cytotoxicity (ADCC) (Fig 1.1 B). 
Additionally, CD56dim NK cells kill target cells by releasing perforin and granzyme by 
granule exocytosis or by inducing apoptosis following activation of the TNF-related 
apoptosis induced ligand (TRAIL) or Fas/FasL cell death pathways. Phenotypically, 
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CD56dim NK cells are also characterised by the high expression of KIR. CD56dim NK 
cells have significantly lower or scarce expression of L-selectin (CD62L) when 
compared to CD56bright NK cells (Frey et al., 1998). Unlike CD56bright NK cells, resting 
CD56dim NK cells express the heterodimeric intermediate affinity IL-2 receptor (IL-
2R#!) and require higher doses of IL-2 for proliferation. Moreover, CD56dim NK cells 
express high levels of LFA-1, which is key for the formation of conjugates with target 
cells. In addition, CD56dim NK cells express CXCR1 and CX3CR1, which are 
chemokine receptors involved in NK cell trafficking towards non-lymphoid inflamed 
tissues (Cooper et al., 2001a). 
 
 
Figure 1.1 Human peripheral blood circulating NK cell subsets. A) CD56bright 
NK cells are potent producers of inflammatory cytokines. B) CD56dim NK cells are 
characterised by their high expression of CD16 and of granzymes and perforin, both of 
which are involved in the cytotoxic function of NK cells (Cooper et al., 2001a). License 
obtained from Elsevier; 3505490975127 
 
1.2.2 NK cell development 
NK cell development and differentiation occurs in the bone marrow (BM), however, 


























the existence of thymus-derived NK cells characterised by CD127 and GATA-3 
expression (Vosshenrich et al., 2006), which have been recently classified as type 2 
innate lymphoid cells (ILC2) (Vosshenrich and Di Santo, 2013). A distinct CD56bright 
population derived from CD34dimCD45+ cells has been found in lymph nodes (LNs) 
(Freud et al., 2005). Furthermore, CD34+ cells present in the human decidua can give 
rise to functionally distinct NK cells that are involved in immunomodulation and tissue 
remodelling (Vacca et al., 2011). Nonetheless, the consensus is that NK cells develop in 
the BM from CD34+ haematopoietic stem cells (HSC) and that NK cells present in 
other organs represent a very low percentage that are indicative of less mature NK cells 
or of distinct lineages of NK cells (Freud and Caligiuri, 2006). 
 
Common lymphoid progenitors (CLP) generated from CD34+ HSC can differentiate 
into any lymphoid lineage. Commitment to the NK cell lineage is dependent on the 
acquisition of the IL-2/IL15R# (CD122) and of IL-2/IL-15R! (CD132). The expression 
of these common ! chain receptors renders NK cell progenitors (NKPs) responsive to 
IL-15, which is abundantly present in the BM microenvironment (Colucci et al., 2003). 
Although exogenous IL-15 drives NK cell differentiation in vitro, IL-15 is mainly trans-
presented in vivo by BM-derived accessory cells as a membrane-bound protein coupled 
to the IL-15R". Using a humanised mouse model, Huntington and colleagues showed 
that the administration of IL-15R agonist (human IL-15 pre-incubated with IL-15R") 
induces NK cell maturation and homoeostasis in vivo as compared to administration of 
IL-15 alone (Huntington et al., 2009). Therefore, there are two main characteristics that 
define NKPs; the lack of expression of surface antigens associated with other lymphoid 
lineages such as CD3 or CD19 and the expression of IL-2/IL15R# that marks the 
transition from CLP into the NK cell lineage. Stage 1 of NK cell differentiation is 
characterised by expression of CD34, CD45RA and CD10. As NKPs become 
responsive to IL-15 they differentiate into pre-NK cells (stage 2) that express CD117 
and downregulate CD10 expression (Fig 1.2). However, the surface expression of IL-
2/IL15R# remains undetectable by flow cytometry during early stages of differentiation 
(stage 1-3) (Freud et al., 2006). 
 
Pre-NK cells give rise to stage 3 immature NK (iNK) cells that are committed to the 
NK cell lineage and are no longer capable of developing into other lymphoid cells. iNK 
cells express CD56 and some NK cell receptors such as CD161, NKp44 and 2B4. 
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These cells are committed to the NK cell lineage, but lack several of the main features 
of NK cells. Firstly, iNK cells do not produce IFN-! nor do they mediate killing of 
MHC class I negative targets in a perforin-dependent manner (Freud et al., 2006). 
Alternatively, iNK cells produce type II cytokines (e.g. IL-5 and IL-13) upon 
stimulation with high doses of IL-2 and kill target cells by activation of the TRAIL 
pathway (Zamai et al., 1998). In addition, iNK cells lack expression of some key NK 
cell receptors that are involved in the direct recognition of compromised targets 
including NKG2D, KIR, NKp46 and CD16 (Freud et al., 2006).  
 
Next, iNK cells differentiate into CD56bright NK cells (stage 4). At this stage, the 
acquisition of several NK cell receptors occurs concomitantly with the loss of CD117 
and CD34 expression. CD56bright NK cells express NKG2D, NKp46, exhibit 
intracellular expression of IFN-! and perforin, and express high levels of 
CD94/NKG2A. As NK cells proceed to stage 5 of differentiation, they display the most 
mature NK cell phenotype, CD56dimCD16brightKIR+, and show lower CD94/NKG2A 
expression than stage 4 CD56bright NK cells (Freud et al., 2006).  
 
 
Figure 1.2 Human NK cell development stages in vivo as proposed by Freud 
and Caliguiri (Freud and Caligiuri, 2006).  CD34+ HSCs differentiate into NK cells 
via distinct developmental stages. The progression from stage 1 to stage 3 dictates 
commitment to the NK cell lineage. Stages 4 and 5 represent where NK cells gain 
functional maturation that are defined as CD56bright and CD56dim NK cells and 















































1.2.3 Missing-self hypothesis  
The missing-self hypothesis was first proposed by Klas Karre and colleagues who 
noticed that the loss of self-MHC expression by murine lymphoma cells triggers NK 
cell effector function (Karre et al., 1986). The basis of this hypothesis is that the 
engagement of self-MHC molecules with inhibitory receptors such as killer Ig-like 
receptors (KIR) and CD94/NKG2A in humans or the lectin-like Ly49 receptors in mice, 
results in inhibition of NK cell cytotoxic function. Thus, NK cells attack target cells 
that lose self-MHC expression while those that express self-MHC will be spared. 
However, it has also now been proven that triggering of NK cell effector function 
actually requires an additional signal delivered by an activating receptor (Raulet, 2006). 
 
1.2.4 NK cell education 
During differentiation, NK cells undergo education. NK cells become fully competent 
in distinguishing between self and non-self by interaction with MHC class I in the BM 
microenvironment. This hypothesis was proposed by Kim and colleagues after the 
detection of impaired NK cell effector functions in MHC class I-deficient hosts (Kim et 
al., 2005). NK cell education involves positive engagement of NK cell inhibitory 
receptors with self-MHC class I molecules during maturation and is key for NK cells to 
become functionally responsive (licenced) (Kim et al., 2005). Thus, licenced NK cells 
are inhibited by self-MHC class I molecules that they encounter during maturation, 
which prevents them from attacking healthy cells. In contrast, unlicensed NK cells are 
hypo-functional.  
 
However, the absence of expression of self-inhibitory receptors on NK cells was 
observed in mice (Fernandez et al., 2005) and led to a new concept known as the 
arming/disarming of NK cells (Fig 1.3 A, B). In the arming model, positive engagement 
of inhibitory receptors expressed by NK cells with MHC class I is a requirement for the 
induction of functionally mature NK cells. Thus, the function of NK cell inhibitory 
receptors during development differs from their function in mature NK cells. 
Accordingly, cells that fail to interact with MHC class I during maturation such as in a 
MHC class I deficient host are “un-armed” and hence do not attack MHC class I-
negative targets (Fig 1.3 A). Conversely, according to the disarming model NK cells are 
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activated by default and the expression of inhibitory receptors rescue NK cells from 
becoming hyporesponsive (Fig 1.3 B) (Raulet and Vance, 2006). Therefore, the lack of 
expression of inhibitory receptors for self-MHC by developing NK cells alongside 
prolonged activation by an activating ligand results in hyporesponsiveness of NK cells 
due to continuous stimulation, a phenomenon similar to T and B cell anergy (Raulet, 
2006).   
 
Another model of education suggests that MHC class I molecules interact with 
inhibitory receptors within the same cell in a cis-interaction manner (Fig 1.3 C). It is 
hypothesised that some inhibitory receptors such as Ly49A deliver an inhibitory signal 
even in the absence of interaction with its ligand and that unengaged inhibitory 
receptors accumulate at the NK cell/target cell interface in the immunological synapse. 
Thus, cis-interaction sequesters inhibitory Ly49A receptors restricting interaction with 
target cells and preventing the relocation of inhibitory receptors to the immunological 
synapse. As a result, inhibition via Ly49A receptors is reduced and NK cells become 
more responsive (Chalifour et al., 2009). 
 
Finally, in the rheostat model (Fig 1.3 D), NK cell responsiveness is adjusted in a 
quantitative manner based on the number of inhibitory receptors they express. Early 
encounter of NK cells with healthy cells during development dictates their threshold of 
responsiveness. If NK cells lack the expression of self-MHC inhibitory receptors, NK 
cell responsiveness will be tuned down. Conversely, NK cell responsiveness is tuned up 
when NK cells express one or more inhibitory receptors. Hence, NK cell 
responsiveness is tuned to an optimal point of balance based on the inhibitory and 
activating signals it receives from healthy cells. This model of NK cell education 
ensures self-tolerance as well as the detection of any changes occurring within healthy 




Figure 1.3 Models of NK cell education. A) The arming model states that the 
arming of NK cells requires positive engagement of inhibitory receptors with MHC 
class I on educating cells, whereas the lack of interaction results in NK cell 
hyporesponsiveness. B) The disarming model states that disarming of NK cells occurs 
as a result of the lack of expression of inhibitory receptors, thus persistent stimulation 
of NK cells leads to hyporesponsiveness of NK cells. C) The cis-interaction model 
states that cis-interaction between inhibitory receptors and MHC class I molecules on 
the same cell sequesters the inhibitory signal at the immunological synapse. D) The 
rheostat model suggests that the strength of responsiveness of NK cells depends on the 
strength of inhibition delivered by inhibitory receptors (Höglund and Brodin, 2010). 
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1.2.5 NK cell receptors 
NK cell functions are regulated by balancing signals delivered by inhibitory and 
activating receptors. Accordingly, a target cell that downregulates MHC class I 
expression or upregulates stress ligands will trigger NK cell effector function (Fig 1.4).  
 
 
Figure 1.4 Regulation of NK cell recognition of target cells by activating and 
inhibitory receptors. A) Inhibitory receptors on NK cells interact with MHC class I 
molecules expressed by healthy self-cells mediating an inhibitory signal. B) Target cells 
that have downregulated MHC class I expression due to stress and upregulated 
expression of an activating ligand trigger NK cell-mediated killing. C) Target cells 
express MHC class I molecules, however, when stress ligands are upregulated by target 
cells they trigger NK cell cytotoxicity because the activation signal overrides the 
inhibitory signal. Inhibitory signal (%ve), activation signal (+ve) (Vivier et al., 2012). 

















































1.2.5.1 Inhibitory receptors  
NK cells express a repertoire of inhibitory receptors that regulate their activation. Some 
of these receptors belong to the Ig superfamily such as killer immunoglobulin-like 
receptors (KIR) that bind to MHC class I, while others are C-type lectin receptors 
(CD94/NKG2A) that recognise human leucocyte antigen (HLA)-E. Although the 
structure of these receptors varies, they all share a common motif, the immune-receptor 
tyrosine-based inhibitory motif (ITIM) in their cytoplasmic domain. The engagement of 
inhibitory receptors with their ligands leads to the phosphorylation of the ITIM motif 
and production of phosphatases that prevent Ca2+ influx, shutting down NK cell effector 
function (Ravetch and Lanier, 2000). Thus, inhibitory receptors play substantial roles in 
NK cell self-tolerance and regulation of NK cell activation. NK cells express a 
minimum of one inhibitory receptor, specific for self-MHC molecules in order to avoid 
killing of healthy self-cells. Table 1.2 summarises NK cell inhibitory receptors and their 
HLA-based cognate ligands.  
 
Table 1.2 Human inhibitory receptors expressed by NK cells and their cognate 
ligands 
Inhibitory receptor (s) Ligand (s) 
CD94/NKG2A HLA-E  
KIR2DL1 HLA-C group 2 alleles (C*02, C*04, C*05, C*06) 
KIR2DL2 HLA-C group 1 alleles (C*01, C*03, C*07, C*08) 
KIR2DL3 HLA-C group 1 alleles (C*01, C*03, C*07, C*08) 
KIR3DL1 Some HLA-A and B alleles expressing Bw4 epitope 
KIR3DL2 Some HLA-A alleles (A*03, A*11) 
KIR3DL3  Unknown 
KIR2DL4 HLA-G  
KIR2DL5 Unknown 
 
1.2.5.1.1 Killer immunoglobulin-like receptors 
NK cells and a subset of T cells express KIRs, receptors that recognise MHC class I 
molecules (Moretta and Moretta, 2004). This interaction mediates NK cell tolerance to 
self-healthy cells, whereas cells that have downregulated MHC class I due to 
transformation or viral infection become susceptible targets of NK cells. The KIR 
ligands, HLA-A, HLA-B and HLA-C, are expressed abundantly by nucleated cells 
(Lanier, 1998). Inhibitory KIRs are characterised by a long cytoplasmic tail (KIR-L) 
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containing an ITIM. The extracellular Ig domain of inhibitory KIRs confers specificity 
to different HLA class I alleles. Accordingly, KIRs are divided into two major groups; 
KIR2DL recognising HLA-C alleles and KIR3DL recognising HLA-A and HLA-B 
alleles (Thielens et al., 2012).  
 
HLA-C alleles are polymorphic and bind to different types of KIR receptors. 
Accordingly, HLA-C alleles are classified into two groups: the C2 group (C*02, C*04, 
C*05, C*06), which bind to KIR2DL1 and the C1 group (C*01, C*03, C*07, C*08), 
which bind to KIR2DL2/3. Nonetheless, KIR2DL2/3 receptors recognise some HLA-C 
alleles belonging to the C2 group including C*05:01 and C*02:02 as well as some 
HLA-B alleles (B*46:01 and B*73:01). On the other hand, KIR3DL1 and KIR3DL2 do 
not recognise any HLA-C alleles. Instead, these inhibitory receptors recognise HLA-A 
alleles (Thielens et al., 2012).  
 
KIR expression occurs at the latest stage of NK cell differentiation and correlates with 
fully functional NK cells. A role for KIRs and their ligands in the context of unrelated 
haploidentical haematopoietic stem cell transplantation (HSCT) and NK cell-based 
therapy has been suggested. Ruggeri and colleagues proposed that KIR-mismatched 
donor NK cells are effective in destroying leukaemic blasts (Ruggeri et al., 2002, 
Ruggeri et al., 2005). In this context, NK cell killing of autologous cells is inhibited by 
KIR, as they interact with self-MHC class I alleles expressed by targets. On the other 
hand, a mismatch between donor allogeneic NK cells and recipient MHC class I alleles 
triggers NK cell alloreactivity. Thus, alloreactive NK cells are able to destroy residual 
leukaemic blasts improving the outcome of transplantation (Ruggeri et al., 2005). 
 
1.2.5.1.2 CD94/NKGA 
NKG2A is an inhibitory receptor expressed by NK cells as a heterodimer with CD94. 
This lectin-like inhibitory receptor interacts only with HLA-E, a non-classical MHC 
class I molecule that has restricted sequence variability. Assembling of HLA-E 
molecules occurs in the endoplasmic reticulum (ER) using signal peptides of the 
classical MHC molecules; HLA-A, B and C (Braud et al., 1998). The expression of 
HLA-E on the cell surface requires association with MHC class I leader-derived 
peptides and monitors classical MHC class I expression by an indirect mechanism. 
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Hence, if the expression of MHC class I is downregulated, the expression of HLA-E 
decreases accordingly. Therefore, NKG2A interaction with HLA-E regulates NK cell 
functions when MHC class I is dysregulated due to infection or transformation (Kaiser 
et al., 2005).  
 
1.2.5.1.3 Other inhibitory receptors 
NK cell effector function is also regulated by another group of Ig superfamily receptors 
known as the Ig-like transcripts (ILTs) or leukocyte Ig-like receptors (LIRs). Among 
these receptors, ILT-2 or LIR-1 contains four typical ITIMs in its cytoplasmic domain 
that mediate inhibition of NK cell functions. Although these receptors are homologous 
to KIRs, they display low affinity binding to HLA class I molecules (HLA-A, B and C). 
LIR1, however, interacts with non-classical HLA-G molecules with better specificity 
(Vitale et al., 1999).  
 
NK cell inhibition can be mediated independently of MHC class I based-inhibition. 
Carcinoembryonic antigen-related cell adhesion molecule (CEACAM)-1 has been 
found to be upregulated on NK cells in melanoma patients (Stern et al., 2005). This 
protein contains ITIM that inhibit NK cell cytotoxicity upon interaction with 
carcinoembryonic antigens on target cells (Stern et al., 2005). In addition, NK cells 
express killer cell lectin-like receptor G1 (KLRG1) that also bears an ITIM and regulate 
NK cell functions (Ito et al., 2006). KLRG1 is expressed by 30-50 % of NK cells and is 
upregulated as a result of NK cell activation and viral infection. Moreover, upregulation 
of KLRG1 expression by NK cells correlates with NK cell maturation and 
homoeostasis (Huntington et al., 2007). Furthermore, a subset of NK cells express the 
NK cell receptor protein 1A (CD161) that binds to Lectin-like transcript-1 (LLT1) 
(Aldemir et al., 2005). LLT1 ligand has been found to be expressed by activated DCs 
and its interaction with CD161 on NK cells inhibits NK cell cytotoxicity and cytokine 
production (Rosen et al., 2008).  
 
1.2.5.2 Activating receptors 
At early maturation stages, NK cells acquire the expression of a variety of natural 
cytotoxicity receptors (NCRs). The engagement of these receptors results in positive 
stimulation of NK cells and direct lysis of target cells (Moretta et al., 2000). 
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Furthermore, NK cells express other activating receptors including NKG2D, DNAM-1, 
2B4 and NKp80 that can directly mediate killing or act as co-receptors (Fig 1.5) 
(Moretta et al., 2000).  
 
 
Figure 1.5 Interactions of NK cell-activating receptors with different ligands 
expressed by target cells. 
 
1.2.5.2.1 Natural cytotoxicity receptors (NCRs) 
NCRs are a group of NK cell receptors that mediate direct killing of stressed cells. 
There are three identified NCRs: NKp30, NKp44 and NKp46. NCRs are germ-line 
encoded transmembrane receptors that belong to the Ig superfamily. Yet, they are 
dissimilar in structure and amino-acid sequence.  
 
1.2.5.2.1.1 NKp30 
NKp30 is characterised by a V-type single extracellular domain. The NKp30 
transmembrane domain has an arginine residue that is attached to an ITAM containing 
CD3& and Fc'R! adaptors (Pende et al., 1999). This receptor is constitutively expressed 
by both resting or cytokine-activated NK cells (Moretta et al., 2000) and plays a 
substantial role in NK cell interaction with DCs. NK cell recognition of infected DCs 
occurs via NKp30, a process that leads to NK cell expansion, cytokine production and 
priming of the adaptive immune response (Ferlazzo et al., 2002). Different cellular 
ligands for NKp30 have been identified including HLA–B-associated-transcript 3 
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protein (Arnon et al., 2005). However, these are not considered as tumour induced 
ligands as their expression is induced by heat-shock or infection, respectively. The only 
tumour related stress ligand identified for NKp30 is a member of the B7 family, B7-H6 
(Brandt et al., 2009). This ligand is undetectable on healthy tissues and is not induced 
by stress such as heat-shock or toxicity. In contrast, B7-H6 is broadly expressed by 
tumour cells including B and T cell lymphomas, carcinomas, melanomas and myeloid 
leukaemia (Brandt et al., 2009).  
 
1.2.5.2.1.2 NKp44 
The second NCR in this group is NKp44 or NCR2. Molecular analysis of NKp44 
showed that this receptor has a single extracellular domain displayed as a V-shape. The 
transmembrane domain of NKp44 comprises a lysine residue that together with the 
ITAM-containing DAP12 (12 kD signal-transducing adapter) mediate signal 
transduction (Cantoni et al., 1999). Early studies showed that IL-2 activation induces 
lysis of different targets resistant to killing by resting NK cells (Grimm et al., 1982, 
Trinchieri, 1989). Later, it was shown that NKp44 is exclusively expressed by activated 
NK cells (Vitale et al., 1998). Thus, upregulation of NKp44 by activated NK cells 
mediates additional binding to stress ligands expressed by target cells, enhancing NK 
cell killing capacity accordingly (Moretta et al., 2000). In addition, certain type of cells 
express NKp44 including decidual NK cells (Hanna et al., 2006), mucosal-associated 
lymphoid tissue NK-22 cells (Cella et al., 2010), that are now classified as ILC3 
(Vosshenrich and Di Santo, 2013),  and a subset of IFN-!-producing cells in the tonsils 
(Ferlazzo et al., 2004). NKp44 masking using mAbs results in partial inhibition of NK 
cell cytotoxicity against MHC class I-negative tumour cells (Vitale et al., 1998). NKp44 
was shown to induce cytotoxicity cooperatively with NKp46 as blocking both receptors 
led to increased inhibition of NK cell cytolytic function (Moretta et al., 2000). The 
identification of a stress-induced ligand for NKp44 has been a challenge for a long 
time. In HIV patients, NKp44 is over-expressed by NK cells. Interestingly, a cellular 
ligand for NKp44 was found to be expressed on HIV infected CD4 T cells mediating 
NK cell killing (Vieillard et al., 2005). However, isolation and identification of the 
NKp44 ligand (NKp44L) was only achieved recently by Baychelier and colleagues 
(Baychelier et al., 2013). NKp44L is a variant of mixed-lineage leukemia-5 (MLL5) 
that is strikingly expressed by tumour or stressed cells but not found on healthy cells. 
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This ligand is highly conserved and contains a C-terminal-motif in its outer domain that 
interacts specifically with NKp44 (Baychelier et al., 2013). Yet, this does not exclude 
the existence of other undetected ligands for NKp44. 
 
1.2.5.2.1.3 NKp46 
NKp46 (in human) or NCR1 (in mouse) contains C2-type Ig-like domains in its outer 
membrane whereas the intracellular domain contains ITAM-bearing polypeptide 
adapters (CD3& and Fc'R!) that mediate signal transduction. This receptor is expressed 
by both resting and activated NK cells triggering NK cell cytotoxicity and cytokine 
production (Moretta et al., 2000). NK cells express NKp46 at high density 
(NKp46bright), however it was shown that some individuals have NK cells that exhibit a 
NKp46dim population constituting up to 90 % of the total NK cell population (Sivori et 
al., 1999). This was associated with low cytotoxicity against NK cell-sensitive-tumour 
targets by both freshly isolated NK cells or clones derived from NKp46dim individuals 
suggesting a major role of this receptor in eliminating stressed cells (Sivori et al., 1999). 
Masking this receptor using anti-NKp46 mAbs resulted in inhibition of NK cell-
mediated killing of a variety of human tumours including melanoma, breast carcinoma, 
liver carcinoma and Epstein Barr virus transformed cell lines. NKp46 was shown to be 
sufficient to trigger NK cell cytotoxicity against murine tumour cells such as Bw-1502 
and YAC-cells (Sivori et al., 1999). Human NKp46 is the only activating receptor that 
is able to recognise ligands expressed on murine cells indicating that NKp46 ligand is 
conserved between the two species (Biassoni et al., 1999, Moretta et al., 2000). NKp46 
recognises influenza virus haemagglutinin (HA), yet no specific tumour ligand for this 
receptor has been identified (Arnon et al., 2004). Interestingly, NCR1 knockout mice 
revealed a central role of NKp46 in preventing the metastasis of B16 melanoma and 
Lewis-lung carcinoma tumours (Glasner et al., 2012). Using the Neo mouse model, 
Narni-Mancinelli demonstrated a regulatory role of NKp46 including downregulation 
of NK cell activity and development of T cell responses (Narni-Mancinelli et al., 2012). 
These mutant mice showed enhanced resistance to viral and bacterial infections 
associated with hyper-responsiveness of NK cells compared to NK cells from WT mice. 
Genome analysis revealed a mutation of Ncr1 genes that encode NKp46 where Neo 
mice have no detectable surface expression of NKp46. Interestingly, in vivo blockade of 
NCR1 in WT mice using mAbs enhanced NK cell activity against YAC-1 tumour cells 
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suggesting this could be a possible immunotherapeutic tool to augment NK cell activity 
in the absence of T cells, particularly after HSCT.  
 
1.2.5.2.2 Activating receptors belonging to the CD94/NKG2 family 
The NK cell group 2 (NKG2) family is a group of C-type lectin-like receptors 
comprising CD94/NKG2C and CD94/NKG2E that are specific for HLA-E. These 
receptors are expressed as heterodimers coupled with CD94, which is a membrane 
glycoprotein. CD94/NKG2C and E signal via DAP12 signalling molecules and both 
have been implicated in viral immunity (Braud et al., 1998, Fang et al., 2011). The 
expansion of NK cell subsets preferentially expressing CD94/NKG2C was observed as 
a result of specific viral infections including CMV, chronic hepatitis B virus (HBV) and 
hepatitis C virus (HCV) (Béziat et al., 2012). In addition, a distinct subset of NK cells 
exist in CMV infected individuals that display high levels of CD94/NKG2C expression 
together with CD57 expression (Lopez-Vergès et al., 2011). In HSCT settings, 
reactivation of CMV promotes the expansion of a CD94/NKG2C+ NK cell subset that is 
associated with a mature NK cell phenotype and enhanced IFN-! production (Foley et 
al., 2012). Hence, the selective expansion of NKG2C+ NK cells as a result of viral 
infection, as well as other associated factors including their mature phenotype and 
extended life-span, are suggestive of a memory-like function by NK cells (Min-Oo et 
al., 2013). 
 
Another important receptor that belongs to the NKG2 family is NKG2D. NKG2D is a 
transmembrane receptor that is expressed as a homodimer. NKG2D signals via the 
signalling molecule DAP10 (Wu et al., 1999). This receptor is expressed by almost all 
NK cells, as well as by !( T cells and CD8 T cells. NKG2D binds to MHC class I-
related chain A/B molecules (MICA/MICB) and UL-16 binding proteins (ULBPs), 
which are stress-induced molecules that are expressed by tumour cells and viral 
infected cells to initiate NK cell cytolytic activity (Bauer et al., 1999, Cosman et al., 
2001). Remarkably, NK cell activation by NKG2D overrides the inhibition mediated by 
KIR because the signalling cascade for DAP10 is distinct and not affected by SHP, 
which is a component of ITIM bearing inhibitory receptors (Watzl, 2003). In mice, the 
interaction between NKG2D and NKG2D ligands (RAE-1 or H-60), which are 
expressed by several murine tumour cell lines, results in rejection of cancerous cells 
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alongside the priming of CTL responses (Cerwenka et al., 2001). Ligands for NKG2D 
are constitutively expressed in many tumours of epithelial origin including lung, breast, 
kidney, and colon carcinoma (Groh et al., 1999, Jinushi et al., 2003). In leukaemia 
patients, Salih et al. reported elevated levels of soluble NKG2D ligands which impair 
NKG2D-mediated killing in the sera of patients, including MICA and MICB (Salih et 
al., 2003). Overall, recognition of these ligands by effector cells enhances tumour 
immune-surveillance against cancerous cells (Raulet, 2003).  
 
1.2.5.2.3 DNAX accessory-molecule type-1 (DNAM-1) 
DNAM-1 (CD226) is a receptor that belongs to the Ig superfamily of receptors, which 
comprise two Ig V-type external domains. Besides NK cells, this receptor is also 
expressed by a variety of cell types including T cells, a subset of B cells, monocytes 
and platelets. Ligands for DNAM-1 are Nectin2 (CD155) and PVR (CD112) both of 
which are expressed by tumour cell lines of neuronal and epithelia origin (Pende et al., 
2005). Masking DNAM-1 with mAbs results in inhibition of NK cell-mediated 
cytotoxic function against target cells expressing Nectin2 or PVR ligands, thereby 
confirming the central role of this receptor in tumour-mediated lysis by NK cells (Pende 
et al., 2005). In addition, the association of DNAM-1 with lymphocyte function 
associated antigen-1 (LFA-1) triggers NK cell cytotoxicity and cytokine secretion 
(Shibuya et al., 1999). The signal transduction pathway used by this receptor remains to 
be defined.  
 
1.2.5.2.4 2B4 
2B4 (CD224) is a member of the signalling lymphocyte activation molecule (SLAM) 
family. 2B4 is expressed by NK cells and memory CD8+ T cells and binds to CD48 
which is expressed on lymphocytes and myeloid cells with high affinity (Brown et al., 
1998). 2B4 also acts as a co-receptor that induces cytotoxicity and IFN-! production by 
NK cells (Nakajima et al., 1999, Kubin et al., 1999). Generally, 2B4 is an activating 
receptor in humans and an inhibitory receptor in mice. In this context, it has been 
shown that 2B4-CD48 interactions may result in inhibition of tumour cell lysis. Hence, 
2B4 may mediate a regulatory role of NK cells in MHC class I-deficient hosts, or for 
cells that have downregulated self-MHC expression (McNerney et al., 2005). CD48 has 
been found to be upregulated by lymphocytes and myeloid cells in response to EBV or 
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stimulation with mitogens and IFNs (Parolini et al., 2000, Tissot et al., 1997). 2B4 
bears cytoplasmic immunoreceptor tyrosine-based switch motifs (ITSM; TxYxxV/I) in 
its cytoplasmic domain, which play an important role in modifying the function of this 
receptor, which can be both activating and inhibitory. ITSM binds SH2 domains 
containing either activating or inhibitory molecules (SHP-1, SHP-2, SAP, and EAT-2). 
In particular, SAP is implicated in dictating 2B4 signalling (Endt et al., 2007). 
Immature NK cells in humans and mice lack the expression of SAP transcript. In this 
context, 2B4 has been shown to play an inhibitory role during early stages of NK cell 
development mediating self-tolerance before NK cells become fully competent (Sivori 
et al., 2002).  
 
1.2.5.2.5 NKp80 
Almost all NK cells, a subset of !( T cells and a subset of CD8 T cells express NKp80. 
NKp80 recognises a receptor expressed by myeloid cells named activation-induced C-
type lectin (AICL). NKp80 interaction with this receptor results in triggering of NK cell 
cytotoxic functions. Unlike other ITAM-bearing activating receptors, the NKp80 
signalling pathway has been shown to be distinct. Using an IL-2-dependent cell line, it 
was recently found that NKp80 signals via an atypical hemi-ITAM activating the Syk-
kinase pathway (Dennehy et al., 2011). 
 
1.2.5.2.6 Activating killer immunoglobulin receptors 
KIR genes are complex and highly polymorphic combining KIR-L (long cytoplasmic 
domain) and KIR-S (short cytoplasmic domain) genes that both display similarities in 
their extracellular domains. KIR-S receptors, however, have short cytoplasmic tails that 
do not contain ITIM. In addition, the KIR-S transmembrane region contains charged 
residues that attach to the DAP12 signalling molecule to transmit the activating signal 
accordingly (Thielens et al., 2012). Although KIR2DS1 has been found to interact with 
HLA-C2, there is no evidence of interaction between KIR2DS2 with C1 molecules 





NK cells have abundant expression of the Fc receptor CD16 (Fc!RIII). CD16 
recognises antibody-bound stressed cells via the Fc portion of IgG initiating ADCC, a 
pathway that induces apoptosis of target cells (Lanier et al., 1991). CD16 is expressed 
abundantly by CD56dim NK cells. Activation of NK cells via CD16 is very potent and 
CD16 is the only NK cell activating receptor which is able to trigger NK cell 
cytotoxicity on its own (Bryceson et al., 2006). 
 
1.2.5.2.8 Other activating receptors 
NK cells constitutively express CD2, which is thought to act as an adhesion molecule. 
However, there is evidence to suggest that CD2 also acts as a co-stimulatory molecule 
(Inoue et al., 2002). CD69 is another receptor expressed by NK cells upon activation 
and its expression enhances effector functions of NK cells including, cytotoxicity, 
proliferation, upregulation of adhesion molecules and cytokine production (Borrego et 
al., 1999). The CD69 ligand has not yet been identified. 
 
1.2.6 Receptors that mediate NK cell trafficking 
NK cell express different chemokine receptors, integrins, adhesion molecules as well as 
proteins such as sphingosine 1-phosphate (S1P) receptors that regulate their trafficking 
to different sites. As part of their role in immune surveillance, NK cells are distributed 
throughout the body. NK cell trafficking is very important for NK cell-based therapies, 
as NK cells need to traffic to tumour sites in order to deliver meaningful clinical 
outcomes. 
 
1.2.6.1 Adhesion molecules 
NK cells express CD2, CD44, CD54 (ICAM-1), CD56, CD58 as well as different 
integrins. Integrins are a large family of molecules expressed on the leukocyte cell 
surface as heterodimers of non-covalently attached " and # subunits. Based on their # 
subunit, integrins are divided into different subfamilies. The #1 and #3 (cytoadhesion) 
subunits act as extracellular matrix receptors, whereas the #2 (Leu-CAM) subunit 
supports cell-to-cell adhesion (Patarroyo et al., 1990). NK cells express "4#1 that 
interacts with VCAM-1, "5#1 that interacts with fibronectin and "6#1 that interacts 
! "#$%&'(!)!!
! 41 
with laminin. The second subfamily of integrins, #2, plays a critical role in NK cell 
signalling and formation of conjugates with target cells (Morris and Ley, 2004). In 
particular, LFA-1 (CD11a/18) is a key receptor in endothelial cell binding and for the 
formation of the immunological synapse (Orange, 2008). Moreover, LFA-1 acts as a 
co-receptor stimulating NK cell functions (Shibuya et al., 1999).  
 
Another crucial component for NK cell migratory function is L-selectin (CD62L). L-
selectin is an adhesion molecule which facilitates extravasation of NK cells into high 
endothelial venules in lymph nodes (LN). This molecule is expressed at differential 
levels among NK cell populations. CD56bright NK cells express high levels of L-
selectin, whereas CD56dim NK cells display lower and variable expression among 
individuals (Mäenpää et al., 1993, Uksila et al., 1997). Interestingly, it was shown that a 
unique subset of CD56dimL-selectin+ NK cells that exhibit high production of IFN-!, 
high proliferative capacity as well as enhanced cytotoxicity compared to CD56dimL-
selectin% NK cells (Juelke et al., 2010). L-selectin expression is associated with NK cell 
migration to the LN, in which NK cells are able to prime adaptive responses by 
releasing IFN-! and interacting with resident LN DCs (Chen et al., 2005). L-selectin 
expression is upregulated upon stimulation of NK cells with IL-12 or IFN-", whereas 
stimulation with IL-2 or IL-15 downregulates L-selectin expression by NK cells (Frey 
et al., 1998). 
 
1.2.6.2 C and CX-Chemokine receptors 
NK cells develop in the BM; hence, during the early stages of NK cell differentiation 
NKP and iNK cells express high levels of CXCR4 in response to CXCL12 (SDF1-") 
expressed by the BM parenchyma. As a result, iNK cells are retained in the BM in 
order to complete their maturation (Mayol et al., 2011). Mobilisation of NK cells from 
the BM is assisted by CCR1 which mediates downregulation of CXCR4 expression by 
mature NK cells (Bernardini et al., 2008). However, NK cells display homogenous 
CXCR4 expression and other factors such as S1P5 also contribute to NK cell egress 
from the BM (Walzer et al., 2007). Less mature NK cells express low levels of 
CX3CR1 and are located at the BM parenchyma, whereas terminally differentiated NK 
cells exhibit high density of CX3CR1 and are located in BM sinusoids. The acquisition 
of high CX3CR1 expression supports NK cell egress from the BM and entry into the 
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circulation. In addition, S1P5 expression increases on mature NK cells mediating their 
entry into the blood stream (Mayol et al., 2011).  
 
Chemokine receptor expression varies among NK cell subsets. The majority of 
circulating mature NK cells express additional receptors including CXCR1, Chemrin23 
(Chem23), which along with CX3CR1 support NK cell recruitment towards inflamed 
tissues via IL-8 and soluble fractalkines. Conversely, CD56bright NK cells display low 
levels of CX3CR1 expression and do not express CXCR1 (Robertson, 2002). Instead, 
CD56bright NK cells express CCR7 that is associated with migration to secondary 
lymphoid tissues in response to CCL19 and CCL21 expressed in the T cell zone. In 
addition, CD56bright NK cells have high CXCR3 expression, which is a chemokine 
receptor that mediates binding to CXCL10 and CXCL11 (Campbell et al., 2001). This 
chemokine receptor is implicated in trafficking of NK cells to LN as well as tumour 
infiltration as NK cells from Cxcr3!/! knock-out mice display poor capacity to 
accumulate at tumour sites (Wendel et al., 2008).  
 
Chemokine receptor expression by NK cells is altered upon inflammation during 
infection or in autoimmune disorders (Peng and Tian, 2013). This is associated with the 
upregulation of chemokine ligands in the disease state that are not typically expressed at 
steady state. For example, CCR5 is highly expressed by NK cells in rheumatoid arthritis 
patients and its ligands (CCL3 and CCL5) were found to be upregulated accordingly in 
inflamed joints (Mack et al., 1999).  
 
In vitro, stimulation with cytokines modifies chemokine expression by NK cells with 
some receptors being upregulated and some downregulated. IL-2 stimulation 
upregulates the expression of CCR1, CCR2, CCR4, CCR5 and CCR8 by NK cells 
(Inngjerdingen et al., 2001). Furthermore, NK cell activation with IL-18 induces the 
expression of CCR7 (Mailliard et al., 2005). On the other hand, IL-15 stimulation 
downregulates CX3CR1 expression (Barlic et al., 2003) and IL-12 stimulation 
downregulates CXCR3 expression by NK cells (Hodge et al., 2002).  
 
A newly described subset of liver-resident NK cells exhibiting features of 
immunological memory has been characterised by high levels of CXCR6 expression 
(Paust et al., 2010). The ligand for this chemokine receptor (CXCL16) is secreted by 
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the liver sinusoids. Interestingly, the maintenance of natural killer T cells (NKT cells), 
which are innate immune cells enriched within the liver, depends on the interaction of 
CXCR6 with CXCL16 (Geissmann et al., 2005). Thus, it is likely that those cells 
derived from liver haematopoietic progenitors actually have a unique chemokine 
receptor repertoire ensuring the retention of these cells within the liver (Peng and Tian, 
2013). Table 1.3 summarises the expression of some chemokine receptors by NK cells 
and their effect in vivo. 
 







NK cells Ligand (s) Effect (s) 
Reference (s) 
CCR1 High  Low  CCL3 and CCL5 Egress from the BM 
(Bernardini et 
al., 2008) 
CCR2  Negative Negative CCL2 and CCL7 
Recruitment of NK 
cells to the liver during 
CMV infection 
(Hokeness et al., 
2005) 
CCR4 Negative  Variable CCL17, CCL22 
NK cell responses 
against mycobacterial 
infections  
(Stolberg et al., 
2011) 
CCR5 High Negative CCL3, CCL4 and CCL5 
Accumulation of NK 
cells during viral 
infections and 
autoimmune diseases.  
(Grégoire et al., 
2007, Grégoire 
et al., 2008) 




Migration to LN 








(Barlic et al., 
2003) 





et al., 2001, 
Parolini et al., 
2007) 




Migration to LN, 
tumour infiltration 
(Martín-
Fontecha et al., 
2004) 
CXCR4 High High CXCL12 Retention within BM (Mayol et al., 2011) 
CXCR6 Variable Negative CXCL16 Liver NK cells (memory function?) 
(Paust et al., 
2010) 
 
1.2.7 NK cell effector function 
Upon recognition of stressed cells, adhesion molecules play an indispensable role in 
initiating interactions between NK cells with their targets to form what is known as a 
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lytic immunological synapse (IS). NK cells store cytotoxic mediators in granules within 
lysosomes whereby they can effectively kill target cells by exocytosis. In addition, NK 
cells kill their targets by other mechanisms including death-receptor and ADCC 
pathways and are able to prime other immune responses via secretory cytokines. 
1.2.7.1 NK cell killing via the perforin-dependent pathway (exocytosis) 
Exocytosis is the main mechanism that NK cells utilise to kill targets. NK cells from 
perforin-deficient mice show reduced cytotoxicity and fail to lyse some tumorigenic 
targets (Kagi et al., 1994). Cytolytic granules of cytotoxic cells contain perforin and 
structurally related proteases (granzymes). Perforin mediates pore formation in the 
plasma membrane of the target cell where granzymes are delivered in a calcium-
dependent manner and diffused into the target cell. Granzyme B is the most powerful 
activator of caspase-dependent and caspase-independent cell death, cleaving target cell 
proteins at multiple and specific residues (Trapani and Smyth, 2002). In contrast, 
granzyme A cannot activate the caspase pathway, but directly can cleave nuclear 
proteins (Beresford et al., 1999).  
 
Granzyme B diffusion into target cells is partially mediated by cation-independent 
mannose 6-phosphate receptor in an endocytosis-dependent manner. Granzyme B 
activates caspases or the pro-apoptotic member of the Bcl-2 family (BH3-interacting 
domain death agonist) to result in apoptosis (Thomas et al., 2001). Interestingly, 
cytotoxic cells contain a lysosomal protease (cathepsin B) within their cytotoxic 
granules that inactivates perforin supporting its diffusion back to the cytotoxic cell 
membrane after degranulation is complete (Balaji et al., 2002). This pathway is potent, 
resulting in rapid killing of viral-infected and tumour-transformed cells within minutes.  
 
NK cell cytotoxic function relies on the ability of transporting lytic granules to the IS. 
During degranulation, the lysosome associated membrane protein (CD107a) is 
transported to the surface of NK cells facilitating the mobility of the lytic granules 




1.2.7.2 NK cell mediated cytotoxicity via death receptor pathways 
NK cells can also induce death of target cells in a death receptor-dependent manner. 
NK cells express receptors belonging to the TNF family, including FasL and TRAIL. 
Interaction of these receptors with their ligands results in apoptosis (Smyth et al., 2005).  
 
The majority of NK cells and CTLs constitutively express FasL. Interaction of Fas with 
its ligand, FasL, leads to the clustering of death domains (DD) on target cells. 
Subsequently, DD binds caspase-8 activating effector caspases that are committed to 
cellular apoptosis (Ashkenazi and Dixit, 1998). Although many tumour types do not 
express Fas, NK cells contribute to the induction of Fas expression by stressed target 
cells via the secretion of IFN-!. Thus, Fas-FasL interaction correlates with tumour 
regression in vivo and is an important pathway in cancer clearance (Screpanti et al., 
2001).  
 
In addition, NK cells express TRAIL, which is a type II membrane protein. TRAIL 
plays a central role in eliminating TRAIL-sensitive tumour cell lines such as 
fibrosarcoma, renal adenocarcinoma and B-cell hybridoma in an IFN-! dependent 
manner (Takeda et al., 2001b). Many ligands for TRAIL have been described to which 
two of them can effectively induce apoptotic signals; TRAIL-R1 (DR4) and TRAIL-R2 
(DR5). NK cell killing of TRAIL-sensitive targets is caspase-dependent by clustering of 
DD (Ashkenazi and Dixit, 1998). The anti-metastatic effect of NK cells has been found 
to be partially mediated by TRAIL (Takeda et al., 2001a). Furthermore, TRAIL is also 
implicated in anti-viral activity as the secretion of IFN-" or # upregulates TRAIL 
expression by NK cells as well as increasing the expression of TRAIL ligand by virally 
infected cells (Sato et al., 2001). Similarly, in vitro activation of NK cells by cytokines 
such as IL-2 or IL-15 results in upregulation of TRAIL expression (Smyth et al., 2005).  
 
1.2.7.3 Production of inflammatory cytokines by NK cells 
NK cells participate in a variety of responses via the production of inflammatory and 
immunoregulatory cytokines. Typically, CD56bright NK cells produce inflammatory 
cytokines more abundantly compared to CD56dim NK cells. The type of cytokines 
produced by NK cells in early inflammatory events elicits different responses against 




IFN-! production by NK cells is induced by cytokines produced by macrophages and 
DCs, typically IL-12 and IL-18. In addition, IFN-", a cytokine that is abundantly 
produced during viral infection, synergises with IL-12 or IL-18 to promote IFN-! 
production (Matikainen et al., 2001). TNF-" is another cytokine that mediates an 
additive effect with IFN-" by stimulating IFN-! production by NK cells (Marshall et 
al., 2006). NK cell recognition of target cells via activating receptors such as NKG2D 
also induces the production of IFN-!. Secreted IFN-! by NK cells mediates critical 
roles in anti-microbial and anti-tumour responses including: (i) triggering the transition 
from the innate to the adaptive immune response by priming T helper cells; (ii) 
stimulation of B cell isotype switch; (iii) promoting the interaction of leukocytes with 
epithelial cells; and (iv) upregulation of the expression of adhesion molecules (ICAM-
1, VCAM-1) and chemokines (CXCL9, CXCL10, CCL2, CCL3, CCL4, CCL5), 
thereby mediating trafficking of effector cells to sites of inflammation (Schroder et al., 
2004). In addition, secretion of IFN-! by NK cells inhibits tumour angiogenesis 
(Hayakawa et al., 2002). IFN-! production is negatively regulated by IL-4, IL-10 and 
TGF-# (Schindler et al., 2001). 
 
NK cells produce modest levels of TNF-" upon stimulation with cytokines or mitogens 
(Cooper et al., 2001c). In vivo, it is believed that the engagement of NKp30 on NK cells 
with DCs triggers TNF-" production, which in turn mediates DC maturation and shapes 
the adaptive immune response accordingly (Vitale et al., 2005). In addition, TNF-" 
enhances NK cell cytotoxicity by upregulating the adhesion molecule ICAM-1 in a NF-
$B-dependent manner (Wang et al., 2012).  
 
Granulocyte macrophage-colony-stimulating factor (GM-CSF) is abundantly produced 
by NK cells. This cytokine mediates a critical function, in that it stimulates 
haematopoietic stem cells (HSC) to rapidly produce granulocytes in order to combat 
infections. GM-CSF production is enhanced in response to cytokines such as IL-15 or 
its combination with IL-12 or IL-18 (Cooper et al., 2001c). NK cells under certain 
stimulating conditions produce other cytokines including IL-5 (Warren et al., 1995, 
Loza et al., 2002), IL-6 (Hall et al., 2010), IL-8 (Roda et al., 2006), IL-10 and IL-13 




1.2.8 Tissue-specific NK cells 
1.2.8.1 Liver NK cells 
NK cells constitute up to 50 % of total hepatic leukocytes (Norris et al., 1998). Almost 
equal proportions of CD56bright and CD56dim NK cells exist within the liver. It is 
believed that liver NK cells are generated from NKP recruited from the BM to the liver 
via the blood circulation and therein acquire their distinct characteristics and are 
retained within the liver (Moroso et al., 2011). Liver CD56bright NK cells express 
significantly higher levels of CD69, NKp44 and HLA-DR, and less L-selectin than PB 
CD56bright NK cells. In addition, liver CD56dim NK cells express less KIRs and show 
reduced cytotoxicity compared to PB CD56dim NK cells (Burt et al., 2009). The fact that 
liver NK cells are less cytotoxic regardless of their activation status indicates that liver 
NK cells have a regulatory function. In this context, the liver contains a high percentage 
of NKG2A+/Ly49% NK cells that are not responsive to IL-12 and IL-18 stimulation. In 
addition, liver NK cells are exposed to high levels of IL-10 produced by kuppfer cells 
which dampens the effect of other inflammatory cytokines (Lassen et al., 2010). This 
indicates a tolerogenic nature of liver-resident NK cells to gut-derived antigens. Indeed, 
the liver microenvironment is persistently exposed to endotoxins. In addition, the 
expression of MHC class I by hepatocytes has been shown to be low or absent. Thus, 
liver NK cells are required to be less aggressive to prevent hyperactivity. However, 
liver NK cells become potent killers when co-cultured with kupffer cells in the presence 
of LPS indicating an intrinsic capacity to protect the liver during infection or again 
tumour cells (Burt et al., 2009). Experiments in mouse showed that two subpopulations 
of NK cells exist in the liver; DX5+CD49% NK cells that are found in afferent and 
efferent blood and DX5%CD49+ NK cells that are present within the liver sinusoids. The 
latter subpopulation is believed to develop distinctly from hepatic haematopoietic 
progenitors and can mediate memory like functions (Peng et al., 2013).  
 
Liver NK cells influence to the pathogenesis of liver infections such as HBV (Maini 
and Peppa, 2013) and HCV (Glasner et al., 2012). Liver NK cells can directly kill 
infected hepatocytes by exocytosis or via the death-receptor pathway. In addition, the 
production of IFN-! and TNF-" by liver NK cells mediates T cell responses against 
infected hepatocytes. However, in chronic infection, liver NK cells promote liver 
damage as a result of NK cell mediated-lysis of infected hepatocytes or by elimination 
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of effector T cells. In particular, TRAIL has been found to be upregulated by liver NK 
cells as a result of liver inflammation, and its ligand (DR5) has been found to be 
expressed by liver hepatocytes in chronic HBV, thereby mediating apoptosis (Dunn et 
al., 2007).  
 
1.2.8.2 NK-22 cells 
NK-22 cells, recently classified as ILC3 cells (Vosshenrich and Di Santo, 2013), are 
selectively present at the gut mucosa, Peyer’s patches and tonsils. NK-22 cells display 
poor cytotoxic function and almost no secretion of IFN-!. As the term indicates, NK-22 
cells produce high levels of IL-22, as well as IL-26 and leukaemia inhibitory factor, that 
both of which are believed to mediate epithelial protection and have an innate anti-
inflammatory role (Cella et al., 2009).  
 
1.2.8.3 Thymic NK cells 
Thymic NK cells were firstly described by Vosshenrich and colleagues (Vosshenrich et 
al., 2006). These cells represent a distinct lineage of NK cells expressing high levels of 
CD56, CD127 (IL-7R") and the transcription factor GATA-3, and hence classified as 
ILC2 (Vosshenrich and Di Santo, 2013). Thymic NK cells produce cytokines including 
IFN-!, TNF-" and GM-CSF, yet exhibit a lower killing capacity which associated with 
a lower expression of granzyme B compared to splenic NK cells (Vosshenrich et al., 
2006). 
 
1.2.8.4 Uterine NK cells  
During pregnancy, more than 40 % of leukocytes in the maternal uterine mucosa 
(decidua) are CD56bright NK cells. These cells are known as decidual NK (dNK) cells 
and they mediate an essential role in vascular remodelling and placental growth (Hanna 
et al., 2006). The interaction between dNK cells and trophoblasts stimulates the 
production of pro-angiogenic molecules and regulates trophoblast evasion (Moffett-
King, 2002). As these cells are specialised in pregnancy-specific activities, dNK cells 




dNK cells express NKp44 and NKp30. The interaction of these receptors with their 
ligands that are expressed by stromal decidual cells and trophoblasts induces the 
production of vascular endothelial growth factor (VEGF), placental growth factor 
(PlGF), angiopoietins and TGF-#1, all of which are mediators that promote vascular 
growth (Moffett-King, 2002, Vacca et al., 2008). In addition, trophoblast cells secrete 
HLA-G as soluble ligands that bind to KIR2DL4 expressed by dNK cells promoting the 
induction of pro-angiogenic cytokines. dNK cells have been shown to produce high 
levels of IL-8 and CXCL10 that regulate the migration of extravillous trophoblast cells 
towards the decidual basalis (Hanna et al., 2006). This recruitment pattern mediates 
spiral artery invasion and is critically important for uterine vascular remodelling and 
placental development (Le Bouteiller, 2013). 
 
1.2.8.5 Cord blood NK cells 
NK cells constitute 15 – 30 % of the total CB mononuclear cell (CBMC) population 
(Kotylo et al., 1990). CD56dim NK cells comprise 90 % of CB NK cells whereas 
CD56bright constitute 10 % showing similar NK cell subset proportions to PB (Dalle et 
al., 2005, Tanaka et al., 2003). Studies of CB NK cell function show inconsistencies. It 
has been reported that CB NK cells have less lytic capabilities than PB NK cells, 
although CB NK cells were responsive to IL-2 and IL-12 (Gaddy et al., 1995). 
Additionally, CB contains CD56-CD16+ cells, a population that is not found in PB 
(Gaddy et al., 1995). CD56dim CB NK cells express similar percentages of triggering 
receptors (NKp46 and NKG2D) to PB NK cells (Dalle et al., 2005, Wang et al., 2007). 
However, Tanaka et al. reported that only one-third of CB CD56dim NK cells were able 
to react against K562 cells, which was attributed to a lower expression of adhesion 
molecules (CD2, CD11a, CD18, DNAM-1) in comparison to PB NK cells. Dalle et al. 
reported the lack of L-selectin expression by CB NK cells as a contributory factor for 
their unresponsiveness to K562 cells (Dalle et al., 2005). Finally, other researchers 
attributed the reduced CB NK cell function to higher expression of the inhibitory 
receptors NKG2A/CD94, along with a lower expression of granzyme B (Wang et al., 
2007).  
 
Our group also conducted a study that aimed to characterise CB NK cells in comparison 
to PB NK cells (Luevano et al., 2012a). The proportion of CD56bright NK cells was 
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higher in CB than PB thereby contradicting other reports (Dalle et al., 2005, Tanaka et 
al., 2003). CB NK cells expressed higher levels of CD94/NKG2A and lower levels of 
granzyme B, perforin, and Fas-ligand, affecting their killing capacity. CB NK cells 
expressed lower levels of triggering receptors involved in cancer cell ligation including 
DNAM-1 and NKp46. Although there was no difference in the percentage of NKG2D 
expression, mean fluorescence intensity was lower on CB than PB NK cells. CXCR4 
was highly expressed by CB NK cells indicating their tendency to home to the BM. CB 
NK cells degranulated to a level comparable to PB NK cells in response to the K562 
cell line, but were not able to kill K562 cells unless activated with IL-2 (Luevano et al., 
2012a).  
 
1.2.9 Do NK cells have memory? 
Immunological memory is a property of adaptive immune cells in which B and T cells 
display specific recognition of a particular antigen and a robust response upon 
secondary exposure. B and T cells undergo receptor rearrangement and retain long-
lasting immunity for that antigen. Unlike B and T cells, NK cell recognition relies on a 
limited number of germ-line encoded activating and inhibitory receptors. In general, 
NK cell activity is dictated by the signal delivered by inhibitory and/or activating 
receptors triggered by downregulation of MHC expression or upregulation of activating 
ligands by stressed targets. However, evidence of NK cell memory-like properties has 
been recently reported, raising the possibility that NK cells can retain specific memory. 
 
The first example of NK cell memory was demonstrated in a MCMV model by Sun and 
colleagues (Sun et al., 2009). NK cell-deficient mice display elevated rates of viral 
replication. MCMV infected cells express the glycoprotein m157, which is a viral MHC 
class I-like decoy molecule (Adams et al., 2007). In C57BL/6 mice, NK cells express 
Ly49H, which is an activating receptor that signals via ITAM-bearing DAP12 and the 
adapter DAP10. Recognition of m157 by Ly49H+ NK cells results in activation of 
signalling components and production of IL-12 by infected DCs, promoting NK cell 
cytotoxic functions accordingly. Interestingly, Ly49H+ NK cells undergo clonal-like 
expansion, resulting in three times more NK cells in the spleen and ten times more in 
the liver during the first week of exposure. Thereafter, Ly49H+ NK cells undergo a 
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contraction phase, but a pool of long-lived cells persists for several months. Adoptive 
transfer of Ly49H+ NK cells into a naïve host followed by MCMV challenge results in 
a robust anti-viral response against m157 glycoproteins suggestive of NK cell 
immunological memory (Sun et al., 2009). Similarly, many reports have described 
enhanced and selective expansion of CD94/NKG2C+ NK cells during HCMV infection 
(Gumá et al., 2006, Kuijpers et al., 2008). In this context, a higher frequency of 
CD94/NKG2C+ NK cells were detected in HCMV seropositive individuals whereas the 
frequency of this subset in uninfected individuals was very low (1 %) (Gumá et al., 
2004, Gumá et al., 2006). In addition, NK cells were also shown to “remember” 
previous exposure to herpes simplex virus- 2 (HSV-2) antigens by displaying higher 
IFN-! production as compared to naïve NK cells, which mediated anti-viral protection 
(Abdul-Careem et al., 2012).  
 
Further evidence of liver-restricted memory NK cells was observed in mice following 
sensitisation with chemical haptens such as DNFB and oxazolone suggesting an 
antigen-specific response by NK cells. This model was demonstrated by Von Andrian 
and colleagues and was based on hapten-induced contact-hypersensitivity (CHS) 
(O'Leary et al., 2006). It was thought that T cells mediate CHS, however, Rag-deficient 
mice that do not have T cells can develop CHS, which was mediated by NK cells. NK 
cells exposed to hapten persisted for four weeks after initial exposure and could be 
restimulated restrictively by the same antigen. Furthermore, DNFB-sensitised donor 
hepatic NK cells mediate vigorous CHS responses when adoptively transferred into 
naïve Rag2!/!IL2R"c!/! mice (O'Leary et al., 2006). Hapten specific memory was 
mostly mediated by the Thy-1+ and Ly49C/I+ NK cell subsets among hepatic NK cells. 
Yet, it remains unknown why hapten-specific memory NK cells accumulate favourably 
in the liver. Unlike MCMV memory NK cells, liver restricted memory NK cells do not 
undergo clonal expansion but display memory features by exhibiting specificity for the 
sensitising agent. The distribution of these cells resembles invariant NKT (iNKT) cells, 
whereby the homeostasis and survival of these cells is CXCR6-dependent (Paust et al., 
2010). CXCR6 expression by liver restricted memory NK cells allows the cells to 
respond to CXCL16, which is constitutively expressed by liver sinusoids. However, 
CXCR6 expression alone is not sufficient to induce memory features of NK cells, as 20 
% of liver NK cells are CXCR6+ (Geissmann et al., 2005). Thus, CXCR6 expression by 
liver-restricted memory NK cells is required for their persistence, but not for their 
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recognition. Furthermore, hepatic NK cells from viral antigen immunised mice 
(including influenza virus or vesicular stomatitis virus) mediate a sustained delayed 
hypersensitivity response compared to splenic NK cells exposed to viral infection when 
adoptively transferred into naïve Rag2!/!IL2R"c!/! mice (Paust et al., 2010). 
 
In addition, memory-like features of NK cells could be observed following cytokine 
stimulation. Cooper and colleagues showed that NK cells activated with IL-12 and IL-
18 could be detected up to three weeks after transfer into naïve hosts (Cooper et al., 
2009). Interestingly, these NK cells are able to produce higher levels of IFN-! than 
unstimulated NK cells when restimulated with IL-15 and IL-12. Thus, cytokine-induced 
memory-like NK cells display two important characteristics of an adaptive response - 
they are long-lived and they retain the intrinsic capability to respond differently to 
restimulation than naïve NK cells. However, cytokine-induced memory-like NK cells 
have no specificity and do not exhibit enhanced cytotoxicity or proliferation compared 




1.3 Regulation of NK cell functions by cytokines 
NK cell functions are controlled by cytokines. Cytokines are soluble mediators released 
by innate or adaptive immune cells that play a key role in NK cell development, 
activation, expansion, trafficking and survival. Different cytokines trigger different NK 
cell effector functions. NK cells express receptors for several cytokines that confer 
different binding affinities and responsiveness. In particular, cytokines of the common ! 
chain (!c) family including IL-2, IL-7, IL-15 and IL-21 are implicated in NK cell 
function. In addition, NK cells effectively respond to cytokines released by activated 
innate immune cells including IL-12 and IL-18, bridging the innate immune response 
with the adaptive immune response. Table 1.4 summarises the cytokines known to 





Table 1.4 Cytokines that induce biological effects on NK cells 
Cytokine (s)  Source (s) Positive biological effect (s) 
Negative biological 
effect (s) Reference (s) 
IL-2 Activated T cells (TH1) 
NK cell proliferation Expansion of Tregs 
 (Barkholt et al., 
2009, Ghiringhelli et 
al., 2005) 
Induction of LAK Induction of AICD   
IL-7 BM stroma, Fibroblast  
NK cell development 
and homeostasis 
No contribution to NK 
cell cytotoxic function  (Cavazzana-Calvo 
et al., 1996) 
IL-12 DCs and macrophages 






 (Huang et al., 2011, 
Marcenaro et al., 
2005, Smyth et al., 
2000) 
NK cell cytotoxicity    
Upregulation of 






NK cell development 
and survival   
 (Liu et al., 2000, 
Özdemir et al., 
2005, Pillet et al., 
2009, Ranson et al., 
2003) 
NK cell expansion  None 
  
NK cell cytotoxicity     





 (Agaugue et al., 
2008, Bellora et al., 
2010, Dinarello, 
1999, Mailliard et 











NK cell proliferation  Inhibition of IL-15-induced proliferation  (Brady et al., 2004, Burgess et al., 2006) 





production)   




1.3.1 Interleukin-2  
IL-2 was the first interleukin described and was initially called a T cell growth factor. 
This cytokine is primarily released by activated T cells and supports T cell 
differentiation, growth and proliferation. Later on, it was found that IL-2 augments NK 
cell cytotoxic function both in vitro and in vivo. Notably, IL-2 deficient individuals 
develop severe combined immune deficiency (Caligiuri et al., 1993, Henney et al., 
1981).  
 
The IL-2 receptor (IL-2R) complex consists of three subunits: IL-2R", IL-2R# and IL-
2R!. IL-2 binding to IL-2R# and IL-2R!, which are expressed constitutively by all NK 
cells, confers intermediate affinity binding (Fig 1.6). However, CD56bright NK cells 
express the trimeric receptor complex, associated with IL-2R", that leads to high 
affinity binding (Caligiuri et al., 1990). Also, it is worth noting that kinetics of 
association and dissociation of IL-2 to its receptor subunits can vary. IL-2 rapidly 
associates with IL-2R" subunit within seconds, but dissociates in similar kinetic rates. 
Whereas the involvement of both receptors, IL-2R" and IL-2R#, confers fast 
association with IL-2 and slow dissociation, hence provide a stable interaction 
(Waldmann, 1991). The !c is a critical component of this receptor, as it is associated 
with the signal transducing molecule Janus tyrosine-kinase (JAK). Phosphorylation of 
JAK-1 and JAK-3 initiates different signal transducer and activator transcripts (STAT) 
pathways. IL-2 mainly phosphorylates STAT5 (STAT5a and STAT5b), but also 
activates other signalling pathways to a lesser extent including STAT1 and STAT3. 
STAT5 dimerises upon phosphorylation and diffuses into the nucleus to activate 
transcription of target genes (Sugamura et al., 1996). It is noteworthy that IL-2R" by 
itself has low affinity for IL-2 and is devoid of activating signalling components 
(Becknell and Caligiuri, 2005). IL-2R" is upregulated upon stimulation and is also 
expressed by regulatory T cells (Tregs). Thus, IL-2 acts as a regulatory cytokine 
mediating peripheral tolerance, as well as contributing to activation-induced cell death 
(AICD) in some circumstances (Lenardo, 1996). Defects in IL-2 or IL-2R" genes 
results in lymphoproliferative and autoimmune disorders (Sadlack et al., 1995, 
Willerford et al., 1995), whereas IL-2R# deficient mice lack NK cells (Gilmour et al., 
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2001, Suzuki et al., 1997). Thus, IL-2 does not appear to be necessary for NK cell 
development although its intermediate affinity subunit (IL-2R# and IL-2R!) is strictly 
required as IL-15 binding to this subunit drives NK cell development.  
 
In vivo, CD56bright NK cells constitutively express the heterotrimer complex of the IL-2 
receptor. Thus, low concentrations of IL-2 are sufficient to deliver high affinity binding 
to CD56bright NK cells and activation of inflammatory cascades. CD56bright NK cells 
produce relatively high levels of IFN-!, which further stimulates APCs to produce IL-
12 and consequently polarises T cell specific responses (Fehniger et al., 2003). CD56dim 
NK cells can also respond to IL-2, although they require higher concentrations (Cooper 
et al., 2001a). Culture of NK cells in the presence of IL-2 leads to upregulation of 
activation receptors, proliferation and enhanced killing of targets cells. Due to the 
potent effects of IL-2 in immune responses, IL-2 was the first cytokine administered in 
clinical trials in order to enhance NK cell cytotoxicity against tumour cells (Burns et al., 
2003, Caligiuri et al., 1993, Rosenberg et al., 1987). 
 
 
Figure 1.6 IL-2 receptors and STAT5 signalling components. IL-2R" has a very 
short cytoplasmic tail that is not attached to signalling components whereas IL-2R# and 
IL-2R! are capable of signal transduction (Waldmann, 2006). License obtained from 
















IL-7 is a !c cytokine that also shares the IL-2/IL-15R# subunit. IL-7 promotes 
maturation and proliferation of NK cells. The role of this cytokine in NK cell 
maturation was assessed by experiments that aimed to generate NK cells from CD34+ 
HSC, as it was shown that IL-7 alongside IL-2 and stem cell factor (SCF) mediates 
maturation of committed NK cells (Cavazzana-Calvo et al., 1996). 
 
1.3.3 Interleukin-12 
Il-12 is a heterodimeric cytokine also named NK stimulating factor (NKSF). Initially, it 
was observed that IL-12 was produced by transformed human B-cell lines and found to 
stimulate the generation of lymphokine activated killer (LAK) cells. IL-12 is produced 
by APCs including macrophages and DCs, and it modulates functions of both innate 
and adaptive immune cells. This cytokine stimulates the transcription and production of 
IFN-! that promotes TH1 cell differentiation. IL-12 also promotes the production of 
other cytokines such as GM-CSF and TNFs. Moreover, IL-12 enhances NK cell 
cytotoxic function against many resistant tumour targets (Gately et al., 1994, Trinchieri, 
1995). 
 
The IL-12 receptor (IL-12R) consists of two subunits: IL-12R#1 and IL-12R#2. NK 
cells and resting T cells constitutively express IL-12R#1, whereas IL-12R#2 expression 
is induced by cytokines (Fig 1.7) (Presky et al., 1996, Wang et al., 2000). The IL-12R is 
also expressed by DCs and B cell lines. IL-12 interaction with the IL-12R#1 and IL-
12R#2 subunits results in activation of several Jak/STAT pathways including STAT1, 
STAT3 and STAT5 (Presky et al., 1996). Nonetheless, IL-12 primarily activates the 
STAT4 pathway which appears to be vital for T cell and NK cell functions, as IL-12 
activity entirely abrogated in STAT4-deficient mice (Kaplan et al., 1996). Interestingly, 
activation of the STAT4 signalling pathway by IL-12 leads to the transient activation of 
NK cells. This results in increased production of ROS and induction of NK cell 
apoptosis in the case of prolonged stimulation (Huang et al., 2011). 
 
Besides the central role that IL-12 has in NK cell function, IL-12 has also been 
implicated in NK cell development and differentiation (Loza and Perussia, 2004). IL-12 
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has been shown to enhance the cytotoxicity of NK cells generated in vitro. NK cells 
differentiated from CD34+ CB HSCs secrete significantly higher levels of TNF-" and 
GM-CSF when stimulated with combinations of IL-12 and IL-15 or IL-21 (Bonanno et 
al., 2009). This was also confirmed by our group in studies have shown that NK cells 
generated from CB HSC in vitro exhibited an increased cytotoxicity and cytokine 
secretion after IL-12 stimulation (Luevano et al., 2014). A recent study showed that the 
addition of low concentrations of IL-12 to ex vivo differentiated CB NK cells promotes 
the expression of L-selectin and KIR, but conversely reduces the expression of CXCR3 
(Lehmann et al., 2014). Overall, IL-12 is a powerful enhancer of anti-tumour activities 
including: (i) NK cell production of inflammatory cytokines, (ii) NK cell killing of 
tumour targets by the perforin-dependent pathway, (iii) maturation of DCs and priming 
of adaptive responses accordingly (Agaugue et al., 2008, Smyth et al., 2000). However, 
systemic administration of IL-12 as an immunotherapeutic drug often results in 
significant toxicities (Car et al., 1999, Nastala et al., 1994).  
 
 
Figure 1.7 Activation of STAT4 pathway by IL-12. IL-12 produced by 
macrophages and DCs binds to constitutively expressed heterodimer IL-12 receptor on 
NK cells leading to phosphorylation of Tyk-2 and Jak2 and activation of STAT4 
signalling pathway (Trinchieri, 2003). License obtained from Nature Publishing Group; 
3505950881267.  
1.3.4 Interleukin-15 
IL-15 is essential for the main functions of NK cells including development, 












Mrozek et al., 1996, Ranson et al., 2003). IL-15 shares many physiological properties 
with IL-2 and also binds to the IL-2R# and IL-2R! subunits to initiate signalling 
cascades that are similar to those induced by IL-2 (Carson et al., 1994). However, IL-15 
is more ubiquitous than IL-2 as many cell types including DCs, macrophages, and 
thymus and BM stromal cells produce it. As such, IL-15 serves a crucial role in NK cell 
development and homeostasis. IL-15 possesses its own receptor, IL-15R", that unlike 
the IL-2R" confers high affinity binding of IL-15. The IL-15R" mediates several modes 
of interaction with IL-15. Although it was proven that IL-15 can be trans-presented via 
IL-15R" on macrophages and DCs to NK cells (Koka et al., 2004), there is evidence 
that IL-15 could be also presented in “cis” by the IL-15R" on NK cells in an autocrine 
manner (Fig 1.8) (Zanoni et al., 2013). In addition, IL-15R" can form a trimeric 
receptor complex by association with IL-2/15R# and IL-2/15R! mediating high affinity 
binding to IL-15 (Ring et al., 2012). 
 
The similarities between IL-2 and IL-15 raised an important question as to “how two 
cytokines sharing similar receptors and signalling pathways induce distinctive 
biological effects?” Indeed, while IL-15 predominantly induces NK cell survival and 
proliferation by upregulating the anti-apoptotic gene Bcl-2 (Ranson et al., 2003), IL-2 
seems to potentiate NK cell activity, but also induces cell death (Waldmann, 2006). The 
clear difference between the two cytokines is their unique " subunits. The IL-2R" unit 
has a short cytoplasmic tail (13 residue) and it is not known whether it attaches to any 
signalling component. In contrast, the IL-15R" subunit contains 43 residues in its 
cytoplasmic domain and it can recruit other signalling molecules such as the TNF-
receptor-associated factor 2 (TRAF2) and Syk (Becknell and Caligiuri, 2005, Bulfone-
Paus et al., 1999). In addition, the mechanism of action seems to be different between 
these two cytokines. In vitro, IL-2R# and IL-2R! are expressed by T cells and the 
addition of IL-2 results in induction of IL-2R" and IL-2 receptors that are closely 
associated with each other (Damjanovich et al., 1997). Conversely, IL-15 is presented 
to NK cells by DCs mainly in a membrane-bound form via the IL-15R" to form an 
immunological synapse (Dubois et al., 2002). This results in the secretion of IFN and 
stimulation of nuclear factor-$B (NF-$B) (Waldmann, 2006). The IL-15R"/IL-15 
complex can be recycled in endosomal vesicles and expressed for many days. 
Moreover, this complex presents IL-15 to cells expressing IL-2R# and IL-2R!, but not 




Due to the potent effect of IL-15 on NK cells, this cytokine has become a potential 
candidate for NK cell-based therapy. In this regard, IL-15 may mediate many functions; 
promotion of NK cell effector functions, maintenance of mature NK cells and 
peripheral homeostasis, as well as the differentiation of NK cells from haematopoietic 
progenitors in the context of HSCT.  
Figure 1.8 Mechanisms of IL-15 action via IL-15R! and IL-2/15R"# receptors. 
IL-15 presented in a membrane bound form via the IL-15R" subunit (trans-
presentation) by APCs to IL-2/15R#! on NK cells. IL-15 can also be delivered as a 
soluble protein directly to NK cells (cis-presentation). “This figure has been reproduced 




























IL-18 is a member of the IL-1 cytokine family that was initially known as an IFN-! 
inducing factor (Dinarello, 1999). IL-18 was identified in mouse serum after the 
administration of endotoxins and was found to share similar properties with IL-12 
(Okamura et al., 1995). IL-18 is closely related to IL-1#, however, while IL-1# 
expression is absent in healthy individuals, monocytes and epithelial cells of healthy 
individuals express IL-18 abundantly. Macrophages and DCs contain IL-18 precursors 
that are cleaved in a caspase-dependent manner and released outside the cell upon 
stimulation. In this context, it was shown that the interaction between immature DCs 
and NK cells leads to cytoskeleton rearrangement, increasing Ca2+ influx and followed 
by accumulation of secretory IL-18 at the DC/NK cell synapse (Semino et al., 2005). 
IL-18 induces the production of IFN-! by T cells and NK cells (Nakanishi et al., 2001). 
Moreover, IL-18 induces upregulation of adhesion molecules and chemokine receptors 
by NK cells, and enhances cytotoxicity of NK cells (Mailliard et al., 2005). 
 
The IL-18 receptor consists of two subunits, IL-18R" and IL-18R# (Fig 1.9). The alpha 
subunit plays key role in responses to IL-18, as IL-18R"-deficient mice do not display 
any response to IL-18 and are unable to initiate signalling via this pathway (Hoshino et 
al., 1999). The expression of IL-18 receptors is largely regulated by IL-12. In this 
context, IL-12 promotes the induction of IL-18R", whereas IL-18 upregulates IL-
12R#2 thereby providing a positive loop of stimulation by the two cytokines. However, 
NK cells can be stimulated independently by each cytokine, in particular CD56bright NK 
cells, as they constitutively express IL-12R#2 and IL-18R" (Kunikata et al., 1998, 
Wang et al., 2000). Upon binding of IL-18 to its receptor, the NF-$B signalling 
pathway is activated via the MyD88 and IRK signal transduction molecules (Takeuchi 
et al., 2000). The outcome of signalling is NF-$B binding to the IFN-! promoter within 
the nucleus to enhance transcription of IFN-! (Kojima et al., 1999).  
 
IL-18 participates in the development of TH cell responses via the production of 
cytokines. Mailliard and colleagues showed that IL-18 stimulation also induces 
“helper” function of NK cells (Mailliard et al., 2005). Although IL-18 activated NK 
cells do not secrete IFN-! spontaneously, induction of CCR7 expression allows them to 
migrate to LN. Thereby, exposure of NK cells to DC-derived cytokines (IL-12 and IFN-
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") as well as T cell-derived cytokines (IL-2) leads to production of high levels of IFN-! 
by NK cells. Subsequently, NK cells are able to polarise the TH response towards IFN-! 
production by TH1 cells (Agaugue et al., 2008, Mailliard et al., 2005). On the other 
hand, IL-18 has been also found to induce TH2 responses by facilitating the production 
of IL-4 (Pollock et al., 2003). 
 
IL-18 enhances NK cell cytotoxicity by upregulating the expression of FasL on NK 
cells (Hashimoto et al., 2003). Thus, IL-18 has been implicated as a mediator of tumour 
regression and as a potential immunotherapeutic cytokine. Intravenous administration 
of IL-18 to patients with solid tumours was well-tolerated with a significant response 
observed in a patient who demonstrated 69 % regression of tumour lesions (Robertson 
et al., 2006). However, a phase II clinical trial that aimed to treat metastatic melanoma 
concluded that IL-18 alone had limited anti-tumour activity (Tarhini et al., 2009). 
Currently, IL-18 is used to augment rituximab activity, in the treatment of non-
Hodgkins lymphoma, by enhancing IFN-! production and the ADCC pathway 
(Srivastava et al., 2013). 
 
Figure 1.9 Activation cascade of the NK-$B pathway triggered by IL-18. IL-18 
produced by activated macrophages and DCs binds to IL-18 heterodimer receptor 
activating the components of the NK-$B pathway. “This figure has been reproduced 

















IL-21 is a !c cytokine that is structurally similar to IL-2 and IL-15. The IL-21R is a 
homologue of the IL-2/IL-15R# subunit. IL-21 has both activating and inhibitory 
effects on lymphoid cells, as it enhances CTL function as well as inhibits antibody 
production by B cells. IL-21 also induces pleiotropic effects on NK cells. While IL-21 
activation increases the size of NK cells and granule expression, it reduces their 
viability and proliferative capacity. Nonetheless, IL-21 potentially induces terminal 
maturation of NK cells associated with enhanced anti-tumour effects and cytokine 
secretion (Brady et al., 2004). The use of IL-21 for cancer immunotherapy is currently 
being assessed in a phase II clinical trial to treat non-Hodgkin’s lymphoma, metastatic 
melanoma and renal cell carcinoma (clinicaltrials.gov, trial numbers; NCT00336986, 
NCT00389285 and NCT00347971) (Frederiksen et al., 2008).   
1.4 Cancer immunotherapy 
Immunotherapy strategies aim to enhance the recipients’ immune response to help clear 
cancerous cells. Recipients may receive cytokine therapy to boost the function of their 
own NK cells and CTLs or receive direct cellular therapy. Cells that have the capacity 
to fight tumours have the potential to be expanded and adoptively transferred. In 
addition, in the context of haematological malignancies, patients may receive HSCT 
along with ex vivo expanded NK cells whereby both adoptively transferred and 
reconstituted NK cells mediate anti-tumour effects.  
 
1.4.1 Haematopoietic stem cell transplantation 
Early work in animal models revealed that irradiated recipients could be rescued by the 
transplantation of BM cells from syngeneic mice or with stored autologous cells. 
Thomas and colleagues pioneered haematopoietic stem cell transplantation (HSCT) by 
infusing BM from an identical twin to treat a patient who suffered from leukaemia 
(Thomas et al., 1959). After the identification of HLA in 1960, the transplantation of 
allogeneic HSC became more feasible. HLA genes are inherited as haplotypes from 
parents giving 1 in 4 probabilities of two siblings to be HLA-identical. In 1970, Thomas 
and colleagues treated patients suffering from end-stage leukaemia using BM of HLA-
identical siblings establishing the foundation of HSCT (Thomas et al., 1977). Although 
HSCT is now mainly used to treat haematological and lymphoid cancers, it is also used 
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to treat other diseases including immunodeficiency, autoimmune disorders and 
anaemia. HSCs can be obtained from the host prior chemotherapy (autologous) or from 
a suitable HLA-matched donor (allogeneic). Treatment with autologous HSCs is safe, 
although autologous HSCT is not curative and is only used to prolong the life of 
patients. In contrast, the use of allogeneic HSC sources offers better outcomes in 
treating haematological malignancies although it is associated with complications 
(Copelan, 2006).  
 
1.4.1.1 Preparative regimens 
The objectives of preparative regimens are (i) to destroy the BM of the recipient prior 
transplantation and to suppress the recipient’s immune system; (ii) to create space 
within the recipient BM for donor HSC engraftment; (iii) to destroy cancer cells and 
mediate an anti-tumour mechanism through presentation of tumorigenic antigens by 
APCs (Lake and Robinson, 2005). Several conditioning regimes are used to eradicate 
tumour cells and suppress the immune system. Total body irradiation (TBI) is a 
myeloablative approach that effectively eliminates cancer cells, however it is associated 
with toxicity and high transplantation related mortality. This led to the development of 
reduced intensity regimens, whereby the elimination of cancer cells depends primarily 
on the graft (Shimoni and Nagler, 2004). After transplantation, successful outcomes are 
associated with the ability of the graft to generate new lymphoid and myeloid cells, 
which is referred to as immune reconstitution. This is a very important determinant of 
HSCT outcome as slow immune reconstitution results in increased susceptibility to 
infections, especially in the myeloablative regime setting (Welniak et al., 2007).  
 
1.4.1.2 Haematopoietic stem cell sources 
BM is a rich source of HSC and was the only HSC source used until the 1990s. BM is 
collected by aspiration from iliac crests of donors under general anaesthesia and then 
infused into patients. One of the major complications after BM transplantation (BMT) 
is the high incidence of graft-versus-host disease (GvHD). Hence, T cell depletion 
(manipulated graft) is often performed, however, it may increase the risk of relapse and 
affect survival rates when compared to non-manipulated BM graft (Copelan, 2006, Lan 




As compared to BM, PB contains low numbers of HSC. However, HSCs can be 
collected in large quantities and harvested by apheresis following granulocyte-colony 
stimulating factor (G-CSF) infusion, a procedure which is also referred to as 
mobilisation (Bensinger et al., 2001, Schmitz et al., 1995). Mobilised PB (mPB) using 
G-CSF is currently a gold standard procedure because of the higher numbers of HSC 
obtained by apheresis, which promotes faster engraftment of neutrophils and earlier 
lymphocyte reconstitution. However, the incidence of chronic GvHD after mPB 
transplantation compared to BMT may be higher (Schmitz et al., 2005). 
 
The first successful cord blood transplantation (CBT) was performed in a patient with 
Fanconi’s anaemia in 1988 using cryopreserved CB from a healthy HLA matched 
sibling (Gluckman et al., 1989). Nowadays, CB is being increasingly used as an 
alternative source of HSC for transplantation. It has clinical advantages over other 
sources of HSC including off-the-shelf availability reducing waiting time for recipients. 
Indeed, more than 50 CB banks worldwide have been established with around 606,000 
CB units available from registries (http://www.bmdw.org/). Furthermore, CBT allows 
for less stringent HLA-matching than other sources of HSC (Wagner et al., 1996) and 
importantly it shows reduced incidence and severity of GvHD whilst preserving the 
graft-versus-leukaemia (GvL) effect (Rocha et al., 2001). However, CB contains a 
lower number of HSC than BM or mobilised mPB resulting in slow immune 
reconstitution rendering the recipient susceptible to infections (Rocha et al., 2001, 
Laughlin et al., 2004, Gluckman, 2009). One of the main causes of CBT-related 
morbidity is CMV infection. CMV infection is reactivated in CMV seropositive CB 
recipients early after transplantation in whom no protective T cell responses have yet 
been develped (McGoldrick et al., 2013).  
 
Early CBT procedures were performed only for children mainly because CB contains a 
low number of HSCs. Nevertheless, several strategies have been explored in order to 
increase the HSC dose in order to enable CBT to be performed in adult patients. These 
include infusing two CB units (Barker et al., 2005) or ex vivo expansion of CB HSC 
using mesenchymal stromal cells (de Lima et al., 2012), hence promoting faster 
engraftment. In addition, CB cells can be injected directly into the bone of the recipient 
to deliver better engraftment (Frassoni et al., 2008). In this context, it was shown in 
animal models that less than 20 % of HSC injected intravenously are able to reach the 
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BM (Cui et al., 1999). Hence, direct injection of CB into the BM prevents trapping of 
progenitors within tissues that do no support haematopoiesis and improves colonisation 
of HSC within the recipient BM (Brunstein and Wagner, 2006). In addition, another 
strategy to improve the outcome of CBT has been developed by co-infusion of CB 
alongside with purified HSCs from a haploidentical donor. This approach resulted in 
faster short-term and long-term engraftment and immune reconstitution (Fernández, 
2009, Fernández et al., 2005) 
 
Immune reconstitution varies among lymphocyte subsets after HSCT. In general, NK 
cells reconstitute first within a month after transplant. Within T cell subsets, the CD4+ T 
cell count reaches normal levels within 9 to 12 months, whereas reconstitution of CD8+ 
T cells begins from 4 months post-transplant and reaches normal values within 9 
months. B cell count remains low, as it takes up to 12 months for B cells to recover 
post-transplantation (Petersen et al., 2003). After CBT, NK cell reconstitution in the 
host occurs as early as 2 months with detectable lytic function within one month. NK 
cells are therefore believed to play a key role in mediating GvL after CBT (Thomson et 
al., 2000, Béziat et al., 2009).  
 
1.4.1.3 Early and delayed complications 
Patients who undergo HSCT are susceptible to several complications due to immune 
deficiency as a result of the use of immunosuppressive drugs or due to delayed immune 
reconstitution. There are several complications that occur early after transplantation 
including mucositis (fungal infections) (Spielberger et al., 2004), sinusoidal obstruction 
syndrome (hepatomegaly, jaundice and fluid retention) (DeLeve et al., 2002), 
transplantation related lung disease (Cooke and Yanik, 2004), and viral infections 
including CMV (Boeckh et al., 2003) and EBV (Brunstein et al., 2006). Graft failure is 
another major complication that may occur after allogeneic transplantation. The 
incidence of graft failure increases in HLA-mismatched transplantation, unrelated 
transplantation or in patients treated with reduced intensity conditioning regimens. 
Graft failure corresponds to the absence of engraftment of donor cells after HSCT and 
is associated with graft rejection by the recipient immune system, mainly by recipient T 




Donor cells can attack recipient cells in a condition known as graft-versus-host disease 
(GvHD) (Ferrara et al., 2009) . This disease is initiated when APCs prime donor T cells 
resulting in T cell activation and expansion and is associated with cytokine storm 
(Ferrara and Reddy, 2006). Donor activated T cells attack the skin, gut and liver of the 
recipient causing debilitating injuries. The incidence of GvHD, however, decreases the 
probability of tumour relapse since donor T cells also attack residual leukaemia cells 
remaining after chemotherapy (Apperley et al., 1986, Mackinnon et al., 1995, Kolb et 
al., 1995). GvHD can be treated with corticosteroids; yet, this could result in 
immunodeficiency and increased susceptibility to infections. Although GvHD occurs 
mainly as a result of HLA-mismatch, recipients of HLA-matched sources may still 
develop GvHD because of minor histocompatibility antigen (MiHA) mismatches 
between donor and recipient (Warren et al., 2012). Other risk factors including age and 
graft source may contribute to the increased incidence of chronic GvHD. In addition, 
the incidence of secondary cancers increases after transplantation, which could be a 
result of the type of chemotherapy used before transplantation (Curtis et al., 1997, 
Metayer et al., 2003).  
 
1.4.1.4 Role of NK cells in haematological stem cell transplantation 
NK cells have been shown to be key effectors of the GvL effect in HSCT (Ruggeri et 
al., 2002, Ruggeri et al., 2005). Ruggeri et al. reported the efficacy of alloreactive NK 
cells in inducing an anti-tumour effect in haematopoietic transplants. NK cells with 
KIR-ligand incompatibility (HLA-C1, C2 or Bw4) were able to lyse recipients’ APC 
and hence reduced the incidence of GvHD, in addition to leukaemia cell lysis providing 
GvL. Acute myeloid leukaemia-engrafted NOD-scid mice infused with alloreactive NK 
cells have been shown to be able to clear leukaemia cells, indicating their role in the 
GvL effect (Ruggeri et al., 2002, Ruggeri et al., 2005). However, the beneficial effect of 
KIR-ligand incompatibility in mediating NK cell alloreactivity has remained 
controversial, as several groups have not observed any influence of KIR mismatch. This 
may be due to differences in transplantation procedure, graft source, underlying 
malignancy or T cell manipulation (T cell depletion or repletion) (Davies et al., 2002, 




1.4.2 Tumour immune evasion 
Cancerous cells have evolved mechanisms to evade the effector functions of immune 
cells. Tumour cells can produce immunosuppressive cytokines such as TGF-# or IL-10 
to suppress effector mechanisms, and thereby establish an immunoprivileged 
microenvironment (Aruga et al., 1997, Mamessier et al., 2011). Tumour cells often 
skew the adaptive response towards TH2 immunity which is less effective in combating 
tumours (Aruga et al., 1997). Moreover, tumour cells suppress DC maturation by 
altering the expression of IL-6, IL-10 and GM-CSF (Morse et al., 2002). In some 
malignancies, regulatory T cells expand and suppress the specific function of TH1 cells 
and CTL (Yamaguchi and Sakaguchi, 2006). Furthermore, tumour cells downregulate 
or shed NKG2D ligands such as MICA/MICB or UL-16 binding protein and evade NK 
cell effector functions (Salih et al., 2002, Waldhauer and Steinle, 2006). Furthermore, 
malignant cells in certain conditions eliminate effector immune cells by AICD or via 
FasL (Saff et al., 2004).  
 
1.4.3 NK cell-based therapy 
Various strategies have been developed to overcome an inadequate anti-tumour 
immune response. In this context, NK cells provide a potential cellular source for 
cancer immunotherapy. NK cells induce direct killing of tumour cells and assist with 
the differentiation of antigen-specific anti-tumour responses (Fig 1.10). The following 
section discusses strategies that have been implemented to exploit NK cell effector 





Figure 1.10 NK cell anti-tumour responses. NK cell effector functions are 
triggered by cells that have downregulated MHC class I expression or upregulated 
stress ligands. Tumour cells are killed directly by exocytosis of cytotoxic granules, 
death receptor-pathway activation or ADCC. Cytokines released by DCs trigger the 
production of inflammatory cytokines such as IFN-! and TNF-" by NK cells that, in 
turn, enhance further activation and maturation of DCs. Mature DCs uptake and present 
tumour-derived antigens to naïve T cells that leads to T cell differentiation into effector 
TH cells and CTLs. The production of IFN-! by NK cells also primes T cells directly. 
While CTLs mediate direct elimination of tumour cells, interactions between T helper 
cells and B cells results in the production of tumour antigen specific-antibodies (Cheng 
et al., 2013). License obtained from Nature Publishing Group; 3397701357939.        
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Table 1.5 NK cell-based therapy strategies 
NK cell-based therapy Effect(s) Limitation(s) 
Stimulation of autologous NK cells with cytokines (IL-2, IL-
12, IL-15, IL-18 and IL-21), adoptive transfer of ex vivo 
stimulated NK cells with or without systemic administration 
of cytokines 
Upregulation of activating receptors and adhesion 
molecules and enhanced NK cell functionality associated 
with upregulation of perforin and granzymes. 
Toxicity of cytokine 
administration, suppression of 
NK cell activity by self-MHC 
molecules Stimulation of autologous NK cells with antibodies (IFN type 
I, KIR) 
NK cell limited anti-tumour activity against many types of 
tumours  
Adoptive transfer of un-stimulated donor NK cells NK cell alloreactivity mediated by KIR mismatch 
Cells cannot be maintained in 
culture and difficult to access 
the same donor for several 
infusions 
Adoptive transfer of ex vivo cytokine expanded allogeneic 
NK cells (IL-15) 
Enhanced cytotoxicity, large-scale expansion of NK cells 
to allow multiple infusions 
Exhaustion and cytokine 
addiction 
Systemic administration of tumour specific monoclonal 
antibodies stimulating the ADCC pathway 
Efficient killing of Ab-coated cells by ADCC  
Drug toxicity Many drugs are in use; Rituxumab to treat non-Hodgkin’s 
lymphoma (NHL) patients and Trastuzumab/Herceptin to 
treat metastatic breast and gastric carcinoma patients 
Adoptive transfer of ex vivo expanded NK cell lines 
Enhanced killing capacity and cytokine production by NK 
cells Rejection by recipient’s 
immune system 
Large-scale production of NK cells 
Adoptive transfer of genetically modified NK cells 
(upregulation of activating receptors or suppression of 
inhibitory receptors by interference with transcription genes)  
Effective killing of tumour cells and enhanced signalling 
via activating receptors 





1.4.3.1 Autologous NK cells 
Initial studies proposed that NK cell anti-tumour activity could be enhanced by 
systemic administration of cytokines. Administration of IL-2 (Burns et al., 2003, 
Rosenberg et al., 1987), IL-12 (Atkins et al., 1997), IL-18 (Nakamura et al., 2000), IL-
21 (Frederiksen et al., 2008) and type I IFN (Kantarjian et al., 1995) stimulated the 
production of host LAK cells. Cells displayed enhanced cytotoxicity, upregulated 
adhesion molecules and activating receptors, increased expression of perforin, FasL and 
TRAIL, and produced increased amounts of inflammatory cytokines. Despite the 
greater NK cell cytotoxicity, these studies showed limited success and life-threatening 
toxicities (Smyth et al., 2004). A phase I clinical trial that tested the safety and 
feasibility of using a Heat shock protien-70 peptide and IL-2 ex vivo activated 
autologous NK cells to treat colon and lung cancer showed enhanced cytotoxic function 
of NK cells (Krause et al., 2004). However, in IL-2 based trials, expansion of Tregs was 
observed that resulted in the induction of AICD and inhibition of NK cell effector 
function against malignant cells. Accordingly, this strategy was optimised by using 
adoptive transfer of ex vivo IL-2 activated NK cells showing better outcomes than the 
systemic administration of IL-2 (Barkholt et al., 2009). Recently, it was shown by 
Miller and colleagues that depletion of Tregs using IL-2 diphtheria toxin before the 
infusion of ex vivo IL-2 activated NK cells enhances their expansion in AML patients 
by up to 1000 NK cells/µL (Bachanova et al., 2014). Similarly, transfer of ex vivo 
expanded autologous NK cells with IL-15 and hydrocortisone resulted in effective anti-
tumour responses against lung cancer cells in a mouse model. In this model, high doses 
of IL-15 were required for effective elimination of cancer cells where IL-15 was trans-
presented in a membrane-bound form via the IL-15R! leading to enhanced tumour 
immunosurveillance in vivo (Kobayashi et al., 2005).  
 
Although the use of autologous NK cells together with the systemic administration of 
cytokines shows considerable success, this strategy has several limitations. First, the 
administration of cytokines results in toxicity and cytokine-induced NK cell apoptosis. 
Second, the cytotoxicity of NK cells against tumour cells observed in vitro was not 
reflected in vivo. In this context, the effector function of autologous NK cells is 
inhibited by interaction with self-MHC molecules on leukaemia targets (Miller et al., 
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2005). Accordingly, allogeneic NK cell-based therapies may provide a better option 
than autologous NK cells in terms of providing an anti-tumour effect. 
 
1.4.3.2 Allogeneic NK cells 
Allogeneic NK cells offer greater cytotoxicity than autologous NK cells and have been 
shown to be effective at controlling AML relapse (Miller et al., 2007, Miller et al., 
2005, Ruggeri et al., 2002). Allogeneic NK cells induce killing of leukaemia blast when 
MHC class I alleles on target cells are incompatible with KIR epitopes expressed by 
NK cells (Ruggeri et al., 2002, Ruggeri et al., 2005). Currently, criteria for selection of 
haploidentical donors with KIR type mismatches against the recipient’s MHC class I 
have been established (Pende et al., 2009). In addition, allogeneic NK cells have been 
shown to be potent against solid tumours. This strategy has proven to be safe and 
effective to treat several types of cancers including metastatic melanoma, renal cell 
carcinoma, Hodgkin’s disease and poor-prognosis AML (Miller et al., 2005). 
Furthermore, allogeneic NK cells can be expanded in vitro. Allogeneic NK cells 
expanded with IL-15 and hydrocortisone are being tested for the treatment of non-small 
cell lung carcinoma in a phase I safety clinical trial. Expanded allogeneic NK cells have 
been shown to be safe and effective for the treatment of adenocarcinoma and squamous 
cell carcinoma (Iliopoulou et al., 2010). Thus, the use of IL-15 with allogeneic NK cells 
could provide a good basis for future immunotherapy. Unlike IL-2, IL-15 activated NK 
cells survive the methylprednisolone treatment promoting potential use of this cytokine 
in patients treated with steroids (Chiossone et al., 2007). 
 
1.4.3.3 Antibody-based NK cell therapy 
CD16 expression by NK cells enables them to bind to antibody-coated targets initiating 
the ADCC pathway that eventually results in elimination of target cells. Antibody-
based drugs are widely used in cancer therapy. In particular anti-CD20 (Rituxumab) is 
used to treat non-Hodgkin’s lymphoma (Maloney et al., 1997), anti-HER2 
(Trastuzumab) is used to treat metastatic breast cancer and gastric carcinoma (Hofmann 
et al., 2008, Pegram et al., 1998) and anti-CD52 (Alemtuzumab) is used to treat B-CLL 
and GvHD post-HSCT (Ratzinger et al., 2003). Antibody-based therapies have been 
modified to reduce toxicity by humanisation of antibodies and alleviation of 
complement activation (Alderson and Sondel, 2011). In addition, the anti-tumour effect 
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mediated via the ADCC pathway could be enhanced by co-administration of cytokines, 
TLR agonists or using antibodies that stimulated NK cell activating receptors or block 
NK cell inhibitory receptors (Alderson and Sondel, 2011, Iannello and Ahmad, 2005). 
 
In MHC class I expressing tumour cells, effector functions of autologous NK cells are 
often inhibited by KIR. Thus, strategies to block KIR expression using antibodies have 
been developed to potentiate NK cell cytotoxicity (Romagné et al., 2009). The use of 
anti-KIR (IPH2101) is currently being tested in a phase I clinical trial to treat 
relapsed/refractory multiple myeloma (clinicaltrials.gov, trial number; NCT00552396) 
(Benson et al., 2012).  
 
1.4.3.4 NK cell lines 
There are several immortalised NK cell lines that are able to mediate anti-tumour 
activity. These include NK-92, KHYG-1, NKL and NKG. Although the NK-92 cell-line 
lacks expression of KIR, it is able to induce target killing by exocytosis and is the only 
cell line that has received FDA approval. NK-92 has been tested as a therapy for renal 
cell carcinoma and advanced malignant melanoma and has been demonstrated to be 
beneficial and safe (Tonn et al., 2001). KHYG-1 and NKL showed greater anti-tumour 
activity than NK-92, however, administration of these cell lines into human remains to 
be tested (Cheng et al., 2011, Suck et al., 2005). The main advantage of using NK cell 
lines is the ability to maintain their expansion in vitro under good manufacturing 
practice (GMP) conditions, thereby yielding large-scale NK cell products for NK cell-
based immunotherapy.  
 
1.4.3.5 Genetic manipulation of NK cells 
Genetic manipulation of NK cells could be an effective approach to mediate specific 
NK cell anti-tumour effects against different targets. This approach involves genetic 
transfer of chimeric receptors specific for an antigen or manipulating the expression of 
activating and inhibitory receptors. For example, the transduction of a CD19 chimeric 
receptor into NK cells enhanced NK cell killing capacity against malignant B cells 
(Imai et al., 2005). Similarly, the genetic modification of the NK-92 cell line using a 
chimeric receptor that contains a CD20-specific fragment increases NK cell 
cytotoxicity against CD20+ targets (Müller et al., 2008). This approach has several 
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limitations including the use of murine derived chimeric receptor that could trigger the 
host immune response, the persistence of genetically modified NK cells after adoptive 
transfer and limited specificity of the anti-tumour activity by NK cells being mediated 
by the transduced receptors. 
 
1.4.3.6 NK cell differentiation from haematopoietic stem cells 
Over the two past decades, models aiming to investigate NK cell differentiation from 
HSCs have been established. The main purpose of these models was to study NK cell 
ontogenesis. However, the establishment of these models has also proven to be useful to 
generate high numbers of NK cells in vitro. HSCs can be obtained from different 
sources including BM (Miller et al., 1994, Mrozek et al., 1996), mPB (Yoon et al., 
2010), human embryonic HESCs (Woll et al., 2009) or CB (Luevano et al., 2012b, 
Spanholtz et al., 2010). In these protocols, the BM microenvironment is provided by the 
addition of cytokines such as IL-7, IL-15, SCF and Flt3L, which are involved in 
commitment of HSCs to the lymphoid lineage and differentiation of progenitors into 
NK cell precursors. This approach is promising, as large number of NK cells can be 
generated from fresh or frozen HSCs after only a few weeks of culture (Luevano et al., 
2014). However, the use of in vitro generated NK cells for clinical application is 
associated with several obstacles. Most protocols use animal-derived sera and cytokines 
in addition to feeder cell lines that currently makes them unsuitable for clinical use. 
 
CB CD34+ HSCs appear to be the most promising HSC source for large-scale 
production of NK cells. Different groups have described distinct protocols to generate 
NK cells from CB CD34+ HSCs. Perez and colleagues generated NK cells with high 
expression of NKG2D, perforin, NKp46 and high cytotoxicity (Perez et al., 2006). 
Similarly, Grzywacz et al. produced NK cells with high expression of NKp44 and 
NKp30 that exhibited a killing capacity of almost 50 % of K562 at an effector to target 
ratio of 5 to 1 (Grzywacz et al., 2006). Other groups successfully generated NK cells 
from CB CD34+ HSCs with varied purity, phenotype and cytotoxicity which could have 
resulted from using different feeder layers and cytokines in different protocols 
(Bonanno et al., 2009, Frias et al., 2008, Haddad et al., 2004, Luevano et al., 2014). 
Spanholtz et al. established a GMP cytokine-based culture-system for the expansion of 
NK cells from fresh or frozen CB CD34+ HSCs using clinical-grade reagents 
! "#$%&'(!)!
! 75 
(Spanholtz et al., 2010). With purity exceeding 95 %, 3-log NK cell expansion from 
frozen CB CD34+ HSCs and 4-log NK cell expansion from fresh CB CD34+ HSCs 
could be achieved. NK cells generated using this approach express high levels of 
NKG2D and NCRs and are able to kill melanoma and myeloid cell lines, as well as 
primary AML cells in vitro. The generated NK cells are CD56+CD16+ with up to 60 % 
being NKG2A+ and 10 % KIR+, with only a minor population being NKG2A!KIR!. As 
NK cells were generated in 24-well plates, the same group has modified the protocol 
into a fully closed two-step culture system for clinical use (Spanholtz et al., 2011). 
Firstly, cryopreserved CB units were thawed and then CD34+ HSCs were enriched 
using a closed CliniMACS system. Secondly, automated bioreactors (gas-permeable 
culture bags) were used to generate NK cells in a feeder-free system as shown 
previously by Sutlu et al. (Sutlu et al., 2010). The purity of the final product was 90 % 
with a 2000-fold expansion of NK cells and the generated NK cells express NCRs and 
showed enhanced cytotoxic activity against K562 cells (Spanholtz et al., 2011). In 
addition, Shah and colleagues developed a protocol for large-scale expansion of CB NK 
cells using K562-derived artificial APCs (aAPCs) as a feeder layer (Shah et al., 2013). 
The use of aAPC-expanded CB NK cells following autologous HSCT to treat multiple 
myeloma is currently being tested in a phase I clinical trial (clinicaltrials.gov, trial 
number; NCT01729091). Another trial is underway to treat AML using ex vivo 
expanded NK cells from non-HLA matched CB CD34+ progenitors (clinicaltrials.gov, 
trial number; NCT01031368).  
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1.5 Aims of the study 
NK cells mediate a potent anti-tumour effect providing an immunotherapeutic option to 
treat cancers. NK cells can be readily obtained from PB or CB. The latter source is a 
potentially valuable source of NK cells, as CB NK cells constitute up to 30 % of the 
total CB mononuclear cell population (Kotylo et al., 1990). In addition, CB NK cells 
have been shown to mediate GvL in CBT settings (Béziat et al., 2009). However, CB 
NK cells have been previously shown to exhibit poor cytotoxicity when resting, and to 
have an immature phenotype (Gaddy et al., 1995, Luevano et al., 2012a, Wang et al., 
2007). Activation with cytokine can enhance the cytotoxic potential of CB NK cells 
(Dalle et al., 2005, Gaddy et al., 1995, Luevano et al., 2012a). However, previous 
studies have shown that CB NK cells require significantly higher doses of IL-2 for 
activation compared to PB NK cells (Condiotti et al., 2001, Luevano et al., 2012a), 
which could be suggestive of differential mechanisms of activation for PB and CB NK 
cells. Therefore, I hypothesise that the different activation mechanisms for PB and CB 
NK cells may imply distinctive immunological roles of NK cells in neonates and in 
adults. So far, studies that have investigated CB NK cell activation are incomplete. In 
this context, it was shown that CB NK cells become cytotoxic after stimulation with IL-
2 (Luevano et al., 2012a, Xing et al., 2010), IL-12 (Gaddy et al., 1995), IL-15 (Dalle et 
al., 2005) or IL-18 (Nomura et al., 2001). However, collective analysis of the effect of 
each cytokine on CB NK cells when compared to PB NK cells has not yet been 
performed. Furthermore, although a few studies have assessed intracellular production 
of inflammatory cytokines including IFN-! and TNF-" by NK cells (Dalle et al., 2005, 
Krampera et al., 2000, Luevano et al., 2012a, Wang et al., 2007), no study has assessed 
cytokine secretion by CB NK cells following cytokine stimulation. Furthermore, the 
migratory capacity of activated CB NK cells has not been assessed. The finding that CB 
NK cells require higher doses of IL-2 for activation and proliferation (Condiotti et al., 
2001, Luevano et al., 2012a) is suggestive that IL-2 might not be the ideal cytokine to 
induce fully functional CB NK cells. Besides IL-2, there are many cytokines that induce 
biological effects on NK cells including IL-15, which is critical for NK cell 
development, survival, effector functions and proliferation; IL-12 and IL-18, which 
both induce NK cell cytotoxicity and cytokine production. Hence, the main aim of this 
study is to perform a comprehensive analysis of CB NK cell activation following 
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stimulation with IL-2, IL-12, IL-15, IL-18, the combination of IL-15+IL-2 and IL-
15+IL-18 to compare with PB NK cells as follows: 
 
1. Comparative analysis of the phenotypic characteristics of cytokine-activated PB 
and CB NK cells: this analysis focuses on the expression of activating and 
inhibitory receptors as well as the study of cytokine receptors and their 
signalling components (Chapter 3).  
2. Functional analysis of cytokine-activated PB and CB NK cells: this study aims 
to measure NK cell effector functions including NK cell proliferation, 
cytotoxicity and inflammatory cytokine production following stimulation with 
different cytokines (Chapter 4).   
3. Analysis of the NK cell trafficking repertoire: this analysis focuses on the 
upregulation of LN homing receptors by PB and CB NK cells as well as 
assessment of NK cell migration in vitro following cytokine stimulation 
(Chapter 5). 
4. The production of memory-like NK cells using cytokines: this study aimed to 
generate memory-like NK cells from PB and for the first time from CB using 




Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Reagents 
All the reagents used in this thesis are listed in Table 2.1. 
Table 2.1 List of reagents   
Reagent Company 
10X Phosphate buffered saline (PBS) Lonza, Belgium 
1450 microbeta Plus liquid Scintillation Perkin Elmer, UK 
Absolute Ethanol VWR BDH Prolabo, UK 
BD Pharm Lyse BD Biosciences, UK 
Carboxyfluorescein succinimidyl ester (CFSE) Life Technologies, UK 
51Chromium Perkin Elmer, UK 
Distilled water Baxter, Switzerland 
Ethylenediaminetetraacetic acid (EDTA) 0.5 M 
ultra pure pH 8.0 Life Technologies, UK 
Ficoll—Paque PLUS GE Healthcare, Sweden 
Heparin sodium 1000 IU/mL Sigma, UK 
Lympholyte-H VH Bio Ltd., UK 
Penicillin and streptomycin mixture (Pen-Strep) Lonza, Belgium 
RPMI 1640 Lonza, Belgium 
Trisodium citrate Sigma-Aldrich, USA 
Triton 100X VWR International, USA 
Trypan blue (0.4 %) Sigma, UK 
Turk's stain Sigma, UK 






All materials used in this thesis are listed in Table 2.2. 
Table 2.2 List of materials 
Materials Company 
Falcon tubes (15 and 50 mL) Sarstedt, Germany 
HTS transwell 96-well plate with 5-µm 
polycarbonate membrane Corning Life Technologies, USA 
LS columns Miltenyi Biotech, Germany 
Minisart sterile filter (0.45 µm) Sartorius Stedim Biotech, Germany 
Multi-stand MACS Magnet Miltenyi Biotech, Germany 
Partec CellTrics 30 micron filters Partec, Germany 
Pasteur pipettes Fisher, UK  
Serological pipettes (5, 10 and 25 mL)  Sarstedt, Germany 
Tissue culture flask (25, 75 and 150 cm2) Sarstedt, Germany 
U-bottom 96-well plates Sarstedt, Germany 
V-Bottom 96-well plates Sarstedt, Germany 
 
2.1.3 Serum 
The sera used for cell culture and analysis are listed in Table 2.4. 
Table 2.3 List of sera 
Serum Manufacturer 
Bovine Serum Albumin (BSA) fraction V Calbiochem, Germany 
Bovine Serum Albumin Sigma, UK 
Foetal bovine serum (FBS) Lonza, Belgium 








All buffers used for cell staining, isolation and washing are listed in Table 2.3. 
Table 2.4 List of buffers 
Buffer Components 
FACS buffer 1X PBS and 10 % v/v FBS 
Lysing buffer 10X BD Pharm Lyse diluted to 1X with distilled water 
MACS buffer 1X PBS, 1 % w/v BSA and 2 mM EDTA 




All the media used for cellular studies are listed in Table 2.5. 




Culture medium RPMI 1640, 5 µM !-ME,  1 % Pen-Strep and 10 % v/v FBS 
Cytokine-induced 
memory NK cell 
medium 
RPMI 1640, 5 µM !-ME,  
1 % Pen-Strep and 10 % v/v AB Serum 
Transport medium RPMI 1640, 33 % w/v Tri-sodium citrate, 5 µM !-ME 
Transwell migration 
medium 
RPMI 1640, 5 µM !-ME,  





All the commercial kits used for cellular isolation, RNA extraction, signalling pathway 
analysis and cytokine analysis are listed in Table 2.6. 
 
Table 2.6 List of kits 
Kit Manufacturer 
Cytofix/CytopermTM plus BD Biosciences, USA 
Human Granulocyte Depletion Kit Stem Cell Technologies, France 
Human TH1/TH2 11plex Ready-to-
Use Kit FlowCytomix eBioscience, Austria 
NK Cell Isolation Kit Miltenyi Biotec, Germany 
Phosflow Starter Kit BD Bioscience, USA 
RNeasy Mini kit Qiagen, Germany 
 
2.1.7 Cytokines 
All the cytokines described in this thesis are listed in Table 2.7. 
Table 2.7 List of cytokines 
Cytokine Provider 
IL-2  ProSpec, Israel 
IL-12  PeproTech, UK 
IL-15  PeproTech, UK 





2.1.8 Monoclonal antibodies 
The antibodies used for flow cytometry analysis are listed in Table 2.8. 
Table 2.8 List of antibodies 
Marker FC* Clone Isotype Manufacturer 
7AAD - - - BD Pharmingen 
Annexin V FITC - - BD Pharmingen 
CCR7 PE 3D12 Mouse IgG2a k BD Pharmingen 
CCR7 PE 150503 Mouse IgG2a k R&D Systems 
CD3 PerCP SK7 Mouse IgG1 k BD Pharmingen 
CD3 PE SK7 Mouse IgG1 k BD Pharmingen 
CD16 FITC NKP15 Mouse IgG1 k BD Pharmingen 
CD16 APC 3G8 Mouse IgG1 k Biolegend 
CD56 PE-Cy5 B159 Mouse IgG1 k BD Pharmingen 
CD56 APC B159 Mouse IgG1 k BD Pharmingen 
CD62L FITC Dreg56 Mouse IgG1 k BD Pharmingen 
CD69 APC L78 Mouse IgG1 k BD Pharmingen 
CD94 FITC HP-3D9 Mouse IgG1 k BD Pharmingen 
CD158a FITC HP-3EA Mouse IgM k BD Pharmingen 
CD158b FITC CH-L Mouse IgG2b k BD Pharmingen 
CXCR3 APC 1C6/CXCR3 Mouse IgG1 k BD Pharmingen 
IFN-! FITC 4S.B3 Mouse IgG1 k BD Pharmingen 
CD25 
(IL-2R")  APC BC96 Mouse IgG1 k eBioscience 
CD122  
(IL-2R#) PE Mik-B3 Mouse IgG1 k Pharmingen 
CD212 
(IL-12R#1) APC 2.4 E6 Mouse IgG1 k Pharmingen 
CD212 
(IL-12R#2) PE 2B6/12B2 Rat IgG2a k Pharmingen 
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IL-15R! PE eBioJM7A4 Mouse IgG2b eBioscience 
IL-18R! FITC H44 Mouse IgG1 k eBioscience 
NKG2A PE Z199 Mouse IgG2b k Beckman-Coulter 
NKp44 APC P44-8 Mouse IgG1 k Biolegend 
p-Stat4 PE pY693 Mouse IgG2b BD Pharmingen 
p-Stat5 PE pY694 Mouse IgG1 k BD Pharmingen 
FC*= Fluorochrome 
 
2.1.9 Molecular biology techniques 
All the reagents and primers used to perform molecular biology techniques are listed in 
Tables 2.9 and 2.10. 
Table 2.9 List of reagents 
Reagent Company 
0.1 M DTT (0.05 mM/mL) Life Technologies, UK 
2X qPCR MasterMix Primer Design, UK 
5X First-Strand Buffer Life Technologies, UK 
dNTPs (0.1 µmoL/µL) Bioline, UK 
Optical reaction 96-well plates with 
Barcode Applied Biosystems, US 
Random primers (0.5 µg/µL) Promega, UK 
Recombinant RNAsin Ribonuclease 
Inhibitor (40 u/µL) Promega, UK 
SuperScript III RT 200 U/µL Life Technologies, UK 








Table 2.10 List of primers 
Gene Forward primer (F) and Reverse primer (R) Conc. Reference 
BCL-2 F: 5’-CTGCACCTGACGCCCTTCACC-3’                 R: 5’-CACATGACCCCACCGAACTCAAAGA-3’ 600 nM 
(Ge et al., 
2006) 
Granzyme B F: 5'-TGGGGGACCCAGAGATTAAAA-3'               R: 5'-TTTCGTCCATAGGAGACAATGC-3' 300 nM 
(Morissette 
et al., 2007) 
IFN-! F: 5'-TGG CTC TGC ATT ATT TTT C-3'                   R: 5'-CGC TCC CCA AGA AGA C-3' 300 nM 
(Gober et al., 
2007) 
Perforin F: 5'-CGCCTACCTCAGGCTTATCTC-3'                    R: 5'-CCTCGACAGTCAGGCAGTC-3' 900 nM 
(Morissette 
et al., 2007) 
 
2.1.10 Instrumentations and software 
Instrumentation and software used for molecular biology work are provided in table 
2.11. 
Table 2.11 Instrumentations and software 
Instrument Software 
7500 Real Time PCR System (AB 
Applied Biosystems) Sequence detection software version 4.1 
FACSCaliburTM Flow Cytometer (BD, 
US) 
FlowJO version 6.4.2 
FlowCytomixPro version 3.0 
NanoDrop-1000 Spectrophotometer (US) NanoDrop-1000 version 3.3.1  
Perkin Elmer 1450 liquid scintillation 
counter 
Wallac microbeta windows work station  
Version 3.20.002 
 
2.2  Blood Samples  
2.2.1 Cord blood 
All CB units were obtained from the Anthony Nolan Cord Blood Bank in Nottingham 
(NREC 10/H0405/27), UK, under written informed consent from normal or caesarean 
deliveries. CB units were collected into bags containing citrate-phosphate-dextrose 





2.2.2 Peripheral blood 
Healthy adult volunteers from Anthony Nolan donated PB with written informed 
consent. Samples were anticoagulated with heparin (1 IU/mL).   
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2.3  Methods 
2.3.1 Mononuclear cell isolation 
Mononuclear cells from CB and PB were isolated using a density gradient separation 
method. CB samples were incubated prior to mononuclear cell isolation with 5 µL/mL 
of RosetteSep® Human Granulocyte depletion kit to deplete granulocytes. Samples 
were diluted prior to separation by adding an equal volume of blood to transport media 
(RPMI 1640 media supplemented with 33 % w/v trisodium citrate and 5 µM of !-ME). 
The diluted blood was then layered on Lympholyte-H for PB or on Ficoll-Paque PLUS 
for CB at a 2:1 ratio and then centrifuged at 850 x g for 30 min without break to avoid 
disturbance of the cellular interface. The mononuclear cell layer was carefully aspirated 
with a Pasteur pipette and residual red blood cells were lysed using 1X BD PharmaLyse 
for 3 min at 37 °C. 
 
2.3.2 Cellular enumeration 
Cell counts were performed using a haemocytometer and aDMLB microscope (Leica, 
Germany). Trypan blue was used to determine cellular viability and Turk’s staining was 
used to determine the total number of nucleated cells.  
 
2.3.3 NK cell isolation 
NK cell isolation was carried out by negative selection using the NK Cell Isolation Kit 
II (Miltenyi Biotec) following manufacturer’s recommendations with washing 
modifications. Mononuclear cells from PB or CB were incubated with biotin-
conjugated antibodies and then with the NK cell MicroBead cocktail at 4 °C. 
Erythrocytes, granulocytes, monocytes, T lymphocytes, B lymphocytes and stem cells 
were directly labelled with the antibody cocktail, whereas NK cells were left 
untouched. Cell suspensions were then applied to the columns passing through Partec 
CellTrics filters. Columns were washed twice with 7 mL of MACS buffer (Table 2.2) 
and only NK cells were isolated. NK cells were spun down for 10 min at 300 x g and 
resuspended in RPMI containing 10 % v/v FBS. The purity of the isolated NK cells was 
determined by flow cytometry as CD3! CD56+ cells (Fig 2.1). The mean percentage of 
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purified NK cells from CB was 92.27 % ± 4.5 and 90 % ± 2.2 from PB. This data 
represents the purity of all PB and CB NK cells included in this thesis and are shown as 
mean ± SD. 
 
 
Figure 2.1 Assessment of NK cell purity. The purity of isolated NK cells (CB) was 
confirmed by flow cytometry. A) Lymphocytes were gated according to forward scatter 
(FSC) and side scatter (SSC). B) Isolated NK cells are CD3!CD56+. 
 
2.3.4 NK cell culture 
PB or CB NK cells were cultured with IL-2, IL-12, IL-15, IL-18, or the combination of 
IL-15 and IL-2 or IL-15 and IL-18. Various concentrations of these cytokines have 
been used by others to activate CB NK cells (Condiotti et al., 2001, Gaddy et al., 1995, 
Nomura et al., 2001, Satwani et al., 2011). Therefore, I tested higher and lower doses of 
IL-12 and IL-15 as it was previously observed that CB NK cells require up to 5 times 
more IL-2 (Condiotti et al., 2001, Luevano et al., 2012a). For IL-18, I followed the 
protocol of Nomura and colleagues where they showed optimal activation of CB NK 
cells using 100 ng/mL IL-18 compared to other doses (Nomura et al., 2001). NK cells 
were activated with IL-12 and IL-18 for 40 h as these cytokines induce apoptosis upon 
prolonged stimulation (Huang et al., 2010, Huang et al., 2011), whereas NK cells were 
cultured with IL-2 and IL-15 for 5 days due to the ability of these cytokines to promote 
NK cell proliferation and expansion (Becknell and Caligiuri, 2005, Carson et al., 1994).  
 
Culture medium was prepared by adding 1 % Pen-Strep, 5 µM "-ME and 10 % v/v FBS 
to RPMI 1640. Lyophilised human recombinant cytokines were reconstituted in PBS 
supplemented with 0.1 % w/v BSA or according to manufacturer’s recommendations. 
Cytokines were diluted in culture medium prior to use. A volume of 1 mL of media 




































containing cytokines was added to 1 x 106 NK cells (refer to Table 2.12 for cytokine 
concentrations used). Cells were cultured in 96 well-round bottom plates at 37 °C, 5 % 
CO2. For cultures longer than 40 h, the medium was changed by hemi-depletion 




Table 2.12 Cytokine concentrations and incubation times used. 
Cytokine PB NK cells CB NK cells Incubation time 
IL-2 200 IU/mL (Chiossone et al., 2007) 
1000 IU/mL (Condiotti 
et al., 2001) 5 days 
IL-12 10 ng/mL(Cooper et al., 2001c) 10 or 50 ng/mL 40 h 
IL-15 20 ng/mL (Chiossone et al., 2007) 20 or 100 ng/mL 5 days 
IL-18 100 ng/mL (Agaugué et al., 2008) 100 ng/mL 40 h 
IL-15 and 
IL-2 
20 ng/mL and 200 IU/mL 
respectively 
20 ng/mL and 1000 
IU/mL respectively 5 days 
IL-15 and 
IL-18 
20 ng/mL and 100 ng/mL 
respectively 
20 ng/mL and 100 
ng/mL respectively 5 days 
 
 
2.4 Flow cytometry analysis 
2.4.1 Flow cytometry analysis set-up 
Before flow cytometry analysis, BD Calibrate beads were ran to accurate the set-up of 
channels on the FACSCaliburTM machine. Thereafter, four-colour compensation of FL1 
(FITC), FL2 (PE), FL3 (PerCP or PE-Cy5) and FL4 (APC) was performed manually 
and saved for further experimental analysis. Compensation was carried out using 
PBMC or CBMC stained with single colour and unstained as a negative control. For 
negative control, voltages of all four channels were adjusted to place the population at 
the lower left quadrant of the dot plot. Then, a single colour FITC tube containing a 
positive population (CD16), a single colour PE tube containing a positive population 
(CD3), a single colour PerCP or PE-Cy5 tube containing a positive population (CD3 or 
CD56) and a single colour APC tube containing a positive population (CD56) were ran 
and compensation was adjusted accordingly (FL2 – %FL1, FL1 – %FL2, FL3 – %FL2, 
FL4 – %FL3 and FL3 – %FL4). Antibodies were titrated prior use for optimal antigenic 
expression using different dilutions including 1:5, 1:10, 1:20, 1:50, 1:100 and 1:200. 
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2.4.2 Phenotype of activated NK cells 
The expression of surface markers on NK cells was examined using a FACSCaliburTM 
flow cytometer. NK cells (0.5 to 2.5 x 105 cells) were stained in V bottom Nunc® plates 
with fluorochrome-conjugated antibodies for 10 min at 4 °C. FACS buffer was used to 
wash away unbound antibodies by centrifugation at 550 x g for 3 min. Cells were then 
resuspended in 200 µL FACS buffer. The expression of activation markers, KIRs, 
lectin-like inhibitory receptors, chemokine receptors and adhesion molecules was 
assessed on both resting and activated NK cells (Table 2.13). Combinations of 










Table 2.13 Surface markers analysed in this study and their significance. 
Marker Significance FC* Dil.  
CCR7 Lymph-node homing receptor (BD) PE 1:50 
CCR7 Lymph-node homing receptor (R&D) PE 1:10 
CD3 Pan-T cell marker PerCP 1:20 
CD3 Pan-T cell marker PE 1:17 
CD16 Fc!III receptor (ADCC pathway) FITC 1:10 
CD16 Fc!III receptor (ADCC pathway) APC 1:200 
CD56 Pan-NK cell marker PE-Cy5 1:10 
CD56 Pan-NK cell marker APC 1:10 
CD62L Adhesion molecule (L-selectin) FITC 1:50 
CD69 Activation marker APC 1:50 
CD94 Lectin-like killer inhibitory receptor FITC 1:100 
CD158a Killer cell Ig-like receptor FITC 1:5 
CD158b Killer cell Ig-like receptor FITC 1:10 
CXCR3 Lymph-node homing receptor APC 1:10 
NKG2A Lectin-like killer inhibitory receptor PE 1:20 
NKp44 Natural Cytotoxicity receptor APC 1:10 
FC*= Fluorochrome 
 








2.4.3 Analysis of cytokine receptor expression 
Cytokine receptor expression was investigated using flow cytometry. Mononuclear 
cells from both PB and CB were washed and stained using titrated monoclonal 
FITC PE PerCP PE-Cy5 APC 
CD158a CD3   CD56 CD69 
CD158b CD3   CD56 NKp44 
L-selectin CD3   CD56 CXCR3 
CD94 NKG2A CD3 
 
CD56  
CD16 CCR7 CD3 
 
CD56 
Annexin V CD3 7AAD  CD56 
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antibodies (Table 2.15). The expression of cytokine receptors was analysed on 
CD56bright CD16dim and CD56dimCD16bright NK cell subsets. Combinations of 








Table 2.15 Monoclonal antibodies used to analyse the expression of cytokine 




Figure 2.2 Gating strategy to identify CD56bright and CD56dim NK cells. The 
graph shows the gating strategy used to analyse the expression of cytokine receptors by 
NK cell subsets. A) FSC vs. SSC plot showing the lymphocyte gate. B) Gated NK cells 
are CD3!CD56+. C) The expression of each cytokine receptor was assessed on both 
CD56dimCD16bright and CD56brightCD16dim NK cell subsets. 
 
Table 2.16 Panel of monoclonal antibodies used to study the expression of 
cytokine receptors on PB and CB NK cells. 
FITC PE PerCP PE-Cy5 APC 
CD16 CD3   CD56 IL-2R" 
CD16 IL-2R# CD3   CD56 
CD16 CD3   CD56 IL-12R#1 
CD16 IL-12R#2 CD3   CD56 
CD16 IL-15R" CD3   CD56 
IL-18R" CD3   CD56 CD16 
 
 



























































Receptor Alternate name Description 
Dilution 
used 
IL-2R"  CD25 High affinity IL-2 receptor 1:100 
IL-2R# CD122 Intermediate affinity IL-2 receptor 1:20 
IL-12R#1  CD212 Beta-1 subunit, forms heterodimer with Beta-2 required for IL-12 binding 1:20 
IL-12R#2  CD212 Beta-2 subunit, forms heterodimer with Beta-1 required for IL-12 binding 1:50 
IL-15R" - High affinity IL-15 receptor 1:20 
IL-18R" CD218 High affinity IL-18 receptor 1:100 
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2.4.4 Viability of NK cells 
NK cell viability was analysed post-incubation with cytokines using 7AAD and 
Annexin V. Concentrations of 7AAD and Annexin V used were 1/160 and 1/100 
respectively.  
 
2.5 Signalling pathway analysis 
The BD™ Phosflow Protocol (Harsh alcohol method) was used to study activation of 
the STAT signalling pathway in NK cells. Phosphorylation of STAT5 and STAT4 in 
NK cells was assessed at 15 min or two days after cytokine stimulation with IL-2 or IL-
12 at the concentrations indicated in table 2.12. NK cells at concentration of 1 x 105 
were fixed using 100 µL pre-warmed BD Cytofix™ Fixation Buffer and permeabilised 
according to the manufacturers recommendations. Subsequently, NK cells were stained 
with STAT5 (pY694) PE for those cells stimulated with IL-2 and STAT4 (pY693) PE 
for those cells stimulated with IL-12 (Wang et al., 2000). Unstimulated NK cells as well 
as isotypes (PE-Mouse IgG1!, PE-Mouse IgG2b) were included as controls.  
 
2.6 Assessment of NK cell proliferation 
PB and CB NK cells were washed and labelled with 2 µM Carboxyfluorescein 
succinimidyl ester (CFSE) per 106 cells. CFSE was resuspended in DMSO prior to use 
according to the manufacturers recommendations. NK cells were incubated with CFSE 
at 37 ºC 5 % CO2 for 10 min. The cells were then washed twice with cold RPMI 
supplemented with 10 % v/v FBS. CFSE is a light-sensitive chemical; therefore, 
labelling was carried out in the dark. CFSE labelling was detected at time point 0 using 
the FL-1 channel on a FACSCaliburTM flow cytometer. CFSE labelled cells were 
incubated with different cytokines (Table 2.12) and cell proliferation analysed at days 2 
and 5. CFSE fluorescence is diluted in successive generations of NK cells and 
correlates with proliferation.  
 
2.7 Cytokine secretion 
The Human TH1/TH2 11plex Ready-to-Use FlowCytomix Multiplex Kit (eBioscience) 
was used to study cytokine secretion by NK cells according to the manufacturers 
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protocol. Beads coated with antibodies for specific target analytes including human 
IFN-!, IL-1", IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 p70, TNF-# and TNF-" were 
mixed with culture supernatants and secondary biotin-conjugated antibody. 
Subsequently, samples were labelled with Streptavidin-PE. The purpose of using this 
method was to perform wide screening of cytokine production by NK cells. Tests were 
performed using culture supernatants from cytokine-conditioned NK cells (Table 3.12). 
Before running samples, setup beads were used to create a FlowCytomix protocol and 
to adjust both voltage and compensation. The final results were analysed using the 
FlowCytomix 3.0 software (Fig 2.3). 
 
 
Figure 2.3 Gating strategy using antibody-labelled micro-beads as shown by 
FlowCytomix software. The two populations indicate the different sizes of antibody 
coated-beads used to target 11 analytes. 
 
 
2.8 NK cell cytotoxicity 
NK cell cytotoxicity was investigated after 2 and 5 days of activation with cytokines. 
The target cell line used in this assay was K562. The HLA-deficient leukemic cell line 
was sub-cultured prior use with 20% v/v FBS supplemented culture medium. Cells 
were then maintained in 10% v/v FBS culture media and used for the assay when 
reaching the log phase at concentration of 0.5 x 106 /mL. K562 cells were then washed 







cells at 37 °C, 5 % CO2, 96 % humidity for 45 min. Subsequently, K562 cells were 
washed and co-cultured with effector NK cells at different ratios (Effector:target) of 
1:1, 5:1 and 10:1 for 4 h at 37 °C (Fig 2.4). Medium alone was used as a negative 
control and cells lysed with Triton X-100 were used as a positive control. After 
incubation, plates were centrifuged and 30 µL of supernatant was transferred into 
LumaPlates and dried overnight. The next day, scintillation liquid was added to each 
well and the plates were read using a Perkin Elmer 1450 liquid scintillation counter. 
The percentage of specific lysis was calculated as (experimental release – spontaneous 
release*) ÷ (maximum release** – spontaneous release) ! 100.  
Spontaneous release* = negative control. 
Maximum release** = positive control. 
 
 
Figure 2.4 Principle of killing assay using 51Cr-labelled K562 cells.  
 
2.9 Real-time PCR 
2.9.1 RNA extraction 
The RNeasy mini-kit was used to extract RNA from resting or activated (24 h) NK cells 
according to the manufacturers recommendations. A NanoDrop-1000 
Spectrophotometer was used to measure the concentration as well as the purity of the 






















Table 2.17 RNA extracted from PB NK cells used for RT-PCR. 
Sample No. !1 !2 !3 !4 !5 Yield Average 
PB resting 
16.1 23 22.5 
  
RNA ng/µL 20.53 
1.86 2.09 2.15     260/280 ratio 2.03 
PB IL-2 
35.5 16.6 22.5 12.6 22.8 RNA ng/µL 22 
1.92 2.03 2.02 1.89 1.93 260/280 ratio 1.96 
PB IL-15 
17.2 14.8 20 12.3 11.5 RNA ng/µL 15.16 
1.81 2.06 1.87 2.01 1.88 260/280 ratio 1.93 
PB IL-12 
22 14.9 18.7 15.4 11.6 RNA ng/µL 16.52 
1.83 1.66 1.9 1.73 2.3 260/280 ratio 1.88 
PB IL-18 
14.6 22.9 14.3 12.2 20.7 RNA ng/µL 16.94 
1.91 1.78 1.99 1.92 2.3 260/280 ratio 1.98 
PB IL-15+IL-2 
31.8 20.2 21.8 14.2 13.4 RNA ng/µL 20.28 
1.94 1.94 2.19 1.75 1.76 260/280 ratio 1.92 
PB IL-15+IL-
18 
43.4 42.2 9 19.8 18.2 RNA ng/µL 26.52 
2.02 2.1 2.19 1.87 2.07 260/280 ratio 2.05 
 
Table 2.18 RNA extracted from CB NK cells used for RT-PCR. 
Sample No. !1 !2 !3 !4 !5 !6 Yield Average 
CB resting 
49.8 88.8 129.6       RNA ng/µL 89.40 
2.02 1.95 1.94       260/280 ratio 1.97 
CB IL-2 
94 98.9 85.5 
   
RNA ng/µL 92.8 
1.94 1.95 1.94       260/280 ratio 1.94 
CB IL-15 
28.8 72.8 69.3 25.29 14 32.1 RNA ng/µL 40.38 
1.9 1.94 1.97 1.88 1.95 1.93 260/280 ratio 1.93 
CB IL-12 
65.5 70.5 52.1 18 38.1 61.3 RNA ng/µL 50.92 
1.98 2 1.99 2.05 2 1.99 260/280 ratio 2.00 
CB IL-18 
89.6 98.4 73.8 16.3 67.1 68.1 RNA ng/µL 68.88 
1.96 1.92 1.9 1.84 2.05 2.03 260/280 ratio 1.95 
CB IL-15+IL-2 
65.4 58.1 72 51.2 29.3 37.4 RNA ng/µL 52.23 
1.85 1.83 1.9 1.92 1.85 1.9 260/280 ratio 1.88 
CB IL-15+IL-18 
78.6 52.3 83 46.3 31.2 37.8 RNA ng/µL 54.87 
1.86 1.82 1.89 1.84 1.92 1.97 260/280 ratio 1.88 
 
2.9.2 Reverse transcription 
Reverse transcription of extracted RNA was performed using a Mastercycler 
thermocycler (Eppendorf, US). RNA at the concentration of 200 ng was mixed with 2 
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µL of random primers (1 µg) and 1 µL of 25 µmol dNTPs incubated first for 5 min at 65 
°C and then on ice for another 5 min. Afterwards, 5X First-strand buffer, 0.1 M DTT 
and RNAsin inhibitor was added to the reaction and incubated at 25 °C for 10 min 
followed by an additional 2 min at 42 °C. A volume of 1 µL (200 UI) of Superscript 
reverse transcriptase was added to the reaction and incubated at 42 °C for 50 min 
followed by an additional 15 min at 70 °C. Lastly, 40 µL of RNase free water was 
added making the volume of cDNA 60 µL that was then ready to use for real-time PCR. 
 
2.9.3 Real-time PCR plate set-up 
Primers were mixed, according to the concentrations provided in Table 2.10, with 
RNase-free water and precision SYBRgreen MasterMix. A volume of 15 µL of primer-
mastermix was added to MicroaAmp® optical 96-well reaction plates. Then, 5 µL of 
cDNA was added to the wells and plates were covered with MicroAmp® Adhesive 
film. For each sample, three reference housekeeping genes were used including Homo 
sapiens Actin-beta (ACTB), Homo sapiens !2 microglobulin (!2M) and Homo sapiens 
Ubiquitin (UBC). Reference gene primer sequences were provided by PrimerDesign 
and assayed at a concentration of 300 nM. Target genes and reference genes were 
processed in triplicates and ran on a 7500 Real Time PCR AB Biosystem machine at 
conditions the following conditions; 50 °C for 2 min, 95 °C for 10 min, 40 cycles for 15 
sec at 95 °C, 60 °C for 1 min, 95 °C for 15 sec, 60 °C for 1 min and 95 °C for 15 sec. 
Sterile water was used as a negative control to ensure pure primer amplification. mRNA 
quantity of target genes was normalised against the average reference gene quantity. 
 
2.10 Migration assays 
Trans-well migration assays were carried out to test the ability of NK cells to migrate in 
response to chemokines. Trans-well medium (Table 2.5) supplemented with 250 ng/mL 
CCL19/CCL21 or CXCL10/CXCL11 was added to the lower chamber of 96-well HTS 
Trans-well plates supported with a 5.0 µm polycarbonate membrane (Table 2.19). 
Subsequently, resting or activated NK cells (0.1-0.25 x 106) from PB and CB were 
placed into the upper chamber of the trans-well plate. Medium only instead of 
chemokines was included to assess spontaneous migration of NK cells. The plates were 
incubated for 3 h at 37 °C. Cells that migrated to the lower chamber were collected and 
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enumerated by flow cytometry. The percentage of migration was calculated using the 
following formula: % of migration = (No of migrated cells* ÷ Positive control**)!100. 
No of migrated cells*= Number of NK cells migrated in response to CCL/CXCL. 
Positive control**= Total number of cells placed in the lower chamber as a control. 
 
Table 2.19 Chemokines used for migration study 
Chemokine Alternative names Ligand Company 
Human recombinant CCL19 MIP-3" CCR7 Biolegend 
Human recombinant CCL21 6CKine CCR7 Biolegend 
Human recombinant CXCL10 IP-10 CXCR3 Biolegend 
Human recombinant CXCL11 ITAC CXCR3 Biolegend 
 
 
2.11 Cytokine-induced memory-like NK cells 
To generate cytokine-induced memory-like NK cells we followed the approach of 
Romee and colleagues (Romee et al., 2012). For this, freshly isolated NK cells (5 x 106) 
from PB or CB were pre-activated with 10 ng/mL IL-12, 50 ng/mL IL-18 and 1 ng/mL 
IL-15 or only 1 ng/mL IL-15 as a control for 16 h. Cells were washed three times to 
ensure removal of cytokines and cultured in RPMI supplemented with 10 % v/v AB 
serum and 1 ng/mL IL-15 to support survival of NK cells. NK cells were cultured in 96 
U bottom plates and the medium was changed by hemi-depletion every 48 h. At days 7 
and 21, cells were washed and restimulated with 10 ng/mL IL-12 and 100 ng/mL IL-15 
for 6 h (Fig 2.6). Supernatants were collected and kept at -70 °C to be assayed for IFN-# 
production by multiplex assay as described above (section 2.3.8). 
To assess intracellular IFN-# expression, GolgiStop was added to NK cells after 
restimulation with IL-15 and IL-12 at days 7, 14 and 21 to inhibit transportation of 
intracellular IFN-#. Thereafter, NK cells were fixed and permeabilised using 
Cytofix/Cytoperm buffer according to the manufacturers recommendations. Staining 
with monoclonal antibodies against IFN-# following permeablization was then 
performed. An isotype control was used for each condition (IgG1 K FITC, BD 
Biosciences) (Table 2.20). To assess IFN-# mRNA levels, real-time PCR was 




Table 2.20 Panel of monoclonal antibodies used to study intracellular IFN-! 
expression by cytokine-induced memory-like NK cells. 
FITC PE APC 
IgG1K CD3 CD56 





Figure 2.6 Protocol for the generation of cytokine-induced memory-like NK 
cells. “This figure has been reproduced from an open access article under creative 
commons attribution license” (Romee et al., 2014). 
 
2.12 Statistical analysis  
Statistical comparisons were performed with GraphPad Prism software using unpaired 
t-tests. Results are presented as Mean ± SD and p values of <0.05 (*), <0.01 (**) and 


















Chapter 3: Phenotype of Cytokine-activated NK Cells 
 
3.1 Introduction 
Resting CB NK cells exhibit unique phenotypic characteristics in comparison to PB NK 
cells that are suggestive of a certain degree of immaturity of these cells. It has been 
reported that resting CB NK cells exhibit low cytotoxicity against target cells without 
prior activation (Dalle et al., 2005, Gaddy et al., 1995, Luevano et al., 2012a, Wang et 
al., 2007). However, when activated with high doses of IL-2, effector functions of CB 
NK cells are enhanced, but are still lower than for IL-2 activated PB NK cells 
(Condiotti et al., 2001, Luevano et al., 2012a). The phenotype of CB NK cells after 
activation has not been well characterised and therefore it is key to better understand 
the characteristics of these cells after cytokine activation in comparison to PB NK cells. 
 
NK cells express at least one inhibitory receptor for self-MHC to prevent killing of 
healthy cells (Moretta et al., 1996). In particular, KIR (CD158a and CD158b) and 
CD94/NKG2A are key in regulating NK cell functions, as their expression correlates 
with the degree of maturity of NK cells (Freud and Caligiuri, 2006). In this context, it 
has been shown that resting CB NK cells exhibit low KIR expression and high NKG2A 
levels suggesting that CB NK cells are immature and unlicensed (Dalle et al., 2005, 
Luevano et al., 2012a, Wang et al., 2007). It has been reported that murine NK cells 
acquire a licensed phenotype after transfer into a MHC class I sufficient host, or after 
stimulation with IL-12 and IL-18 (Kim et al., 2005). However, cytokine activation of 
human NK cells does not induce responsiveness of KIR- NK cells (Anfossi et al., 2006). 
Although CB NK cells are not licensed as compared to PB NK cells, they seem to 
become competent upon cytokine activation. Wang et al. correlated poor cytotoxicity of 
CB NK cells with high expression of the inhibitory receptor NKG2A (Wang et al., 
2007). Whether cytokine activation impacts on the expression of inhibitory receptors by 
CB NK cells remains to be investigated. 
 
CD69 is an early activation marker expressed by activated lymphocytes, including NK 
cells (Hara et al., 1986, Lanier et al., 1988). Upregulation of CD69 by NK cells has 
been reported to trigger NK cell cytotoxicity (Moretta et al., 1991). Moreover, CD69 
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expression has also been implicated in other functions of NK cells including 
proliferation, cytokine secretion and upregulation of adhesion molecules (Borrego et al., 
1999). NKp44 is a receptor that belongs to the NCR family. Importantly, NKp44 is the 
only NCR that is specifically upregulated by activated NK cells (Vitale et al., 1998) and 
NKp44 upregulation by activated NK cells mediates tumour cell lysis (Vitale et al., 
1998). CB NK cells express CD69 in response to IL-2 (Condiotti et al., 2001), IL-12, 
IL-15 (Lin et al., 2000) or IL-18 (Nomura et al., 2001) stimulation. Moreover, NKp44 
expression by CB NK cells can be induced after stimulation with IL-2 (Xing et al., 
2010) or IL-15 (Tang et al., 2008). However, a complete analysis, as well as a 
comparison of the effects of different cytokines on promoting activation of CB NK cells 
is still required, as some of these studies have been carried out using mononuclear cells 
and not isolated NK cells. 
 
NK cells express a variety of receptors that allow them to respond to cytokines released 
by other immune cells (Caligiuri et al., 1990, Kunikata et al., 1998, Pillet et al., 2009, 
Wang et al., 2000). Cytokine receptor expression is also known to be associated with 
specific NK cell maturation stages. According to the NK cell development model 
proposed by Freud et al., less differentiated NK cells (CD56bright) express high levels of 
IL-2R!, whereas mature NK cells (CD56dim) have scarce expression of this receptor 
(Freud and Caligiuri, 2006). Our group and others have previously shown that CB NK 
cells express IL-2R", but have low expression of IL-2R! (Dalle et al., 2005, Luevano et 
al., 2012a). Yet, the expression of other cytokine receptors by the CD56bright and 
CD56dim CB NK cell subsets remains to be investigated. 
 
Cytokine activation could represent an approach to induce fully functional CB NK 
cells. It has been suggested that the phenotype of NK cells correlates with function 
(Costello et al., 2002). Therefore, the phenotype of CB and PB NK cells following 
cytokine activation was compared by analysing surface expression of CD69, CD94, 
NKG2A, NKp44 and KIR. Upregulation of activating receptor expression was used to 
assess NK cell activation, and to decide which cytokine should be used for optimal 
activation of CB NK cells. Overall, this chapter discusses the effect of cytokine 




3.2.1 Cytokine induced activation of CB and PB NK cells 
3.2.1.1 Cytokine activation induces CD69 expression by PB and CB NK cells  
As upregulation of CD69 results in triggering of NK cell cytotoxicity (Moretta et al., 
1991), the expression of CD69 following cytokine activation was analysed for PB and 
CB NK cells. Resting PB and CB NK cells expressed low levels of CD69 (11.67 ± 2.33 
% and 6.333 ± 1.2 0% respectively) (Fig 3.1). Following cytokine activation, CD69 
expression was differentially upregulated by PB and CB NK cells depending on the 
cytokine used (Fig 3.1A). CB NK cells activated with IL-2 exhibited significantly less 
CD69 expression (43.63 ± 13.94 %) than PB NK cells (82.05 ± 5.69 %) (p = 0.0434) 
(Fig 3.1B). Conversely, CB NK cells activated with IL-12 showed higher upregulation 
of CD69 (90.83 ± 4.40 %) than PB NK cells (67.28 ± 3.52 %) (p = 0.0058) (Fig 3.1B). 
Activation using IL-15 or IL-18 induced comparable upregulation of CD69 for both PB 
and CB NK cells (Fig 3.1B). CD69 expression was not further upregulated by higher 





Figure 3.1 CD69 upregulation by cytokine-activated PB and CB NK cells. A) 
Flow cytometry histograms showing CD69 expression for representative samples of PB 
and CB NK cells activated with cytokines. B) Comparison of CD69 expression between 
resting and cytokine-activated PB and CB NK cells. Analysis was performed on 
purified NK cells and the expression of CD69 was examined 2 days post IL-12 or IL-18 
stimulation, and 5 days post IL-2 or IL-15 stimulation. Results are presented as Mean ± 
SD. N=4, p <0.05 (*) and p<0.01 (**). 
 
Figure 3.2 Upregulation of CD69 by CB NK cells following stimulation with IL-
12 and IL-15. A) CD69 expression by CB NK cells activated with 10 ng/mL or 50 
ng/mL IL-12, N=4. B) CD69 expression by CB NK cells activated with 20 ng/mL or 
100 ng/mL IL-15, N=4. Analysis was performed on purified NK cells stimulated with 
IL-12 for 2 days or IL-15 for 5 days. 
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3.2.1.2 Cytokine activation induces NKp44 expression by PB and CB NK cells 
NKp44 is a NCR that is only expressed by activated NK cells (Moretta et al., 2000). 
Here the induction of NKp44 expression on PB and CB NK cells following cytokine 
activation was analysed. Notably, the NKp44 expression pattern was similar to the 
expression pattern observed for CD69 on NK cells (Fig 3.3A). IL-2 activated CB NK 
cells showed significantly less upregulation of NKp44 (50.28 ± 8.78 %) than PB NK 
cells activated with the same cytokine (17.28 ± 4.72 %) (p = 0.0163) (Fig 3.3B). CB 
NK cells responded better to stimulation with IL-12, showing higher upregulation of 
NKp44 (68.93 ± 9.83 %) than PB NK cells (34.45 ± 2.00 %) (p = 0.0139) (Fig 3.3B). 
NKp44 expression was higher following stimulation with IL-15 than IL-18 for both PB 
and CB NK cells (Fig 3.3B). NKp44 upregulation was neither enhanced nor decreased 
by higher doses of IL-12 (Fig 3.4A) or IL-15 (Fig 3.4B). 
 
Figure 3.3 NKp44 upregulation by cytokine-activated PB and CB NK cells. A) 
Flow cytometry histograms showing NKp44 expression for representative samples of 
PB and CB NK cells activated with cytokines. B) Comparison of NKp44 expression by 
resting and cytokine-activated NK cells from PB and CB. Analysis was performed on 
purified NK cells and the expression of NKp44 was examined 2 days post IL-12 or IL-
18 stimulation, and 5 days post IL-2 or IL-15 stimulation. Results are presented as 
Mean ± SD. N=4, p <0.05 (*). 
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Figure 3.4 NKp44 expression by PB and CB NK cells after stimulation with IL-
12 and IL-15. A) Upregulation of NKp44 expression by CB NK cells activated with 10 
ng/mL or 50 ng/mL IL-12, N=4. B) Upregulation of NKp44 expression by CB NK cells 
activated with 20 ng/mL or 100 ng/mL IL-15, N=4. Analysis was performed on purified 
NK cells stimulated with IL-12 for 2 days or IL-15 for 5 days. 
 
3.2.2 Cytokine activation does not impact on killer immunoglobulin-like receptor 
expression by CB and PB NK cells 
NK cells at late stages of differentiation acquire the expression of KIR, hence, mature 
NK cells are characterised as CD56dimKIR+ (Freud and Caligiuri, 2006). It has 
previously been shown that CB NK cells express less KIR than PB NK cells, which was 
suggestive of CB NK cells being less mature (Luevano et al., 2012a). However, it was 
not known whether cytokine activation could promote KIR expression by NK cells. 
Herein, surface expression of KIR by PB and CB NK cells following cytokine 
stimulation was assessed. Variable expression of CD158a (KIR2DL1) was noted for PB 
NK cells and CB NK cells with a trend towards lower CD158a expression by CB NK 
cells in general, regardless of cytokine stimulation (Fig 3.5A, B). Increasing doses of 
IL-12 (Fig 3.6A) or IL-15 (Fig 3.6B) had no effect on CD158a expression by NK cells. 
Similarly, expression of CD158b (KIR2DL2/3) was significantly lower for both resting 
and cytokine-activated CB NK cells than PB NK cells (Fig 3.7). Higher doses of IL-12 
or IL-15 did not increase CD158b expression by NK cells (Fig 3.8). 
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Figure 3.5 Analysis of CD158a (KIR2DL1) expression by resting and cytokine-
activated CB and PB NK cells. A) Representative flow cytometry histograms showing 
CD158a expression by cytokine-activated PB and CB NK cells from different donors. 
B) Comparison of percent CD158a expression by resting and cytokine-activated PB and 
CB NK cells. Analysis was performed on purified NK cells and the expression of 
CD158a was examined 2 days post IL-12 or IL-18 stimulation, and 5 days post IL-2 or 
IL-15 stimulation. Results are presented as Mean ± SD. N=4. 
 
 
Figure 3.6 CD158a expression by CB NK cells activated with IL-12 and IL-15. 
A) CD158a expression by CB NK cells activated with IL-12 at 10 ng/mL or 50 ng/mL. 
B) CD158a expression by CB NK cells activated with IL-15 at 20 ng/mL or 100 ng/mL. 
N=4. Analysis was performed on purified NK cells stimulated with IL-12 for 2 days or 
IL-15 for 5 days. 
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Figure 3.7 CD158b (KIR2DL2/3) expression by resting and cytokine-activated 
PB and CB NK cells. A) Representative flow cytometry histograms showing the 
expression of CD158a by cytokine-activated PB and CB NK cells from different 
donors. B) CD158b expression by resting and cytokine-activated PB and CB NK cells. 
Analysis was performed on purified NK cells and the expression of CD158b was 
examined 2 days post IL-12 or IL-18 stimulation, and 5 days post IL-2 or IL-15 
stimulation. Results are presented as Mean ± SD. N=4, p values of <0.05 (*) and p 
<0.01 (**). 
 
Figure 3.8 CD158b expression by CB NK cells upon activation with IL-12 and 
IL-15. A) Expression of CD158a by CB NK cells activated with 10 ng/mL or 50 ng/mL 
IL-12. B) CD158b expression by CB NK cells activated with 20 ng/mL or 100 ng/mL 
of IL-15. N=4. Analysis was performed on purified NK cells stimulated with IL-12 for 
2 days or IL-15 for 5 days. 
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3.2.3 CB NK cells exhibit higher expression of lectin-like inhibitory receptors 
than PB NK cells, regardless of the cytokine used for activation 
NKG2A is an inhibitory receptor expressed by NK cells that binds to non-classical 
HLA-E expressed by target cells (Braud et al., 1998). It has been shown that immature 
NK cells are characterised by high expression of NKG2A and low expression of KIR 
(Freud and Caligiuri, 2006). Accordingly, it is thought that higher expression of 
NKG2A by CB NK cells may affect their cytotoxicity (Wang et al., 2007). NKG2A is 
expressed by NK cells as a heterodimer, coupled with CD94 (CD94/NKG2A) (Lazetic 
et al., 1996). Therefore, the expression of CD94 and NKG2A by CB NK cells and PB 
NK cells following cytokine activation was compared in order to assess whether 
cytokine stimulation alters the expression of inhibitory receptors by CB NK cells. A 
trend towards higher CD94/NKG2A expression by resting or cytokine-activated CB 
NK cells was observed when compared to PB NK cells (Fig 3.9A, Fig 3.11A). CD94 
expression was significantly higher for resting CB NK cells (84.27 ± 1.53 %) as 
compared to resting PB NK cells (49.75 ± 7.51 %) (p = 0.0121) (Fig 3.9B). 
Consistently, resting CB NK cells exhibited significantly higher NKG2A expression 
(75.70 ± 1.99 %) than resting PB NK cells (44.40 ± 6.05 %), (p = 0.0080) (Fig 3.9B). 
CD94/NKG2A expression by NK cells was not affected by increasing doses of IL-12 or 





Figure 3.9 CD94 expression by PB and CB NK cells after cytokine activation. 
A) Flow cytometry histograms showing CD94 expression upon activation of PB and 
CB NK cells with cytokines. B) Comparison of CD94 expression by resting and 
cytokine-activated PB and CB NK cells. Analysis was performed on purified NK cells 
and the expression of CD94 was examined 2 days post IL-12 or IL-18 stimulation, and 
5 days post IL-2 or IL-15 stimulation. Results are presented as Mean ± SD. N=4, p 
<0.05 (*) and p <0.01 (**). 
 
 
Figure 3.10 CD94 expression by CB NK cells upon activation with IL-12 and IL-
15. A) CD94 expression by CB NK cells activated with IL-12 at 10 ng/mL or 50 
ng/mL. B) CD94 expression by CB NK cells activated with 20 ng/mL or 100 ng/mL IL-
15. N=4. Analysis was performed on purified NK cells stimulated with IL-12 for 2 days 
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Figure 3.11 NKG2A expression by PB and CB NK cells after cytokine activation. 
A) Flow cytometry histograms showing NKG2A expression upon activation of PB and 
CB NK cells with cytokines. B) Comparison of NKG2A expression by resting and 
cytokine-activated PB and CB NK cells. Analysis was performed on purified NK cells 
and the expression of NKG2A was examined 2 days post IL-12 or IL-18 stimulation, 
and 5 days post IL-2 or IL-15 stimulation. Results are presented as Mean ± SD. N=4, p 
<0.05 (*) and p <0.01 (**). 
 
Figure 3.12 NKG2A expression by CB NK cells upon activation with different 
doses of IL-12 and IL-15. A) NKG2A expression by CB NK cells activated with IL-12 
at 10 ng/mL or 50 ng/mL. B) NKG2A expression by CB NK cells activated with 20 
ng/mL or 100 ng/mL of IL-15. N=4. Analysis was performed on purified NK cells 
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3.2.4 CB NK cells express lower levels of specific cytokine receptors than PB NK 
cells 
Cytokine receptor expression was analysed to determine whether expression correlates 
with the response of PB and CB NK cells to cytokines. Differential expression of 
cytokine receptors by NK cell subsets has been previously reported, therefore the 
expression of cytokine receptors was assessed for both CD56bright and CD56dim NK cells 
(Caligiuri et al., 1990, Kunikata et al., 1998, Voss et al., 1992). CB CD56bright NK cells 
exhibited comparable levels of IL-2R! and IL-2R" to PB CD56bright NK cells (Fig 
3.13A, E). However, CB CD56dim NK cells expressed significantly less IL-2R! (68.28 
± 2.41 %) than PB CD56dim NK cells (87.86 ± 0.94 %) (p < 0.0001) (Fig 3.14A, E). CB 
NK cell subsets exhibited significantly lower levels of IL-12R"1 expression (92.00 ± 
1.65 % by CD56bright NK cells and 70.81 ± 5.86 % by CD56dim NK cells), as compared 
to PB CD56bright and CD56dim NK cells (97.78 ± 1.18 % and 91.92 ± 1.28 % 
respectively) (p < 0.05) (3.13 B and E, 3.14 B and E). Conversely, CB NK cell subsets 
showed slightly higher expression of IL-12R"2 than PB NK cells (Fig 3.13 B, E and 
Fig 3.14 B, E). IL-15R! expression was higher on CD56bright CB NK cells (12.88 ± 2.02 
%) in comparison to PB CD56bright NK cells (6.05 ± 1.21 %) (p = 0.0214) (Fig 3.13 C, 
E), whereas CD56dim CB NK cells showed equivalent IL-15R! expression to PB 
CD56dim NK cells (Fig 3.14 C, E). CD56bright CB NK cells expressed significantly less 
IL-18R! than CD56bright PB NK cells (94.25 ± 1.95 % and 69.99 ± 6.24 % respectively) 
(p = 0.0070) (Fig 3.13 D, E). Similarly, CD56dim CB NK cells showed lower levels of 
IL-18R! (34.18 ± 4.95 %) than CD56dim PB NK cells (56.80 ± 5.19 %) (p = 0.0091) 
(Fig 3.14 D, E). Overall, PB NK cells express higher levels of IL-2R!, IL-12R"1 and 
IL-18R! than CB NK cells, whereas CD56bright CB NK cells express higher levels of 








Figure 3.13 Cytokine receptor expression by CD56bright CB and PB NK cells. 
Gates were adjusted on CD56bright NK cells. Flow cytometric histograms show the 
expression of IL-2 receptor ! (A) and " (B), IL-12 receptor "1 (C) and "2 (D), IL-15 
receptor ! (E) and IL-18 receptor ! (F) by PB and CB CD56bright NK cells. G) 
Comparison of cytokine receptor expression between PB and CB CD56bright NK cells. 
This analysis was performed on resting lymphocytes. The combination of monoclonal 
antibodies used in this analysis is shown in Table 2.16. Results are presented as Mean ± 
SD. PB N=6, CB N=8, (*) p <0.05. 
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Figure 3.14 Cytokine receptor expression by CD56dim CB and PB NK cells. Gates 
were adjusted on CD56dim NK cells. Flow cytometric histograms show the expression 
of IL-2 receptor ! (A) and " (B), IL-12 receptor "1 (C) and "2 (D), IL-15 receptor ! (E) 
and IL-18 receptor ! (F) by PB and CB CD56dim NK cells. G) Comparison of cytokine 
receptor expression between PB and CB CD56dim NK cells. This analysis was 
performed on resting lymphocytes. The combination of monoclonal antibodies used in 
this analysis is shown in Table 2.16. Results are presented as Mean ± SD. PB N=6, CB 
N=8, (*) p <0.05, (**) p <0.01, and (***) p <0.01. 
 
3.2.5 Stimulation of CB NK cells with IL-2 induced less STAT5 phosphorylation 
than stimulation of PB NK cells 
As I observed less activation of CB NK cells following stimulation with IL-2, 
signalling downstream of this receptor was compared for CB and PB NK cells after 
stimulation with IL-2. Binding of IL-2 to its receptor initiates phosphorylation of the 
signal transducer and activator of transcription 5 (STAT5), which is key for NK cell 
activation, proliferation and survival (Becknell and Caligiuri, 2005, Carson et al., 
1994). Intracellular expression of phosphorylated (p)-STAT5 was therefore assessed 
after stimulation of NK cells with IL-2 for 15 min or 48 h. The latter time point was 
selected because optimal induction of IL-2R! expression is reported to occur after 
approximately 48 h of activation and may result in an increased p-STAT5 expression 
(Johnston et al., 1995, Pillet et al., 2009). STAT5 was significantly less phosphorylated 
in CB NK cells compared to PB NK cells (Fig 3.15 A). After 15 min of IL-2 
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stimulation, the percentage of p-STAT5 expression by PB and CB NK cells was 81.94 
± 7.6 7% and 45.80 ± 5.86 % respectively (p = 0.0057). At day two, the percentage of 
p-STAT5 expression by PB NK cells was 89.33 ± 2.81 %, whereas it was 43.00 ± 5.82 
% for CB NK cells (p < 0.0001) (Fig 3.15 B). Lower density of p-STAT5 expression 
(MFI) was observed for CB NK cells after 15 min and two days of activation (p value < 




Figure 3.15 Analysis of phosphorylated STAT5 expression by cytokine-activated 
CB and PB NK cells. A) Flow cytometric analysis of the relative phosphorylation of 
STAT5 (p-STAT5) after 15 min stimulation of PB and CB NK cells with IL-2. B) 
Mean percentage of expression of p-STAT5 after 15 min of stimulation with IL-2. C) 
Density (MFI) of p-STAT5 expression after stimulation with IL-2 for 15 min or 2 days 
for PB and CB NK cells. Analysis was performed on purified NK cells stimulated with 
IL-2 for 15 min or 2 days. Results are presented as Mean ± SD. Control = Unstimulated 
NK cells. PB N=5, CB N=5, Control N=3. p <0.01 (**), and p <0.01 (***). 
 
Higher expression of CD69 and NKp44 was observed for CB NK cells activated with 
IL-12 as compared to PB NK cells activated with the same cytokine. Therefore, 
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activation of signalling molecules downstream of the IL-12 receptor were also 
compared for CB and PB NK cells. Although many STAT proteins are involved in the 
IL-12 signalling pathway, STAT4 plays a significant role in inducing NK cell 
cytotoxicity and IFN-! production via IL-12 (Wang et al., 2000). Thus, intracellular 
staining for p-STAT4 after stimulation of NK cells with IL-12 was performed (Fig 3.16 
A). However, constitutive phosphorylation of STAT4 was observed for both stimulated 
and unstimulated PB and CB NK cells (Fig 3.16 B, C). 
 
 
Figure 3.16 Analysis of phosphorylated STAT4 expression by cytokine-activated 
CB and PB NK cells. A) Flow cytometric analysis of the relative phosphorylation of 
STAT4 (p-STAT4) after 15 min stimulation of PB and CB NK cells with IL-12. B) 
Mean percentage of expression of p-STAT4 after 15 min stimulation with IL-12 C) 
Density (MFI) of p-STAT4 expression after stimulation with IL-12 for 15 min or 2 days 
for PB and CB NK cells. Analysis was performed on purified NK cells stimulated with 
IL-2 for 15 min or 2 days. Results are presented as Mean ± SD. Control = unstimulated 
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3.2.6 Cytokine activation induces formation of an apoptotic population of PB 
and CB NK cells 
As two populations of NK cells are noted on forward scatter versus side scatter flow 
cytometry analysis plots after stimulation with cytokine, NK cell viability and apoptotic 
state were assessed using 7AAD and Annexin V (Fig 3.17 A). Necrotic cells that have 
lost membrane integrity stain positive for 7AAD, whereas apoptotic cells that express 
phosphatidylserine (PS) stain positive for Annexin V. It was found that the smaller 
cells, with respect to forward scatter, were dead cells, as they were positive for 7AAD 
(Fig 3.17 A). In contrast, the cells that responded to cytokines were bigger (with respect 
to forward scatter) and represented live cells (Fig 3.17 A). Expression of the anti-
apoptotic protein B-cell lymphoma (Bcl)-2 was then assessed for NK cells stimulated 
with cytokine using real-time PCR. Selective upregulation of Bcl-2 was observed for 
PB NK cells activated with IL-2 in comparison to CB NK cells activated with IL-2 (p = 
0.0298) (Fig 3.17 B). In addition, Bcl-2 expression was not upregulated by PB or CB 
NK cells for any of the other cytokines tested which could explain the existence of an 






Figure 3.17 NK cell viability and expression of the anti-apoptotic marker Bcl-2 
after stimulation of CB and PB NK cells with cytokines. A) Flow cytometry plot 
showing two populations gated based on forward-scatter versus side-scatter (left panel), 
Annexin V versus 7AAD staining gated on the viable cytokine-responsive NK cells 
(middle panel) or gated on the 7AAD+ necrotic NK cells (right panel). B) Relative Bcl-
2 gene expression after 24 h stimulation with cytokines. mRNA quantity was 
normalised against three reference genes (ACTB, !2M  and UBC). Resting PB and CB 
NK cells N=3, cytokine-activated PB N=4 - 5, CB N=5 – 6. p < 0.05 (*). 
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CB NK cells have unique phenotypic characteristics in comparison to PB NK cells. CB 
NK cells are reported to have higher NKG2A expression and low expression of KIR, 
adhesion molecules and some activating receptors (Dalle et al., 2005, Luevano et al., 
2012a, Tanaka et al., 2003, Wang et al., 2007). These phenotypic features are indicative 
of CB NK cells being less mature, which may suggest that they are less functional. 
Therefore, the effects of cytokine activation on the phenotype of CB NK cells were 
analysed. A comprehensive comparison between PB NK cells and CB NK cells was 
performed to assess different mechanisms of activation and responsiveness to specific 
cytokine. The cytokines used to activate PB and CB NK cells were IL-2, IL-12, IL-15 
and IL-18. Herein, the acquisition of an activated phenotype by CB and PB NK cells 
upon cytokine activation was confirmed.  
 
CB NK cells were less activated following IL-2 stimulation than PB NK cells, as CB 
NK cells expressed lower levels of CD69 and NKp44 after exposure to IL-2. IL-2 binds 
to the ! subunit of the IL-2 receptor with low affinity, whereas binding of IL-2 to the " 
chain and # chain confers intermediate affinity. To achieve high affinity binding, 
association of the intermediate affinity chains (" and #) with the ! chain is required 
(Voss et al., 1992). Here, expression of the # chain by NK cells was not investigated, as 
this molecule is undetectable at the surface of quiescent NK cells (David et al., 1998). 
In contrast, IL-2R" is expressed constitutively by resting PB and CB NK cells (Dalle et 
al., 2005, David et al., 1998, Luevano et al., 2012a) and is believed to play a significant 
role in initiating NK cell activation by IL-2 (Pillet et al., 2009, Pillet et al., 2008). Upon 
binding of IL-2 to IL-2R", rapid expression of the # chain occurs leading to increased 
responsiveness to IL-2. This is followed by the induction of IL-2R! expression, which 
is involved in high affinity binding, although this occurs with slower kinetics than for 
the induction of IL-2R# expression. This may contribute to a sequential response of NK 
cells to IL-2 stimulation, which could be initiated by binding of IL-2 to the IL-2R" 
chain followed by phosphorylation of signalling components. Subsequently, this results 
in the expression of high-affinity receptors and upregulation of activation receptors 




It has been reported that cytokine concentration is a key factor for activation of NK 
cells. High concentrations of cytokine may induce signalling through the intermediate-
affinity chain (Nakamura et al., 1994, Waldmann, 2006). Although CD56bright NK cells 
respond to picomolar doses of IL-2, CD56dim NK cells require higher doses of IL-2 due 
to lower expression of IL-2R! (Cooper et al., 2001a). Thus, signalling events may be 
enhanced through the intermediate affinity receptors by increasing the dose of IL-2. 
Here, activation of CB NK cells required five times more IL-2 (1000 IU/mL) than PB 
NK cells (200 IU/mL), however the activation level observed was remarkably less for 
CB NK cells. Similar expression levels of IL-2R" by CB and PB CD56bright and 
CD56dim NK cells was found, but lower expression of IL-2R! by CB CD56dim NK cells 
was observed, as compared to PB CD56dim NK cells. Binding of IL-2 to IL-2R" is 
known to activate Janus Kinase (JAK) 1 which is downstream of STAT5, and 
phosphorylation of STAT5 induces the transcription of target genes. A significant 
reduction in p-STAT5 expression by CB NK cells was noted after stimulation with IL-2 
as compared to PB NK cells. However, how this correlates with lower activation levels 
observed after stimulation with IL-2 is not known and needs further investigation. In 
addition, less phosphorylation of the STAT5 pathway downstream of the IL-2 receptors 
in CB NK cells may interfere with their responsiveness to IL-2 where STAT5 itself is a 
key regulator of IL-2R! gene expression (Lécine et al., 1996). Interestingly, I observed 
optimal activation of CB NK cells with IL-15, which also signals through STAT5. This 
implies that the reduced response of CB NK cells to IL-2 is a result of lower IL-2R! 
expression levels, rather than downstream signalling components. 
 
A higher level of IL-15R! expression by CB CD56bright NK cells than PB CD56bright NK 
cells was observed. Unlike IL-2R!, IL-15R! provides high affinity binding to IL-15 
and its cytoplasmic domain is directly connected to signalling components. The IL-
15/IL-15R! complex also triggers signalling into IL-15-responsive neighbouring cells 
by a phenomenon called trans-presentation (Dubois et al., 2002, Huntington et al., 
2009). This could explain why I observed maximal activation of CB NK cells using a 
low concentration of IL-15. Moreover, IL-15R! plays a critical role in NK cell 
development (Huntington et al., 2009). Although CB NK cells reach late stages of 
development, their maturation is incomplete. The IL-15/IL15R!-complex has been 
shown to be essential for the progression from a CD56brightCD16-KIR- phenotype to a 
CD56dimCD16+KIR- phenotype and finally to a mature CD56dimCD16+KIR+ NK cell 
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phenotype (Huntington et al., 2009). Therefore, the higher expression of IL-15R! 
suggests an enhanced readiness of CB NK cells to respond to IL-15 exposure that may 
be needed to drive their final maturation.  
 
Here, I showed that both subsets of CB NK cells express significantly less IL-12R!1 
but equivalent levels of IL-12R!2 to PB NK cells. The IL-12R is composed of two low 
affinity chains; IL-12R!1 and IL-12R!2, in which cooperation of the !1 and !2 chains 
is required to initiate phosphorylation of IL-12 signalling components such as STAT4. 
Resting T cells broadly express IL-12R!1, but scarcely express IL-12R!2. In contrast, 
NK cells express IL-12R!2 allowing them to respond promptly to IL-12 activation 
(Wang et al., 2000). Nonetheless, I observed enhanced responsiveness to IL-12 
activation by CB NK cells. This suggests that IL-12R!1 expression may be upregulated 
after stimulation with IL-12, although was not tested here. CB NK cells showed higher 
p-STAT4 MFI than PB NK cells after 15 min stimulation with IL-12, which may 
correspond with better activation. Yet, high background of STAT4 phosphorylation was 
observed for both stimulated and unstimulated NK cells, which could be a result of NK 
cell handling or processing. 
 
A proportion of the cytokine-treated NK cells were apoptotic. This was observed in all 
cultures including PB and CB NK cells. It remains unknown whether these cells were 
exhausted after activation or die as a result of cytokine toxicity. However, it is more 
likely that these cells are not responsive to cytokine. Indeed, reduced expression of high 
affinity cytokine receptors by NK cells could lead to apoptosis due to lack of a survival 
signal. Bcl-2 is an anti-apoptotic protein and its upregulation by NK cells promotes 
their survival. While IL-2 promoted upregulation of Bcl-2 by PB NK cells, this was not 
observed for CB NK cells. IL-15 activation is known to upregulate Bcl-2 expression by 
NK cells to promote their survival (Carson et al., 1997). In this study, the cells were 
stimulated for 24 h because the quantity of the mRNA recovered was very low after 
longer incubation of NK cells with cytokines. This could be because the genes are 
transcribed and translated in order to assemble the Bcl-2 proteins, which yields 




NK cell effector function can be triggered by a variety of receptors. These triggering 
receptors are defined as NCRs belonging to the immunoglobulin superfamily and are 
able to mediate NK cell cytotoxicity upon engagement of their ligands on target cells 
(Moretta et al., 2000). Among these receptors, NKp44 is exclusively expressed by 
activated NK cells and NKp44 upregulation by activated NK cells is involved in killing 
of tumour cells (Vitale et al., 1998). It has been shown that masking of NKp44 using 
monoclonal antibodies affects NK cell mediated killing of susceptible targets (Cantoni 
et al., 1999). NKp44 was upregulated by CB NK cells after activation with all cytokines 
used in this study but to a lesser extent with IL-2. The ligand for this receptor has 
recently been discovered (NKp44L), which is a variant of mixed-lineage leukaemia-5 
(MLL5) (Baychelier et al., 2013). Elevated MLL5 levels were found to be associated 
with better outcomes in AML patients (Damm et al., 2011). Furthermore, NKp44L is 
expressed on a variety of haematopoietic and non-haematopoietic tumour cell lines and 
binds restrictively to NKp44 leading to lysis of tumour cells (Baychelier et al., 2013). 
High expression of NKp44, especially by NK cells activated with IL-15, was noted. 
Thus, IL-15 activated CB NK cells could potentially be effective against cancer cells in 
a NK cell-adoptive transfer therapy setting. Indeed, high levels of NKp44 expression by 
IL-15 activated CB NK cells is considered to be beneficial for NK cell-based therapy 
and IL-15 is currently being clinically tested in this context by Miller and colleagues 
(clinicaltrials.gov, trial number; NCT01385423). IL-15 is a better candidate for 
cytokine-based therapy as compared to other cytokines used in this study for several 
reasons. Firstly, IL-15 is required for NK cell homoeostasis, expansion and survival in 
vivo (Carson et al., 1997, Evans et al., 1997). Secondly, NK cell development and 
differentiation is IL-15 dependent (Mrozek et al., 1996). Thus, IL-15 may enhance NK 
cell differentiation from CD34+ progenitors after HSCT promoting NK cell 
reconstitution and a GvL effect. Moreover, IL-15 does not promote the expansion of 
Treg cells, which was observed to hamper NK cell cytotoxicity in IL-2 based clinical 
trials (Barkholt et al., 2009, Geller et al., 2011). 
 
NK cell activation is a cooperative process involving activating and inhibitory 
receptors. The strength of the transduced signal is largely dependent on the relative 
amounts of activating/inhibitory receptor expression (Wang et al., 2007). Inhibitory 
receptor expression by NK cells also correlates with their degree of maturity. NK cells 
at early stages of differentiation express high densities of CD94/NKG2A and scarce 
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amounts of CD16. The progression towards a fully mature NK cell is associated with 
decreased expression of CD94 and up-regulation of KIR. Hence, CD56dimCD16bright NK 
cells exhibit a more differentiated phenotype with high expression of KIR and enhanced 
killing capacity (Freud and Caligiuri, 2006). The results described here provide an 
indication that in vitro cytokine activation promotes activation of NK cells without 
changing the expression of their inhibitory receptors. In this regard, both resting and 
activated CB NK cells express higher CD94/NKG2A levels and lower levels of KIR 
indicating that they are less mature and have reduced cytotoxicity due to higher 
engagement of inhibitory receptors over activating ones. KIR mismatch is critical for 
inducing NK cell alloreactivity in HSCT. KIR2DL1+ NK cells are selectively able to 
lyse leukaemic blasts expressing C1 HLA group alleles whereas KIR2DL2/3+ NK cells 
are inhibited by C2 HLA group alleles (Pende et al., 2009). Yet, it is unknown how 
much KIR expression is needed to mediate a GvL effect. A study that aimed to predict 
how much KIR expression is required to mediate a GvL effect showed significant 
variation (0-62 %) in KIR expression for potential alloreactive NK cells based on both 
frequency and the type of missing KIR ligands (Fauriat et al., 2008). Herein, CB NK 
cells exhibited KIR expression, although to a lower extent than PB NK cells, suggesting 
that CB NK cells could still mediate alloreactivity. Indeed, the role of KIR mismatch in 
mediating CB NK cell alloreactivity after transplantation cannot be excluded (Beziat et 
al., 2009).  
 
To summarise, cytokine activation induced an activated phenotype of CB NK cells. CB 
NK cells showed enhanced responsiveness to IL-15, IL-18 and IL-12, but were less 
responsive to IL-2 than PB NK cells. This was associated with lower expression of IL-
2R! and reduced phosphorylation of STAT5 upon stimulation with IL-2 for CB NK 
cells. The data presented here shows that CB NK cells can respond to cytokine 
activation. Therefore, the functionality of CB and PB NK cells after cytokine 
stimulation was explored in the following chapters. 
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Chapter 4: Functional analysis of cytokine-activated NK cells 
 
4.1 Introduction 
During infection, activated DCs and macrophages release cytokines including IL-12, 
IL-15 and IL-18 leading to increased NK cell effector functions (Cooper et al., 2004). 
In addition, NK cell exposure to these cytokines during viral infection results in rapid 
proliferation and increased numbers of circulating NK cells (Biron et al., 1983). NK 
cell proliferation during the early phases of infection is non-specific (Dokun et al., 
2001, Yokoyama et al., 2004), however, specific proliferation of a subset of NK cells 
that preferentially express Ly49H receptors was observed in a MCMV mouse model at 
late phases of infection (Dokun et al., 2001, French et al., 2006b). The influence of 
cytokines on proliferation of PB NK cells has been intensively investigated. Typically, 
cytokines of the common ! chain family, IL-2 and IL-15, appear to be key for 
promoting NK cell expansion (Ma et al., 2006). In addition, synergistic proliferative 
responses were seen following stimulation of NK cells with a combination of IL-2 and 
IL-12 (Wang et al., 2000), IL-2 and IL-18 (Son et al., 2001), or a combination of IL-15 
and IL-18 (French et al., 2006a).  
 
As for CB NK cells, it has been shown that IL-2 stimulation induces expansion of CB 
NK cells (Dalle et al., 2005, Wei et al., 2005). Dalle et al. showed that CB NK cells 
respond to nanomolar doses of IL-2 exhibiting proliferative capacity similar to PB NK 
cells after 7 days of stimulation (Dalle et al., 2005). Conversely, it was shown by our 
group that although CB NK cells divide after IL-2 stimulation, their proliferative 
response is slower than PB NK cells (Luevano et al., 2012a). In addition, it was 
reported that CB NK cells require higher doses of IL-2 to expand in vitro (Condiotti et 
al., 2001, Luevano et al., 2012a). However, proliferation of CB NK cells in response to 
other key cytokines requires further study.  
 
In contrast to PB NK cells, resting CB NK cells are unable to lyse K562 cells with high 
efficiency (Dalle et al., 2005, Gaddy et al., 1995, Luevano et al., 2012a)However, the 
cytotoxic function of CB NK cells could be enhanced upon stimulation with IL-2 
(Condiotti et al., 2001, Gaddy et al., 1995, Luevano et al., 2012a, Xing et al., 2010), IL-
12 (Gaddy et al., 1995), IL-15 (Gaddy and Broxmeyer, 1997) or IL-18 (Nomura et al., 
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2001). Killing of K562 cells by NK cells occurs via the granzyme/perforin-mediated 
pathway whereby these molecules induce damage to the target cell membrane and cell 
death (Vujanovic et al., 1996). Notably, poor killing capacity by resting CB NK cells 
seems to be associated with low expression of the cytotoxic mediators granzyme B and 
perforin (Luevano et al., 2012a, Wang et al., 2007). Yet, the effect of other cytokines on 
granzyme B and perforin expression and cytotoxicity of CB NK cells is not known.  
 
Upon stimulation, NK cells release IFN-! and TNF-" that act as a co-stimulatory signal 
for other immune cells (Cooper et al., 2004), inhibit tumour growth (Dighe et al., 1994, 
Ikeda et al., 2002) and enhance killing through upregulation of specific receptors on 
target cells (Wang et al., 2012). Reports analysing IFN-! production by CB NK cells 
show inconsistent results. Comparable production of IFN-! by CB and PB NK cells 
after PMA/ionomycin stimulation was described by Dalle et al. and Wang et al. (Dalle 
et al., 2005, Wang et al., 2007). Conversely, it was shown by Luevano et al. that 
although CB CD56bright NK cells have comparable intracellular IFN-! levels to PB 
CD56bright NK cells, CB CD56dim NK cells express significantly less intracellular IFN-! 
than PB CD56dim NK cells (Luevano et al., 2012a). Similarly, CB NK cells express less 
intracellular TNF-" than PB NK cells (Krampera et al., 2000). Cytokine stimulation, in 
particular with IL-12 and IL-18, induces the production of IFN-! and TNF-" by PB NK 
cells (Fehniger et al., 1999). However, the repertoire of cytokines elaborated by CB NK 
cells upon cytokine activation remains to be investigated as most of the existing studies 
analysed intracellular cytokine expression, which does not necessarily correlate with 
their secretion.  
 
To our knowledge, many features of CB NK cell functionality upon cytokine activation 
have not been investigated. Proliferation of CB NK cells was shown after IL-2 
stimulation but it is still unknown whether other cytokines can induce better 
proliferation of CB NK cells. Furthermore, the killing capacity of CB NK cells was 
investigated following stimulation with cytokines in separate studies but they did not 
address whether these cytokines impact on granzyme B and perforin expression at the 
transcriptional level. 
 
In this chapter, I explored the effect of cytokine activation on CB NK cell proliferation 
and compared it to PB NK cells. Furthermore, I analysed mRNA levels of granzyme B 
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and perforin in PB and CB NK cells following stimulation with cytokines and 
correlated gene expression with cytotoxicity. In addition, secretion of cytokines by 
cytokine-activated CB NK cells was compared to PB NK cells using multiplex assays 
(bead-based immunoassay) in order to identify the specific cytokine secretion patterns 
of different sources of NK cells. The response of PB and CB NK cells to different 
cytokine conditioning regimes will help determine whether different mechanisms of 






4.2.1 Assessment of NK cell proliferation after cytokine stimulation 
4.2.1.1 PB and CB NK cells showed the greatest tendency to proliferate in response 
to IL-15+IL-18 
The majority of NK cells are quiescent in vivo and their expansion occurs following 
exposure to cytokines such as IL-12 and IL-15 produced by activated monocytes, or IL-
2 produced by activated T cells (Warren, 1996). Herein, proliferation of NK cells was 
tracked using CFSE after cytokine stimulation (Table 2.12). CFSE-labelled NK cells 
from both CB and PB showed a similar pattern of proliferation at day 2 regardless of 
the cytokine used (Fig 4.1 and Fig 4.2 respectively). Therefore, it is possible that 
reduced CFSE fluorescence at day 2 resulted from a decay of CFSE intensity rather 
than actual cellular divisions, however this could not be tested as unstimulated CB NK 
cells will undergo apoptosis in this timeframe. At day 5, however, PB and CB NK cells 
showed differential proliferation in response to cytokines. PB NK cells showed the 
highest tendency to proliferate in response to IL-15+IL-18 (Fig 4.1 D), followed by IL-
2 (Fig 4.1 A), IL-15+IL-2 (Fig 4.1 C), and IL-15 (Fig 4.1 B). Different proliferation 
responses to cytokines were seen for CB NK cells, with IL-15+IL-18 (Fig 4.2 D) 
showing the greatest proliferative response, followed by IL-15+IL-2 (Fig 4.2 C) and IL-
15 (Fig 4.2 B). Notably, CB NK cells activated with IL-2 did not proliferate further 
between days 2 and 5 (Fig 4.2 A). Altogether, activation with IL-15+IL-18 induced 
optimum expansion of PB and CB NK cells post-cytokine stimulation. Figure 4.3 







Figure 4.1 Proliferation of PB NK cells in response to stimulation with 
cytokines. CFSE dilution by PB NK cells activated with IL-2 (A), IL-15 (B), IL-15+IL-
2 (C) and IL-15+IL-18 (D) assessed at day 2 (left panel) and day 5 (right panel) post-
stimulation with cytokines. Grey peak indicates CFSE staining at day 0. Histograms 
show representative data from four independent experiments. 
 
















































































































Figure 4.2 Proliferation of CB NK cells in response to stimulation with 
cytokines. CFSE dilution by CB NK cells activated with IL-2 (A), IL-15 (B), IL-
15+IL-2 (C) and IL-15+IL-18 (D) assessed at day 2 (left panel) and day 5 (right panel) 
post-stimulation with cytokines. Grey peak indicates CFSE staining at day 0. 





















































































































Figure 4.3 NK cell proliferation after 5 days stimulation with cytokine. A) 
CFSE dilution by 3 samples of PB NK cells stimulated with IL-2, IL-15, IL-15+IL-2 
and IL-15+18 for 5 days. B) CFSE dilution by 3 samples of CB NK cells stimulated 
with IL-2, IL-15, IL-15+IL-2 and IL-15+18 for 5 days. 
 
4.2.2 Assessment of NK cell cytotoxicity after cytokine stimulation 
Although resting PB NK cells exhibit cytotoxicity against K562 cells, their cytolytic 
function is enhanced upon stimulation with cytokines. In contrast to PB NK cells, 
resting CB NK cells showed poor cytotoxicity in previous studies and their cytolytic 
function was only induced after cytokine stimulation (Dalle et al., 2005, Gaddy et al., 
1995, Luevano et al., 2012a). In order to identify which cytokine or combination of 
cytokines promotes optimum cytolytic function of NK cells, a classical 4 h-51Cr-release 
assay was performed. K562 cells were used as target cells at different effector to target 
ratios including 1:1, 5:1 and 10:1. Effector NK cells were stimulated with cytokines 
prior to co-culture with K562 cells.  
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4.2.2.1 PB NK cells demonstrated enhanced killing capacity post-stimulation with 
IL-2, IL-15 or IL-12, whereas optimal killing capacity of CB NK cells was 
observed post-stimulation with IL-15 or with the combination of IL-15+IL-2  
Cytotoxicity of cytokine-activated NK cells against K562 cells was assessed using a 
51Cr-release assay. Figure 4.4 shows a comparison between the killing of K562 cells by 
PB and CB NK cells at day 2 of stimulation with different cytokines. Interestingly, IL-2 
activated CB NK cells showed poor killing capacity at day 2 post IL-2 stimulation at 
E:T ratios of 5:1 (Fig 4.4 B) and 10:1 (Fig 4.4 C) (% of specific lysis = 14.26 ± 2.87 % 
and 22.36 ± 4.86 % respectively) as compared to PB NK cells at the same E:T ratios 
(26.28 ± 1.61 % and 40.67 ± 4.85%, p = 0.0108 and p = 0.0372 respectively). However, 
the cytotoxicity of CB NK cells had increased at day 5 post-stimulation and was 
comparable to PB NK cells (Fig 4.5). For IL-2 activated CB NK cells, an E:T ratio of 
1:1 was not sufficient to induce killing of K562 cells, whereas better killing was seen 
by PB NK cells at this ratio (Fig 4.4 A, 4.5 A).  
 
NK cell killing capacity was substantially enhanced by IL-15 as compared to IL-2 for 
both CB and PB NK cells at day 2 (Fig 4.4). This was shown at E:T ratios of 10:1 (PB 
= 51.07 ± 4.16 % and CB = 45.28 ± 8.10 %) (Fig 4.4 A) and 5:1 (PB = 42.32 ± 4.54 % 
and CB = 35.93 ± 8.80 %) (Fig 4.4 B). However, the cytolytic activity of CB NK cells 
was reduced by day 5 post-stimulation at E:T ratios of 5:1 and 10:1 (23.53 ± 10.40 % 
and 30.09 ± 8.96 % respectively) (Fig 4.5 B and C). 
 
Stimulation of PB NK cells with IL-12 promoted significantly higher killing of K562 
cells than IL-12 stimulated CB NK cells (Fig 4.4). Interestingly, lower ratios of effector 
cells (E:T ratios of 1:1 or 5:1) were required for killing by IL-12 activated PB NK cells 
(Fig 4.4 A, B). Percent specific lysis of K562 cells by IL-12 activated PB NK cells (5:1 
E:T ratio) was 46.56 ± 5.67 %, whereas specific lysis was significantly less for CB NK 
cells (22.13 ± 6.89 %) (P = 0.0258). Similarly, greater killing was seen for PB NK cells 
at a 10:1 E:T ratio when compared to CB NK cells (50.53 ± 7.91 % and 31.96 ± 8.169 
% respectively). 
 
Although IL-18 promoted killing of K562 cells by PB NK cells, it did not induce 
similar activity by CB NK cells (Fig 4.4). This was found at all E:T ratios used in this 
study. At a 1:1 ratio, specific lysis was 8.31 ± 1.78 % by PB and 1.60 ± 1.12 % by CB 
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NK cells, p = 0.023 (Fig 4.4 A). Increasing the number of effector cells to a 5:1 ratio 
also had no effect on the killing by CB NK cells (6.26 ± 2.480 %) as compared to PB 
NK cells (29.91 ± 3.20 %) (p = 0.0007) (Fig 4.4 B). Similarly, CB NK cells showed 
lower cytotoxicity at a ratio of 10:1 (11.32 ± 4.82 %) compared to PB NK cells (34.88 
± 3.14 %), p = 0.0026 (Fig 4.4 C).  
 
Comparable killing capacity for both IL-15+IL-2 activated PB and CB NK cells was 
seen at day 2 (Fig 4.4). However, CB NK cells showed significantly higher killing 
capacity at day 5 (Fig 4.5). At a 10:1 E:T ratio, mean percent specific lysis by CB NK 
cells was 46.69 ± 4.80 %, whereas for PB NK cells it was 31.54 ± 2.75 % (p = 0.0338) 
(Fig 4.5 C). The killing capacity of IL-15+IL-18 activated CB NK cells was 
significantly lower than IL-15+IL-18 activated PB NK cells at day 2 for all of the ratios 
examined including a 1:1 ratio, (Fig 4.4 A), 5:1 ratio (Fig 4.4 B) and 10:1 ratio (Fig 4.4 
C) (p = 0.0025, p = 0.0023 and p = 0.0003 respectively). However, IL-15+IL-18 
activated CB NK cells exhibited improved killing capacity after 5 days of cytokine 
stimulation (Fig 4.5). At an E:T ratio of 10:1, CB NK cells showed a specific lysis as 
high as 36.93 ± 1.79 %, which was greater than the specific lysis measured for PB NK 
cells at the same time point (28.71 ± 4.258 %) (Fig 4.5 C). Overall, CB NK cells 
showed maximal cytotoxicity following IL-15+IL-2 stimulation, whereas PB NK cells 
showed the highest cytotoxicity after IL-15 and IL-12 stimulation. 
! "#$%&'(!)!!
! 133 
Figure 4.4 Killing of K562 cells by cytokine-activated NK cells 2 days after 
stimulation with cytokines. Comparison of PB (red) and CB (blue) NK cell 
cytotoxicity against K562 cells examined at E:T ratios of 1:1 (A), 5:1 (B) and 10:1 (C) 
by 51Cr-release assay. E:T = effector to target ratio. N=4. p (*) < 0.05, p<0.01 (**), and 
p<0.001 (***). Specific lysis was calculated as (experimental release – spontaneous 
release) ÷ (maximum release – spontaneous release) ! 100. Results are presented as 
Mean ± SD. 
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Figure 4.5 Killing of K562 cells by cytokine-activated NK cells 5 days after 
stimulation with cytokines. Comparison of PB (red) and CB (blue) NK cell 
cytotoxicity against K562 cells examined at E:T ratios of 1:1 (A), 5:1 (B)  and 10:1 (C) 
by 51Cr-release assay. E:T = effector to target ratio. N=4. p (*) < 0.05, (*), p<0.01 (**), 
and p<0.001 (***). Specific lysis was calculated as (experimental release – spontaneous 
release) ÷ (maximum release – spontaneous release) ! 100. Results are presented as 
Mean ± SD. 
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4.2.2.2 Cytokine activation induced comparable granzyme B gene expression by 
PB and CB NK cells except for CB NK cells activated with IL-18 or the 
combination of IL-15+IL-18 that showed significantly less granzyme B expression 
than PB NK cells  
To determine whether the expression of granzyme B and perforin correlates with NK 
cell cytotoxicity, the relative granzyme B and perforin gene expression was assessed 
using real-time PCR. IL-2 activated PB NK cells had higher relative gene expression of 
granzyme B than IL-2 activated CB NK cells, but the difference was not significant 
(Fig 4.6 A). In contrast, comparable levels of perforin were detected in both resting and 
IL-2 activated PB and CB NK cells (Fig 4.6 B). No distinctive granzyme B (Fig 4.6 A) 
or perforin (Fig 4.6 B) gene expression was found for either resting or for IL-12 or IL-
15 activated CB NK cells or PB NK cells. Interestingly, IL-18 activated CB NK cells 
showed significantly less granzyme B (Fig 4.6 A) and perforin (Fig 4.6 B) expression 
as compared to PB NK cells, p = 0.0407. These results indicate that resting CB NK 
cells have higher granzyme B expression than those activated with IL-18, p = 0.0367. 
 
Resting and IL-15+IL-2 activated PB and CB NK cells showed equivalent granzyme B 
(Fig 4.6 A) and perforin (Fig 4.6 B) gene expression. In contrast, activation with IL-
15+IL-18 induced different granzyme B gene expression in PB and CB NK cells. 
Interestingly, granzyme B gene expression was significantly lower for CB NK cells 
activated with IL-15+IL-18 as compared to PB NK cells, p = 0.0005. This could 
explain the lower killing capacity observed for CB NK cells at day 2 post-stimulation 
with IL-15+IL-18. Moreover, granzyme B gene expression was significantly 
upregulated in IL-15+IL-18 activated PB NK cells as compared to resting PB NK cells, 
p = 0.0033 (Fig 4.6 A). Conversely, expression of perforin was not affected by IL-
15+IL-18 stimulation for either PB or CB NK cells (Fig 4.6 B). Altogether, a trend 
toward higher granzyme B expression in PB NK cells than CB NK cells although not 
significant, whereas perforin levels appeared to be comparable between both sources 







Figure 4.6 Analysis of granzyme B and perforin gene expression by cytokine-
activated NK cells. Real-time PCR analysis of granzyme B (A) and perforin (B) 
relative gene expression by cytokine-activated NK cells, as compared to resting NK 
cells. mRNA quantity was normalised against three reference genes (ACTB, !2M  and 
UBC). Results are presented as Mean ± SD. Resting NK cells (N=3), cytokine-activated 
NK cells from PB (N=5) and from CB (N=6). 
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4.2.3 Cytokine secretion by cytokine-activated NK cells 
Secretion of cytokines into culture supernatants was analysed using multiplex (bead-
based immunoassays) at days 2 and 5 post-stimulation with cytokines. Secretion of 
IFN-!, IL-1", IL-4, IL-5, IL-6, IL-8, IL-10, TNF-#, and TNF-" by cytokine-activated 
NK cells was analysed.  
 
4.2.3.1 PB NK cells secreted the highest concentrations of IFN-! post-stimulation 
with IL-2, IL-15 or IL-15+IL-18, whereas CB NK cells showed substantial 
secretion of IFN-! upon stimulation with IL-12 or IL-15+IL-18 
Significantly higher secretion of IFN-! by PB NK cells was observed as compared to 
CB NK cells at days 2 and 5 post-stimulation with IL-2 (10411 ± 846.0 pg/mL and 
1917 ± 1009 pg/mL, p = 0.0002) (Fig 4.7 A). Similarly, PB NK cells secreted 
substantial amounts of IFN-! at day 5 (10130 ± 3034 pg/mL) compared to CB NK cells 
(1380 ± 615, p = 0.0301) (Fig 4.7 B). This was associated with significant upregulation 
of IFN-! gene expression by PB NK cells activated with IL-2 compared to resting PB 
NK cells (p = 0.0063) (Fig 4.7 C). 
 
Both PB and CB NK cells secreted high amounts of IFN-! upon stimulation with IL-15 
(Fig 4.7). Upon analysing IFN-! gene expression by real-time PCR, it was revealed that 
PB NK cells had significantly higher IFN-! than CB NK cells after stimulation with IL-
15, p = 0.0145 (Fig 4.7 C). Furthermore, a significant difference in IFN-! gene 
expression was observed when IL-15 activated PB NK cells were compared to resting 
PB NK cells, p = 0.0285 (Fig 4.7 C). 
 
Interestingly, IL-12 activated CB NK cells secreted high amounts of IFN-! (12853 ± 
4820 pg/mL) that significantly exceeded the amount secreted by PB NK cells (3757 ± 
1268 pg/mL) (p = 0.0441) (Fig 4.7 A). Correspondingly, IL-12 activated CB NK cells 
showed significantly higher IFN-! gene expression as compared to IL-12 activated PB 
NK cells, p = 0.0051 (Fig 4.7 C). Furthermore, IFN-! mRNA was found to be 
significantly increased in IL-12 activated CB NK cells, as compared to resting CB NK 
cells, p = 0.0114 (Fig 4.7 C). Stimulation with IL-18 resulted in higher IFN-! secretion 
by PB NK cells (5545 ± 2104 pg/mL) than CB NK cells (2678 ± 1765 pg/mL) (Fig 4.7 
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A). In accordance, IL-18 activation promoted higher IFN-! gene expression in PB NK 
cells than CB NK cells (Fig 4.7 C), p = 0.0077.   
 
Stimulation with IL-15+IL-2 led to high levels of IFN-! secretion from both PB and CB 
NK cells (Fig 4.7 A, B). Moreover, real-time PCR analysis indicated that IFN-! gene 
expression was significantly increased in cytokine-activated PB NK cells, as compared 
to resting PB NK cells, p = 0.0022 (Fig 4.7 C). Similarly, IL-15+IL-2 activated CB NK 
cells showed a slight increase in IFN-! mRNA levels compared to resting CB NK cells 
(Fig 4.7 C). 
 
High secretion of IFN-! by both IL-15+IL-18 activated PB and CB NK cells was 
observed at both days 2 and day 5 post-stimulation (Fig 4.7 A, B). However, CB NK 
cells showed selective responsiveness to this combination, as the secretion was 
drastically higher at day 2 (20875 ± 2942 pg/mL) and at day 5 (15949 ± 2628 pg/mL) in 
comparison to PB NK cells, (p = 0.0096 and 0.0422) respectively. Interestingly, this 
was associated with a significant increase in IFN-! gene expression by IL-15+IL-18 
activated PB (p = 0.0004) and CB NK cells (p = 0.0340), as compared to resting NK 
cells (Fig 4.7 C). Overall, IL-12 or the combination of IL-15+IL-18 induced the highest 
secretion of IFN-! by CB NK cells that was associated with upregulation of IFN-! 
mRNA levels, whereas PB NK cells secreted high levels of IFN-! post-stimulation with 




Figure 4.7 Analysis of IFN-! secretion and gene expression by cytokine-
activated NK cells. A) Assessment of IFN-! secretion by cytokine-activated PB (red) 
and CB (blue) NK cells tested using multiplex bead-based immunoassay 2 (A) and 5 
(B) days after stimulation with cytokines. C) Relative gene expression of IFN-! 
analysed by real-time PCR for cytokine-activated PB and CB NK cells compared to 
resting NK cells. mRNA quantity was normalised against three reference genes (ACTB, 
"2M and UBC). Results are presented as Mean ± SD. Resting NK cells N=3, PB N=5 
and CB N=6. p <0.05 (*), p<0.01 (**),and p<0.001 (***). 
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4.2.3.2 IL-18 or IL-15+IL-18 activated CB NK cells secreted higher amounts of 
TNF-! than PB NK cells at day 2 post-stimulation 
Differential secretion of TNF-! was observed following stimulation with different 
cytokines (Fig 4.8). CB NK cells activated with IL-18 secreted significantly higher 
amounts of TNF-! than PB NK cells activated with the same cytokine (Fig 4.8 A, p = 
0.0114). Similarly, higher concentrations were secreted by CB NK cells activated with 
IL-15+IL-18 (331.9 ± 78.96 pg/mL) than PB NK cells (92.94 ± 14.96 pg/mL, p = 
0.0178). Moreover, equivalent levels of TNF-! secretion by IL-15 activated PB NK 
cells were observed at day 2 (Fig 4.8 A). Notably, TNF-! levels decreased by day 5 of 
stimulation, but remained higher for CB NK cells activated with IL-15+IL-18 compared 






Figure 4.8 TNF-! secretion by cytokine-activated NK cells. Secretion of TNF-! 
by cytokine-activated PB (red) and CB (blue) NK cells assessed using multiplex bead-
based immunoassay 2 (A) and 5 (B) days after stimulation with cytokines. Results are 
presented as Mean ± SD. p <0.05 (*). PB N=5, CB N=6. 
 
4.2.3.3 CB NK cells secreted higher levels of TNF-" than PB NK cells at day 5 after 
stimulation with cytokines 
Low secretion of TNF-" was observed for cytokine-activated NK cells at day 2 post-
stimulation (Fig 4.9 A). However, it was noticed that the secretion of TNF-" by CB NK 
cells was increased as compared to PB NK cells 5 days after stimulation (Fig 4.9 B). 
Significant TNF-" secretion was observed for CB NK cells activated with IL-15 (117.5 
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± 25.65 pg/mL), IL-15+IL-2 (142.9 ± 43.59 pg/mL), and IL-15+IL-18 (686.5 ± 247.0 
pg/mL, p = 0.0195, 0.0320, and 0.0256 respectively).  
 
 
Figure 4.9 TNF-! secretion by cytokine-activated NK cells. Secretion of TNF-! 
by cytokine-activated PB (red) and CB (blue) NK cells assessed using multiplex bead-
based immunoassay 2 (A) and 5 (B) days after stimulation with cytokines. Results are 
presented as Mean ± SD. p <0.05 (*). PB N=5, CB N=6. 
 
4.2.3.4 Cytokine-activated NK cells secreted considerable amounts of IL-1! 
IL-1! is a pro-inflammatory cytokine produced by activated macrophages that acts as a 
co-stimulator for NK cell proliferation, cytotoxicity and cytokine production (Cooper et 
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al., 2001b). However, NK cells and B cells also produce IL-1! (Dinarello, 2009). 
Variable levels of IL-1! secretion by both PB NK cells and CB NK cells were detected 
2 days after stimulation (Fig 4.10 A). Interestingly, whilst the secretion of IL-1! by PB 
NK cells decreased 5 days after cytokine activation, CB NK cells still secreted higher 
levels of IL-1! at this time point (Fig 4.10 B). 
 
 
Figure 4.10 IL-1! secretion by cytokine-activated NK cells. Secretion of IL-1! by 
cytokine-activated PB (red) and CB (blue) NK cells assessed using multiplex bead-
based immunoassay 2 (A) and 5 (B) days after stimulation with cytokines. Results are 
presented as Mean ± SD. PB N=5, CB N=6. 
 
4.2.3.5 CB NK cells secrete higher levels of IL-6 than PB NK cells upon cytokine 
activation 
Different levels of IL-6 secretion by cytokine-activated PB and CB NK cells were 
detected (Fig 4.11). Both CB and PB NK cells secreted considerable amounts of IL-6 2 
days after stimulation with all cytokines tested, yet a trend towards higher secreted IL-6 
by CB NK cells was observed, especially following stimulation with IL-2, IL-15, IL-18, 
IL-15+IL-2 and IL-15+IL-18 (Fig 4.11 A). Interestingly, while IL-6 secretion by 
cytokine-activated PB NK cells declined at day 5 after activation, CB NK cells 
persistently produced IL-6 at this time point (Fig 4.11 B). 
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Figure 4.11 IL-6 secretion by cytokine-activated NK cells. Secretion of IL-6 by 
cytokine-activated PB (red) and CB (blue) NK cells assessed using multiplex bead-
based immunoassay 2 (A) and 5 (B) days after stimulation with cytokines. Results are 
presented as Mean ± SD. p <0.05 (*). PB N=5, CB N=6. 
 
4.2.3.6 CB and PB NK cells secrete high amounts of IL-8 upon stimulation with 
cytokines 
IL-8 is a T cell recruiting chemokine produced mainly by macrophages, however it has 
also been shown that NK cells produce IL-8 under certain stimulation conditions (Roda 
et al., 2006). Both cytokine-activated PB and CB NK cells secreted IL-8 at day 2 after 
stimulation in all tested conditions (Fig 4.12 A), however IL-8 secretion by PB NK 
cells was reduced by day 5 (Fig 4.12 B). Upon IL-2 stimulation, CB NK cells secreted 
significantly higher amounts of IL-8 (3983 ± 1015 pg/mL) than PB NK cells (301.6 ± 
130.4 pg/mL, p = 0.0098). Similarly, CB NK cells secreted higher amounts of IL-8 
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Figure 4.12 IL-8 secretion by cytokine-activated NK cells. Secretion of IL-8 by 
cytokine-activated PB (red) and CB (blue) NK cells assessed using multiplex bead-
based immunoassay 2 (A) and 5 (B) days after stimulation with cytokines. Results are 
presented as Mean ± SD. p<0.01 (**). PB N=5, CB N=6. 
 
4.2.3.7 Cytokine-activated NK cells secreted negligible amounts of IL-10 and IL-5, 
whereas IL-4 secretion was completely undetectable 
Although NK cells mainly produce type I cytokines, studies have shown that NK cells 
can also produce type II cytokines such as IL-5 and IL-10, which act as 
immunoregulatory cytokines under certain conditions (Cooper et al., 2001c, Warren et 
al., 1995). Cytokine-activated NK cells secreted very low levels of IL-5 (Fig 4.13). In 
contrast, IL-4 secretion by PB and CB NK cells was completely undetectable at both 
time points after stimulation with cytokines. In addition, it was also found that 




Figure 4.13 IL-5 secretion by cytokine-activated NK cells. Secretion of IL-5 by 
cytokine-activated PB (red) and CB (blue) NK cells assessed using multiplex bead-
based immunoassay 2 (A) and 5 (B) days after stimulation with cytokines. Results are 
presented as Mean ± SD. PB N=5, CB N=6. 
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Figure 4.14 IL-10 secretion by cytokine-activated NK cells. Secreted IL-10 by 
cytokine-activated PB (red) and CB (blue) NK cells tested using multiplex bead-based 
immunoassay 2 (A) and 5 (B) days after stimulation with cytokines. Results are 
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CB NK cells have been reported to exhibit low cytotoxicity and reduced IFN-! 
production as compared to PB NK cells (Dalle et al., 2005, Gaddy et al., 1995, Luevano 
et al., 2012a, Xing et al., 2010). Herein, my results show that upon stimulation with 
cytokines, CB NK cells are responsive to cytokine activation and exhibit proliferative 
capacity, cytotoxicity and cytokine secretion. However, differential findings were 
observed based on the type of cytokine used.  
 
I showed that cell proliferation was consistent at day 2 post-stimulation for all cytokines 
tested for both PB and CB NK cells. In line with published models of proliferation, 
there is a time delay observed before the first cellular division, regardless of the dose of 
IL-2 or IL-15 used (Deenick et al., 2003, Zhao and French, 2012). However, higher 
recruitment of non-dividing cells into replicating cycles was observed by increasing the 
concentration of cytokines. By day 5, NK cells showed distinct responses towards 
different cytokines. CB NK cells proliferated more significantly in response to IL-
15+IL-18 or IL-15+IL-2, whereas stimulation with IL-2 alone was not sufficient to 
induce further proliferation at this time point. However, it is noteworthy that CB NK 
cells could be activated with higher doses of IL-2 (1000 IU/mL), whereas PB NK cells 
were activated with lower doses of IL-2 (200 IU/mL) and expanded better in response 
to IL-2 stimulation than CB NK cells. Experiments that aimed to determine the optimal 
IL-2 concentration required to expand CB NK cells have previously shown that higher 
doses of IL-2 (500 or 1000 IU/mL) caused significant expansion of NK cells at day 18 
(Condiotti et al., 2001). Hence, this finding suggests that CB NK cells need additional 
time to proliferate in response to IL-2, possibly due to their naivety. PB and CB NK 
cells favourably proliferated in response to IL-15+IL-18 stimulation. These results are 
in line with the study of Nomura et al. who showed that CB NK cells respond better to 
IL-18 stimulation than PB NK cells (Nomura et al., 2001). Although it is known that 
IL-18 alone induces apoptosis of NK cells, this effect was shown to be inhibited by 
adding high doses of IL-2 resulting in NK cell expansion (Huang et al., 2010). Hence, it 
could be that the addition of IL-15, which shares many biological similarities with IL-2, 




I showed that the use of different cytokine conditioning regimes to stimulate NK cells 
induced different cytotoxic effect against K562 cells by PB and CB NK cells. The 
cytotoxicity of IL-2 activated CB NK cells was low at day 2, but was enhanced at day 5 
after IL-2 stimulation. In contrast, the cytotoxicity of CB NK cells was enhanced at day 
2 when stimulated with IL-15 or IL-15+IL-2. IL-15 induces the potent cytotoxic effect 
of NK cells by upregulating NKG2D, FasL, perforin and TRAIL (Özdemir et al., 2005, 
Zhang et al., 2008). One study carried out by Satwani and colleagues revealed that the 
activation of CB NK cells with fms-like tyrosine kinase-3 (FLT-3) + anti-CD3 
monoclonal antibodies + IL-2 + IL-15 significantly promoted enhanced killing of Daudi 
and K562 cell lines, as compared to those activated with similar conditions, but without 
the addition of IL-15 (Satwani et al., 2011). Furthermore, Zhang et al. reported higher 
cytotoxicity of CB NK cells against K562 and Jurkat cell lines after stimulation with 
the combination of IL-15+IL-2 exceeding those stimulated with IL-2 alone (Zhang et 
al., 2011). However, mechanisms underlying the maximal cytotoxicity of IL-15+IL-2 
activated CB NK cells remained to be clarified.  
 
It was notable that at day 2, CB NK cells activated with IL-12 or IL-15+IL-18 had 
lower cytotoxicity than PB NK cells activated with similar conditions. Interestingly, 
this was associated with substantial production of IFN-!. It was shown here that the 
killing capacity of IL-15+IL-18 activated CB NK cells improved as the level of IFN-! 
production began to decrease at day 5. 
 
Resting and cytokine-activated CB and PB NK cells expressed granzyme B to different 
extents. Interestingly, resting CB NK cells demonstrated lower expression of granzyme 
B than PB NK cells. However, CB NK cells had slightly increased granzyme B 
expression following activation with all cytokines except IL-18. This was associated 
with poor killing capacity for CB NK cells activated with IL-18. As NK cell 
cytotoxicity was measured here using a 4 hour 51Chromium-release assay, CB NK cells 
were not able to utilise a FasL-dependent killing pathway which is known to require 12 
hours to take effect (Arase et al., 1995). Furthermore, it has been previously shown that 
NK cells activated with IL-18 do not increase their expression of perforin or granzyme 
B mRNA (Hyodo et al., 1999). Similarly, I showed here that IL-18 activated CB NK 
cells have similar levels of perforin to those activated with other cytokines, but very 
low levels of granzyme B as compared to other cytokine-activated NK cells.  
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PB NK cells produce substantial amounts of IFN-! upon stimulation with IL-2 that was 
associated with elevated levels of IFN-! mRNA. In contrast to stimulation with IL-2, 
CB NK cells stimulated with IL-12, IL-15 or IL-15+IL-18 selectively secreted high 
quantities of IFN-!. It is likely that abundant secretion of IFN-! by CB NK cells in 
response to IL-15, IL-12 or IL-15+IL-18 is due to the fact that these cytokines are 
ubiquitous in early immune inflammatory responses. The lower responsiveness of CB 
NK cells to IL-2 stimulation as compared to other cytokines could be due to their 
naivety. Indeed, IL-2 is a product of activated T cells and since the majority of CB T 
cells are characterised by a CD45RA+ phenotype, it is less likely that CB NK cells have 
been exposed to IL-2. Instead, CB NK cells theoretically should be readily responsive 
to innate inflammatory cytokine such as IL-18, as Nomura and colleague have 
suggested (Nomura et al., 2001).  
 
In addition to IFN-!, NK cells produce another potent cytokine, TNF-". Quiescent NK 
cells constitutively express trans-membrane TNF-". Upon stimulation, trans-membrane 
TNF-" is converted into soluble TNF-" that plays a major role in antiviral and 
antitumor immunity (Caron et al., 1999). Blocking of TNF-" expressed by CB NK cells 
using monoclonal antibodies affected their survival, proliferation and the development 
of a mature phenotype following cytokine stimulation (Gaddy and Broxmeyer, 1997). 
Resting CB NK cells express significantly less intracellular TNF-" than PB NK cells 
(Krampera et al., 2000). However, it was shown here that CB NK cells secreted greater 
amounts of TNF-", particularly upon stimulation with IL-18 or IL-15+IL-18, exceeding 
the amount produced by PB NK cells under similar conditions. IL-18 stimulation 
mediates the production of TNF-", but inversely affected NK cell viability. Blocking 
experiments showed that IL-18-mediated NK cell apoptosis is partially prevented by the 
addition of anti-TNF-" (Shibatomi et al., 2001). However, TNF-" production here 
appeared to be potentiated by the addition of IL-15, which was also associated with a 
high proliferative capacity of CB NK cells activated with IL-15+IL-18. 
Correspondingly, it was shown previously that endogenous TNF-" is essential for NK 
cell proliferation (Naume et al., 1991). Hence, the substantial proliferation of IL-15+IL-
18 activated CB NK cells observed here is likely to be influenced by elevated 




Another member of the TNF family is TNF-!, which is a highly inducible protein also 
known as lymphotoxin-" (LT"). TNF-! is secreted by activated macrophages and 
lymphocytes, and promotes the phagocytosis of infected cells, as well as T helper cell 
differentiation (Falvo et al., 2013). NK cells, typically CD56bright NK cells, secrete large 
amounts of TNF-! after stimulation with IL-15 and IL-18 (Cooper et al., 2001c). 
Interestingly, TNF-! secreted by NK cells results in inhibition of viral replication in a 
non-cytolytic dependent manner (Iversen et al., 2005). In addition, TNF-! play a key 
role during NK cell differentiation and maturation as Lt!#/# (TNF-!-deficient) knockout 
mice have shown reduced NK cell number and defective cytotoxicity (Iizuka et al., 
1999). Herein, it was shown that TNF-! secretion by PB and CB NK cells was low at 
day 2 after stimulation with cytokines. However, by day 5, CB NK cells demonstrated 
higher secretion of TNF-! than PB NK cells, especially when stimulated with the 
combination of IL-15+IL-18. Together, these data support the hypothesis that the 
combination of IL-15 with IL-18 potently promotes cytokine secretion by CB NK cells. 
Yet, those cells still have the capacity to kill their target by exocytosis as shown using 
51Cr-release assays. 
 
IL-1! is a pro-inflammatory cytokine mainly produced by activated monocytes which 
provides a co-stimulatory signal for NK cells to produce IFN-$ (Cooper et al., 2001b). 
It has been reported that NK cells secrete a modest amount of IL-1! following priming 
with IL-2 (De Sanctis et al., 1997). Here I showed that all cytokine conditions tested 
resulted in the production of IL-1! by NK cells. However, these results should be 
confirmed by intracellular staining, as IL-1! secretion was variable from sample to 
sample. Similarly, many immune cells including neutrophils and APC produce IL-6 
during early inflammatory responses and lymphocytes produce IL-6 during late 
immune responses (Hirano, 1992). NK cells were shown to promote the production of 
IL-6 by DCs and macrophages. However, few reports showed that NK cells directly 
secrete IL-6 (Horikawa et al., 2005, Schmidt et al., 2004). It has also been shown that 
the production of IL-6 by NK cells is crucial to shape T helper immune response after 
vaccination (Hall et al., 2010). I did observe IL-6 production by NK cells at day 2 post-
stimulation with cytokines. However, CB NK cells still produce IL-6 at day 5 post-
stimulation, whereas PB NK cells did not produce any IL-6 beyond day 2. Condiotti 
and colleagues have shown that expanded CB NK cells produced significantly higher 
levels of IL-6 than PB NK cells after 10 days of stimulation with IL-2. These cells were 
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expanded using an autologous lymphocyte feeder layer. Thus, it is unknown whether 
the IL-6 production in the Condiotti study is a result of NK cell interaction with the 
feeder layer or cytokine stimulation (Condiotti et al., 2001). Despite this, herein, it is 
clearly demonstrated that IL-6 secretion by NK cells could be induced by cytokine 
activation alone. 
 
IL-8 is a neutrophil chemotactic factor produced by macrophages and epithelial cells 
which enhances the trafficking of leucocytes, including CD56+ NK cells, to 
inflammatory sites. Herein, cytokine-activated NK cells secreted high levels of IL-8 2 
days after stimulation with cytokines. At day 5 of cytokine activation, it was noticeable 
that IL-8 secretion by PB NK cells decreased, however, CB NK cells secreted higher 
quantities of IL-8 at this time point. The secretion of IL-8 by NK cells has been 
observed under certain conditions including stimulation with IL-15 (El-Shazly and 
Lefebvre, 2011), IL-2 or IL-12 in the presence of breast cancer tumour cells (Roda et 
al., 2006), NK cell following purification in the presence of FCS and after stimulation 
with IL-2 plus anti-CD16 (Somersalo et al., 1994). Moreover, IL-8 is abundantly 
produced by dNK cells and is associated with poor lytic function of these cells (Saito et 
al., 1994, Vacca et al., 2008). Herein, my results demonstrate that both PB and CB NK 
cells produced IL-8 abundantly with a trend toward higher secretion by CB NK cells. 
The observation of a high production of IL-8 could be due to culture conditions, as it 
was shown that the addition of FCS to purified NK cells induces IL-8-mediated 
chemotaxis in contrast to those supplemented with human serum albumin (Somersalo et 
al., 1994). Yet, CB NK cells persistently produce IL-8 that could be correlated with 
their immaturity. 
 
It is believed that under certain conditions NK cells mediate immunoregulatory 
responses regulated by cytokine secretion (Cooper et al., 2001c). IL-10 is an 
immunoregulatory cytokine secreted by T cells, B cells and monocytes upon 
stimulation with GM-CSF, IFN-!, IL-1, IL-12 or TNF-". The secretion of IL-10 inhibits 
antigen-specific proliferation and downregulates the synthesis of inflammatory 
cytokines (Del Prete et al., 1993, Howard and O'Garra, 1992). Although earlier studies 
could not detect IL-10 production by NK cells (Carson et al., 1995, Spagnoli et al., 
1993), subsequent findings have shown that NK cells secrete low amounts of IL-10 
upon stimulation with IL-2, but not following stimulation with IL-12 (Mehrotra et al., 
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1998). Furthermore, NK cells express both IL-10 mRNA and protein intracellularly 
(Mehrotra et al., 1998). Cooper et al. showed that CD56bright NK cells produce 
substantial amounts of IL-10 upon stimulation with IL-15 and IL-12 (Cooper et al., 
2001c). Herein, I showed that cytokine-activated PB and CB NK cells secreted low 
levels of IL-10. It is worth noting that these analyses were carried out by multiplex bead 
array. Reports aiming to evaluate multiplex performance in comparison to traditional 
ELISA showed greater sensitivity of multiplex for detection of small amounts of 
secreted cytokines (duPont et al., 2005, Elshal and McCoy, 2006).  
 
NK cells accumulate at inflammatory sites and initiate interactions with other innate 
immune cells by releasing cytokines. IL-5, produced by NK cells, mediates TH2 
responses through facilitation of mobility and differentiation of eosinophils. In these 
studies, production of IL-5 by NK cells appeared to be regulated by cytokine 
stimulation (Warren et al., 1995). IL-2 was shown to promote IL-5 secretion, whereas 
its secretion was inhibited by IL-12. Herein, I showed that PB NK cells produced 
negligible amounts of IL-5, however, a trend towards higher IL-5 production was 
detected for CB NK cells. It was shown that NK cells at intermediate stages of 
differentiation produce type-II cytokines, including IL-5 and IL-13. Nonetheless, 
progression towards final stages of NK cell maturation is associated with loss of their 
ability to produce these cytokines and subsequent acquisition of an IFN-!+ phenotype 
(Loza and Perussia, 2001, Loza et al., 2002). Hence, secretion of IL-5 by CB NK cells 
is suggestive of a unique cytokine production profile that is possibly correlated with 
their maturation stage.   
 
To summarise, cytokine activation induces fully functional CB NK cells with 
differential findings based on the cytokine conditioning used. While IL-2 seems to be 
an ideal cytokine to stimulate PB NK cells, other cytokines promote unprecedented 
functional capacities of CB NK cells. IL-15 or the combination of IL-15+IL-2 promote 
enhanced killing of K562 cells by CB NK cells whereas the combination of IL-15+IL-
18 selectively promotes proliferation and inflammatory cytokine secretion of CB NK 
cells. Collectively, IL-15 appears to be crucial to promote the functionality of CB NK 
cells. In addition, the cytokine secretion repertoire of CB NK cells is shown to be 
distinct from PB NK cells and could be associated with their degree of maturity. 
Herein, CB NK cells showed functional competency post-cytokine activation.  
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Chapter 5: Analysis of the NK cell homing receptor 
repertoire 
5.1 Introduction 
NK cell migration and trafficking is regulated by chemokines (Inngjerdingen et al., 
2001, Kim et al., 1999, Robertson et al., 2000, Taub et al., 1995). At steady state, the 
majority of NK cells circulate in the periphery as part of their role in immune 
surveillance. However, a low percentage of NK cells, the CD56bright subset, express 
chemokine receptors which allow them to traffic to inflamed lymph nodes (LN) 
(Robertson, 2002). CD56bright NK cells predominantly express a high density of the 
adhesion molecule L-selectin, and this facilitates their rolling on the high endothelial 
venules that are present in LN (Frey et al., 1998). Moreover, CD56bright NK cells 
express CCR7 which binds to CCL19 and CCL21 to promote lymphocyte recruitment 
to the T cell zone of LN (Kim et al., 1999). NK cell recruitment to draining LN results 
in significant secretion of IFN-! and subsequent polarisation of a T helper immune 
response.  
 
At steady state, resting CD56dim NK cells express CXCR1, CX3CR1 and the Chemerin 
Receptor 23 (ChemR23), all of which mediate their homing to inflamed non-lymphoid 
sites in which NK cell effector function is essential (Campbell et al., 2001, Parolini et 
al., 2007). Accumulation of NK cells at inflammation sites faclitates interaction with 
APCs such as macrophages and DCs. Subsequently, CD56dim NK cells can acquire LN 
homing receptors upon activation via inflammatory cytokines such as IL-18 which is 
produced by APCs (Mailliard et al., 2005), or by receptor uptake via interactions with 
mature DCs (Marcenaro et al., 2009). Furthermore, activated NK cells upregulate 
CXCR3 which mediates the potent chemotaxis of NK cells towards its ligands; MIG 
(CXCL9), interferon-!-inducible protein 10 (CXCL10) and interferon-inducible-T-cell-
" (CXCL11) (Inngjerdingen et al., 2001, Campbell et al., 2001).  
 
It has previously been shown by our group and others that CB NK cells do not express 
L-selectin, thereby suggesting that CB NK cells are unable to migrate to draining LN by 
this mechanism (Dalle et al., 2005, Luevano et al., 2012a). Moreover, resting CB NK 
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cells were found to have significantly higher expression of CXCR4 and lower 
expression of CXCR1 than PB NK cells, implying an enhanced capacity of CB NK 
cells to traffic to the BM, but a lower capacity to be recruited to inflamed sites 
(Luevano et al., 2012a). Hence, the aim of this study was to assess whether cytokine 
activation resulted in upregulation of chemokine receptors that mediate NK cell 




5.2.1 Expression of chemokine receptors on resting and cytokine-activated NK 
cells 
Upregulation of CCR7, CXCR3 and L-selectin by NK cells is essential for NK cell 
trafficking to LN and inflamed sites. Hence, the following analysis investigates 
upregulation of those chemokine receptors by PB and CB NK cells upon cytokine 
activation. 
 
5.2.1.1 CB NK cells upregulate L-selectin upon activation with IL-12 or IL-18, 
whereas resting and cytokine-activated PB NK cells constitutively express L-
selectin  
It was previously found that resting CB NK cells do not express L-selectin (CD62L) 
(Dalle et al., 2005, Luevano et al., 2012a). Therefore, the ability to induce L-selectin 
expression by PB and CB NK cells by cytokine activation was tested. IL-12 induced the 
highest levels of L-selectin expression by CB NK cells (56.83 ± 3.45 %) and PB NK 
cells (56.28 ± 3.85 %) (Fig 5.1 A). IL-18 also significantly induced L-selectin 
expression by both PB NK cells (37.20 ± 1.439 %) and CB NK cells (24.63 ± 2.30 %) 
(Fig 5.1 A). PB NK cells responded better to IL-2 activation showing significant 
upregulation of L-selectin (35.78 ± 10.30 %), as compared to CB NK cells (3.44 ± 0.94 
%) (p = 0.0205). As compared to other cytokines, IL-15 activation induced low levels 
of L-selectin expression by CB NK cells (Fig 5.1 B). Increasing doses of IL-12 or IL-15 









Figure 5.1 Expression of L-selectin (CD62L) by PB and CB NK cells after 
cytokine stimulation. A) Histograms showing CD62L upregulation in response to 
cytokine activation. B) Comparison of CD62L expression by resting and cytokine-
activated PB and CB NK cells. Analysis was performed on purified NK cells and the 
expression of CD62L was examined 2 days post IL-12 or IL-18 stimulation, and 5 days 
post IL-2 or IL-15 stimulation. Results are presented as Mean ± SD. N=4, p <0.05 (*) 
and p <0.01 (**). 
 
Figure 5.2 Upregulation of L-selectin (CD62L) by CB NK cells after activation 
with IL-12 and IL-15. L-selectin expression by CB NK cells activated with IL-12 (10 
ng/mL or 50 ng/mL) (A) and IL-15 (20 ng/mL or 100 ng/mL) (B). N=4. Analysis was 
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5.2.1.2 CB NK cells upregulate chemokine receptors involved in lymph node 
homing upon cytokine activation 
Here, expression of the LN homing receptors CXCR3 and CCR7 was assessed on CB 
and PB NK cells following cytokine activation. Upregulation of these two chemokine 
receptors leads to NK cell recruitment into draining LN, which is critical for shaping 
the immune response. Herein, it was observed that resting PB and CB NK cells 
expressed very low levels of CXCR3, however resting PB NK cells exhibited slightly 
higher CXCR3 expression (1.887 ± 0.28 %) as compared to resting CB NK cells 
(0.4333 ± 0.05 %, p = 0.0073) (Fig 5.3 A, B). Activation with all the cytokines tested 
resulted in significant upregulation of CXCR3 by PB and CB NK cells (Fig 5.3 B). A 
unique pattern of expression was observed when CB NK cells were activated with IL-2 
and IL-12, in that induced a significantly higher level of CXCR3 expression (92.10 ± 
2.81 % and 72.50 ± 13.70 % respectively) as compared to that on PB NK cells (67.75 ± 
9.01 % and 25.40 ± 5.11 % respectively). The highest levels of CXCR3 expression by 
PB (97.30 ± 0.93 %) and CB (96.18 ± 1.62 %) NK cells were observed following IL-15 
activation. No detectable change in CXCR3 expression was observed when the 






Figure 5.3 Expression of CXCR3 by PB and CB NK cells after cytokine 
activation. A) CXCR3 upregulation by PB and CB NK cells in response to activation 
with cytokines. B) Comparison of CXCR3 expression by resting and cytokine-activated 
NK cells from PB and CB. Analysis was performed on purified NK cells and the 
expression of CXCR3 was examined 2 days post IL-12 or IL-18 stimulation, and 5 days 
post IL-2 or IL-15 stimulation. Results are presented as Mean ± SD. N=4, p <0.05 (*).  
 
Figure 5.4 Upregulation of CXCR3 after activation with IL-12 and IL-15. 
CXCR3 expression by CB NK cells activated with IL-12 (10 ng/mL or 50 ng/mL) (A) 
and IL-15 (20 ng/mL or 100 ng/mL) (B). N=4. Analysis was performed on purified NK 
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Expression of CCR7 was difficult to consistently detect, as a consequence of staining 
for CCR7 was performed using two different monoclonal antibody clones, one from BD 
Biosciences (clone 3D12) (Fig 5.5 A) and the other one from R&D Systems (clone 
358426) (Fig 5.5 B). Variable CCR7 expression by NK cells was observed using both 
monoclonal antibodies. Notably, the CCR7 clone from R&D Systems detected higher 
CCR7 expression than the clone from BD Biosciences. Figure 5.6 shows CCR7 
expression on CB NK cells with different doses of IL-12 and IL-15. 
 
 
Figure 5.5 Expression of CCR7 by PB and CB NK cells. A) Flow cytometry 
histograms showing CCR7 expression by cytokine-activated NK cells using the clone 
3D12 from BD Biosciences. B) Flow cytometry histograms showing CCR7 expression 
by cytokine-activated NK cells using the clone 358426 from R&D Systems. C and D) 
Comparison of CCR7 expression by resting and cytokine-activated NK cells from CB 
and PB using the 3D12 clone from BD Biosciences and the 358426 clone from R&D 
Systems respectively. Analysis was performed on purified NK cells and the expression 
of CCR7 was examined 2 days post IL-12 or IL-18 stimulation, and 5 days post IL-2 or 














































































































IL-2 IL-15 IL-12 IL-18 
IL-2 IL-15 IL-12 IL-18 
CCR7 (3D12) 
CCR7 (358426) 
Unstained PB NK cells CB NK cells 


























































































































PB NK cells 





Figure 5.6 Upregulation of CCR7 by CB NK cells after activation with IL-12 
and IL-15. CCR7 expression by CB NK cells activated with 10 or 50 ng/mL IL-12 (A) 
and 20 or 100 ng/mL IL-15 (B) tested using the 3D12 clone from BD Biosciences. (C) 
CCR7 expression by CB NK cells activated with 10 or 50 ng/mL IL-12 (D) and 20 or 
100 ng/mL IL-15 tested using the 358426 clone from R&D Systems. N=4. Analysis 




5.2.2 Analysis of NK cell migratory capacity using trans-well migration assay 
The following analysis aimed to assess the migratory capacity of resting or cytokine-
activated NK cells towards LN chemoattractants CCL19/21 or CXCL10/12 in vitro. 
Migrated NK cells in response to chemokines were collected from the lower chamber of 
trans-well plates and the percentage of migration was calculated as (number of migrated 
cells ÷ positive control)!100. The expression of the chemokine receptors, CCR7 and 
CXCR3, which are involved in recruitment of NK cells towards these chemoattractants, 
was also assessed.  
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5.2.2.1 PB and CB NK cells activated with IL-15+IL-2 exhibit significant 
migratory capacity in response to CCL19/21 or CXCL10/11 
Comparable mean percentage of migration towards CCL19/21 was detected for resting 
PB NK cells (13.09 ± 1.25 %) and resting CB NK cells (16.15 ± 2.82 %) (Fig 5.7 A). 
Activation with IL-15+IL-2 induced significant migration of NK cells in response to 
CCL19/21. The mean percentage of migration by IL-15+IL-2 activated PB NK cells 
was 57.35 ± 8.52 %, whereas the mean percentage of migration by IL-15+IL-2 
activated CB NK cells was 42.66 ± 9.37 % (Fig 5.7 A). Correspondingly, it was found 
that CCR7 was significantly upregulated on PB and CB NK cells upon stimulation with 
IL-15+IL-2 (Fig 5.7 B). IL-15+IL-2 activated CB NK cells showed significantly higher 
mean percentage of CCR7 expression (16.33 ± 2.39 %) than PB NK cells (8.388 ± 0.97 
%, p = 0.0220).   
 
In addition, IL-15+IL-2 activation promoted considerable CB NK cell migration 
towards CXCL10/11, as compared to resting NK cells (Fig 5.7 C). While resting PB 
NK cells showed percentage of migration towards CXCL10/11 of 15.70 ± 2.27 %, IL-
15+IL-2 activated PB NK cells exhibited up to 59.88 ± 5.80 % migration (p = 0.0004). 
Similarly, resting CB NK cells showed percentage of migration towards CXCL10/11 of 
11.28 ± 3.25 %, whereas IL-15+IL-2 activated CB NK cells showed 47.71 ± 9.35 % 
migration (p = 0.0026). NK cell migration in response to CXCL10/11 was associated 
with substantial upregulation of CXCR3 by IL-15+IL-2 activated PB and CB NK cells 
(Fig 5.7 D). Notably, stimulation with IL-15+IL-2 substantially upregulated CXCR3 by 






Figure 5.7 Migration of IL-15+IL-2 activated NK cells in response to lymph 
node chemoattractants. A) Percentage of migration of PB and CB NK cells towards 
CCL19/CCL21 by both resting and IL-15+IL-2 activated NK cells. B) CCR7 
expression by NK cells activated with IL-15+IL-2 as compared to resting NK cells. C) 
Percentage of migration of PB and CB NK cells towards CXCL10/11 by both resting 
and IL-15+IL-2 activated NK cells. D) CXCR3 expression by NK cells activated with 
IL-15+IL-2 as compared to resting NK cells. This analysis was performed on purified 
NK cells 2 days post IL-15+IL-2 stimulation. Migrated cells were collected from the 
lower chamber of the trans-well plate and the percentage of migration was calculated as 
(no of migrated cells ÷ positive control)!100. Results are presented as Mean ± SD. 
N=4, p <0.05 (*), p <0.01 (**) and p <0.001 (***). 
 
5.2.2.2 IL-15+IL-12 activation promotes PB NK cell migration, but not CB NK cell 
migration in response to CCL19/21 or CXCL10/11  
The combination of IL-15+IL-12 was included in this study, as it was observed that IL-
12 activation induces L-selectin expression by CB NK cells (Fig 5.1). However, trans-
well migration assays indicate that whilst activation with IL-15+IL-12 leads to 

















































































































































































enhanced PB NK cell migration towards CCL19/21 (34.95 ± 7.24 %), migration of CB 
NK cells towards CCL19/21 was unchanged (23.50 ± 4.14 %) (Fig 5.8 A). Surprisingly, 
CCR7 expression on CB NK cells activated with IL-15+IL-12 was significantly 
upregulated (24.75 ± 3.76 %), as compared to PB NK cells (14.28 ± 1.48 %, p = 0.041), 
which did not translate in an enhanced migratory capacity of CB NK cells (Fig 5.8 B). 
Similarly, IL-15+IL-12 activation resulted in significantly higher percentage of PB NK 
cell migration (35.20 ± 3.68 %) in response to CXCL10/11 as compared to CB NK cells 
(19.90 ± 2.71 %, p = 0.0155) (Fig 5.8 C). Correspondingly, this was associated with 
considerable upregulation of CXCR3 by PB NK cells upon stimulation with IL-15+IL-
12 in comparison to CB NK cells (91.43 ± 0.624 % and 73.18 ± 6.027 % respectively, p 









Figure 5.8 Migration of IL-15+IL-12 activated PB and CB NK cells in response 
to lymph node chemoattractants. A) Percentage of migration of PB and CB NK cells 
towards CCL19/CCL21 by both resting and IL-15+IL-12 activated NK cells. B) CCR7 
expression by NK cells activated with IL-15+IL-12, as compared to resting NK cells. 
C) Percentage of migration of PB and CB NK cells towards CXCL10/11 by both 
resting and IL-15+IL-12 activated NK cells. D) CXCR3 expression by NK cells 
activated with IL-15+IL-12, as compared to resting NK cells. This analysis was 
performed on purified NK cells 2 days post IL-15+IL-12 stimulation. Migrated cells 
were collected from the lower chamber of the trans-well plate and the percentage of 
migration was calculated as (no of migrated cells ÷ positive control)!100. Results are 
presented as Mean ± SD. N=4, p <0.05 (*), p <0.01 (**) and p <0.001 (***). 
 
5.2.2.3 IL-15+IL-18 activation induces significant migration of PB and CB NK 
cells in response to CCL19/21 or CXCL10/11 
Activation with IL-15+IL-18 promoted significant migration towards CCL19/21 by PB 
NK cells (38.98 ± 5.393 %) and CB NK cells (52.16 ± 10.15 %), as compared to resting 
PB and CB NK cells (p = 0.0034 and p = 0.0034 respectively) (Fig 5.9 A). 
Upregulation of CCR7 was consistent with the observed migration pattern as both PB 















































































































































































(10.19 ± 1.21 %) and CB (25.35 ± 4.47 %) NK cells significantly expressed CCR7 after 
stimulation with IL-15+IL-18, as compared to resting PB and CB NK cells (p = 0.0022 
and p = 0.0051 respectively) (Fig 5.9 B). 
 
Similarly, PB and CB NK cells activated with IL-15+IL-18 showed enhanced migration 
towards CXCL10/11 (Fig 5.9 C). The mean percentage of migrated NK cells in 
response to CXCL10/11 was 44.36 ± 7.97 % for PB NK cells and 32.32 ± 9.69 % by 
CB NK cells. NK cell migration towards CXCL10/11 was associated with significant 
upregulation of CXCR3 upon IL-15+IL-18 stimulation for PB NK cells (80.15 ± 2.67 











Figure 5.9 Migration of IL-15+IL-18 activated PB and CB NK cells in response 
to lymph node chemoattractants. A) Percentage of migration of PB and CB NK cells 
towards CCL19/CCL21 by both resting and IL-15+IL-18 activated NK cells. B) CCR7 
expression by NK cells activated with IL-15+IL-18, as compared to resting NK cells. 
C) Percentage of migration of PB and CB NK cells towards CXCL10/11 by both 
resting and IL-15+IL-18 activated NK cells. D) CXCR3 expression by NK cells 
activated with IL-15+IL-18, as compared to resting NK cells. This analysis was 
performed on purified NK cells 2 days post IL-15+IL-18 stimulation. Migrated cells 
were collected from the lower chamber of the trans-well plate and the percentage of 
migration was calculated as (no of migrated cells ÷ positive control)!100. Results are 





















































































































































































To exert their effector functions, NK cells need to express receptors that allow their 
recruitment to sites of inflammation (Robertson et al., 2000). Notably, as for other 
lymphocytes, the regulation of NK cell trafficking is chemokine-dependent. Resting CB 
NK cells have been shown to have low expression of L-selectin, which may influence 
their homing to draining LN. However, it was confirmed here that cytokine activation 
induces the expression of L-selectin and other chemokine receptors resulting in 
migration towards their cognate ligands in vitro. 
 
L-selectin is an adhesion molecule that plays a key role in initiating extravasation of 
lymphocytes towards the luminal surface of HEV. PB CD56dim NK cells express very 
low levels of L-selectin, whereas CD56bright NK cells express a high density of L-
selectin (Nagler et al., 1989, Sedlmayr et al., 1996). It has been reported that L-selectin 
is upregulated by both CD56bright and CD56dim PB NK cells in response to IL-12 (Frey 
et al., 1998). In contrast, it has been found that IL-2 and IL-15 downregulate L-selectin 
expression by PB NK cells (Frey et al., 1998, Uksila et al., 1997, Mäenpää et al., 1993). 
The data presented in this chapter are in line with these reports and suggest that PB NK 
cells may experience rapid loss of L-selectin expression after they reach peak activation 
with IL-2 and IL-15 (Frey et al., 1998). However, neither CD56bright nor CD56dim NK 
cells express L-selectin in CB, which might affect their trafficking capability (Dalle et 
al., 2005, Luevano et al., 2012a). Remarkably, incubation with IL-12 or IL-18 induced 
L-selectin expression on CB NK cells to a level comparable to PB NK cells. This 
suggests that the induction of L-selectin expression by NK cells may require exposure 
to certain cytokines, such as IL-12 or IL-18, produced by activated DCs or 
macrophages. Indeed, variable expression of L-selectin by PB CD56dim NK cells has 
been shown in many reports (Frey et al., 1998, Mäenpää et al., 1993, Uksila et al., 
1997) and was confirmed here. Interestingly, it has previously been reported that 
CD56dim NK cells acquire phenotypic characteristics of less mature NK cells in 
response to infection and that they express a high density of L-selectin (Frey et al., 
1998). 
 
Only CD56bright PB NK cells have the capacity to traffic to LN. Their migratory 
capacity to LN correlates with the expression of some chemokine rece
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CCR7 and CXCR3 (Campbell et al., 2001). It has been reported that CCR7 expression 
could be induced on CD56dim NK cells in vitro by incubation with IL-18 (Mailliard et 
al., 2005). Furthermore, it has been reported that KIR+ NK cells are capable of CCR7 
uptake from mature DC and can therefore migrate to LN where they bind to their 
inflammatory chemokine ligands, CXCL10/CXCL11 and/or CCL19/CCL21. NK cell 
recruitment to the LN is important during haplo-identical HSCT, as alloreactive NK 
cells can kill host DCs that are responsible for priming donor T cells and subsequently 
reduce GvHD (Marcenaro et al., 2009). In mice, NK cell recruitment to lymphoid 
tissues is dependent on CXCR3 expression due to the ability of this receptor to bind to 
CCL21 (Martín-Fontecha et al., 2004). NK cell trafficking to draining LN in response 
to CCL19/21 in humans is CCR7-dependent (Campbell et al., 2001, Kim et al., 1999). 
However, it is noteworthy that mechanisms underlying NK cell homing to LN are not 
fully understood, as blocking L-selectin expression has been shown to significantly 
reduce NK cell recruitment to LN (Martín-Fontecha et al., 2004). Hence, it is 
conceivable that NK cells use one or more chemokine receptors in order to traffic to 
LN. CB NK cells treated with cytokines upregulated CXCR3 in all conditions tested. 
However, inconsistencies were observed regarding CCR7 expression using two 
different monoclonal antibodies, which could be due to the fact that these antibodies 
recognise different epitopes.  
 
In the current study, I showed that the percentage of resting NK cells migrating in 
response to CCL19/21 was low (less than 20 %). However, stimulation with cytokines 
enhanced the migration of NK cells, and this was associated with an upregulation of 
CCR7. CCL19 and CCL21 are differentially distributed within the LN but both are 
ligands for CCR7, whereas CCL19 is expressed by DC residing in the T cell zone of the 
LN (Ngo et al., 1998), CCL21 is expressed by lymphatic endothelial cells in the T cell 
zone of the LN (Willimann et al., 1998). NK cell trafficking to LN allows interaction 
with LN resident cells including DC and T cells, to result in a potent production of IFN-
! (Scharton and Scott, 1993). In addition, CCL19/21 has been shown to co-stimulate the 
proliferation of IL-2 activated CD56dim NK cells (Robertson et al., 2000). Hence, 
CCR7-mediated trafficking of NK cells towards CCL19/21 may confer the ability of 
NK cells to migrate to LN, where many tumour types tend to metastasise (Zlotnik, 
2006). Herein, I showed enhanced migration towards CCL19/21 by PB and CB NK 
cells activated with IL-15+IL-2 or IL-15+IL-18. Both IL-15 and IL-2 have been 
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reported to induce chemotaxis of NK cells facilitating their attachment to endovascular 
epithelium in an LFA-1-dependent manner (Allavena et al., 1997). Yet, IL-18 appeared 
to be a major factor in NK cell recruitment to LN by increasing CCR7 expression by 
NK cells. 
 
Trans-well migration assays were performed to assess NK cell migratory capacity in 
vitro towards CXCL10/11. Herein, the percentage of migration by resting NK cells 
towards CXCL10/11 was less than 20 %. Upon cytokine activation, CXCR3 expression 
was substantially upregulated by PB and CB NK cells. As a result, cytokine-activated 
NK cells showed enhanced migration towards CXCR3 ligands CXCL10/11. The LN 
does not typically express CXCL10/11. In fact, CXCL10/11 is an inducible chemokine 
ligand that is expressed by infected macrophages and DCs in response to IFNs type I 
and II (Cole et al., 1998). The expression of CXCL10/11 leads to recruitment of 
CXCR3+ NK cells to their target cells. However, it has been shown that CXCL10/11 not 
only recruits effector cells to target cells, but also that it is involved in migration and the 
retention of T cells into the draining LN in HIV patients (Foley et al., 2005). Moreover, 
the expression of CXCL10/11 was induced in the LN of rats infected with autoimmune 
encephalomyelitis (McColl et al., 2004). Although it has been shown that mouse NK 
cells expressing CXCR3 could bind CCL19/21 in LN, it is also possible that 
CXCL10/11 is produced by follicular DCs present in LN stroma. The movement of 
activated NK cells from the red pulp to the white pulp of the spleen, which is the T cell 
zone, was found to be CXCR3-dependent in a MCMV mouse model (Grégoire et al., 
2008). Hence, CXCR3 expression is vital for recruitment of NK cells to both inflamed 
non-lymphoid sites and to LN. It was found here that NK cells activated with IL-15+IL-
2 or IL-15+IL-18 showed higher migration than those activated with IL-15+IL-12. This 
was associated with less expression of CXCR3 upon IL-15+IL-12 stimulation 
compared to IL-15+IL-2 or IL-15+IL-18 stimulation. Interestingly, it was reported that 
IL-12, alone or in combination with IL-2, rapidly downregulates CXCR3 mRNA 
expression by NK cells affecting their trafficking towards CXCL10. This was 
suggestive of an immunomodulatory role for NK cells during inflammation whereby 
NK cells could downregulate the expression of certain chemokine receptors to skew the 
immune response towards a more T helper cell type response when acquired (Hodge et 
al., 2002). However, it remains unknown why NK cells exhibit less migration following 





To summarise, PB and CB NK cells upregulate receptors involved in migration to the 
LN following cytokine stimulation including L-selectin, CCR7 and CXCR3. 
Particularly, IL-12 and IL-18 were shown to be potent inducers of L-selectin expression 
on CB NK cells. Combinations of IL-15+IL-2 or IL-15+IL-18 were shown to promote 
in vitro migration of PB and CB NK cells in response to CCL19/21 or CXCL10/11, 






Chapter 6: Cytokine-induced memory-like NK cells 
6.1 Introduction 
Immunological memory is defined based on specific antigen recognition and a robust 
recall response upon subsequent exposure to the same antigen. NK cells are designated 
as innate immune cells due their ability to recognise target with no prior sensitisation 
and to exert cytotoxic functions accordingly. As innate immune cells, it was thought 
that they respond to a stimulus in a similar manner regardless of repeated exposure. 
Surprisingly, NK cell immunological memory has been described in MCMV infected 
mice (Sun et al., 2009). In this model, Ly49H+ NK cells that were transferred into 
Ly49H! mice experienced antigen-specific expansion following MCMV infection. 
Furthermore, these long-lived cells underwent robust secondary expansion, and 
exhibited enhanced cytotoxicity and protection against MCMV infection. 
 
In addition, it was shown by Yokoyama and colleagues that cytokine pre-activation 
could induce memory-like NK cells in mice (Cooper et al., 2009). In this model, IL-12 
and IL-18 pre-activated NK cells infused into naïve hosts could still be detected 22 days 
post-infusion. Moreover, when these cells were restimulated with IL-15 and IL-12 they 
displayed high production of IFN-". Subsequent studies have also showed similar 
findings with regard to high IFN-" production by cytokine pre-activated human NK 
cells (Romee et al., 2012). 
  
Herein, I analysed whether cytokine pre-activation of CB NK cells would induce long-
lived NK cells with memory-like features, as has been observed for PB memory-like 
NK cells with respect to IFN-" production. Hence, I followed the published protocol of 
Romee and colleagues to investigate whether memory-like NK cells can be generated 











The following analysis focused on IFN-! production, secretion and gene expression by 
memory-like NK cells generated from PB and CB. The study was carried out using NK 
cells that were pre-activated with IL-15 only (control NK cells) or NK cells that were 
pre-activated with IL-12, IL-15 and IL-18 (pre-activated NK cells). IFN-! analysis was 
performed after restimulation of NK cells with IL-12 and IL-15 at different time points 
for up to 3 weeks. 
 
6.2.1 Generation of a higher frequency of IFN-! producing PB and CB NK cells 
following pre-activation with cytokines 
The production of IFN-! by cytokine-induced memory-like NK cells from PB and CB 
was investigated by flow cytometry at days 7, 14 and 21 of culture by intracellular 
staining. Overall, levels of intracellular IFN-! were more variable for control NK cells 
than for pre-activated NK cells. This pattern was identical for cells generated from both 
PB (Fig 6.1) and CB (Fig 6.2). At day 7, the percentage of IFN-! producing PB NK 
cells was 43.48 ± 2.71 % for control NK cells and 71.08 ± 2.72 % for pre-activated NK 
cells (p < 0.0001). Similarly, 40.02 ± 3.78 % and 60.02 ± 1.48 % of control NK cells 
and pre-activated NK cells from CB produced IFN-! (p = 0.0006) (Fig 6.3). At day 14, 
the mean percentage of IFN-! production was 48.96 ± 4.04 % and 43.50 ± 3.28 % for 
PB and CB control NK cells respectively (Fig 6.3). Similarly to day 7, IFN-! 
production was significantly increased at day 14 for pre-activated NK cells from PB 
(64.60 ± 0.927 %) and CB (53.33 ± 1.49 %) as compared to control NK cells (p = 
0.0055 and 0.0214 respectively). At day 21, a comparable pattern of IFN-! expression 
was observed for pre-activated NK cells from PB (55.86 ± 1.86 %) and CB (52.95 ± 
3.30 %) than for control NK cells from PB (40.14 ± 2.99 %) and CB (39.00 ± 3.93 %) 
(p = 0.0021 and 0.0217 respectively) (Fig 6.3). Figure 6.4 shows the MFI of IFN-! 
expression as compared to control and pre-activated NK cells. Cytokine-induced 
memory-like NK cells were checked for viability at day 21 using 7AAD only (Fig 6.5), 
Therefore, further analysis is required to examine their apoptotic state using both 





Figure 6.1 Flow cytometric histograms showing IFN-! production by cytokine-
induced memory-like NK cells derived from PB NK cells. The graphs compare IFN-
! production at days 7, 14 and 21 for control (unstimulated) NK cells (left panel) and 
pre-activated (stimulated with IL-12 and IL-18) NK cells (right panel) from one 
representative PB sample. Analysis was performed 6 hr after restimulation with IL-12 
and IL-15. Cut-off values were adjusted based on negative control isotype. 
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Figure 6.2 Flow cytometric histograms showing IFN-! production by cytokine-
induced memory-like NK cells derived from CB NK cells. The graphs compare IFN-
! production at days 7, 14 and 21 for control (unstimulated) NK cells (left panel) and 
pre-activated (stimulated with IL-12 and IL-18) NK cells (right panel) from one 
representative CB sample. Analysis was performed 6 hr after restimulation with IL-12 
and IL-15. Cut-off values were adjusted based using an isotype. 
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Figure 6.3 Comparison of IFN-! production by cytokine-induced memory-like 
NK cells derived from PB and CB NK cells. The graph represents intracellular 
expression of IFN-! analysed by flow cytometry at days 7, 14 and 21 in control and pre-
activated NK cells from PB (red symbols) and CB (blue symbols). PMA and Ionomycin 
were used as positive control for induction of IFN-! expression (at day 0 only as cells 
would die if left with no cytokines). Analysis was performed 6 hr after restimulation 
with IL-12 and IL-15. Results are presented as Mean ± SD. N=5 for PB and 6 for CB, p 
<0.01 (**) and p <0.001 (***). 
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Figure 6.4 Mean fluorescence intensity of intracellular IFN-! by cytokine-
induced memory-like NK cells generated from PB (A) and CB (B). This figure 
compares MFI of IFN-! expression between controls and pre-activated NK cells at days 
7, 14 and 21. N=5 for PB and 6 for CB. 
 
Figure 6.5 Cytokine-induced memory-like NK cell viability. The viability of 
cytokine-induced memory-like NK cells generated from PB (A) and from CB (B) tested 
using 7AAD at day 21. 
 
6.2.2 IFN-! secretion by memory-like NK cells does not correlate with the 
frequency of IFN-!+ expressing NK cells 
Culture supernatants from cytokine-induced memory-like NK cells were collected and 
tested for IFN-! secretion using multiplex bead-based immunoassays. IFN-! secretion 
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cell samples (Fig 6.6). At day 7, IFN-! secretion by control and pre-activated PB NK 
cells was not significantly different (3950 ± 862.0 pg/mL and 5109 ± 794.6 pg/mL 
respectively). In contrast to PB, pre-activated CB NK cells secreted significantly higher 
IFN-! (1586 ± 272.2 pg/mL) than control CB NK cells (153.4 ± 44.55 pg/mL) (p = 
0.0020). At day 21, IFN-! secretion by control PB NK cells was surprisingly higher 
than pre-activated PB NK cells (5109 ± 794.6 pg/mL and 1518 ± 435.2 pg/mL 
respectively, p = 0.0042), suggesting that cytokine pre-activation of PB NK cells may 
induce exhaustion in long-tem cultures. Control CB NK cells secreted comparable 
levels of IFN-! to pre-activated CB NK cells (1035 ± 226.1 pg/mL and 912.5 ± 194.9 
pg/mL respectively) (Fig 6.6). Notably, memory-like NK cells did not secrete any of 
the other cytokines tested by multiplex including TNF-", TNF-#, IL-6 or IL-8.  
 Figure 6.6 IFN-! secretion by cytokine-induced memory-like NK cells. Secretion 
of IFN-! by cytokine-induced memory-like NK cells derived from PB (red bars) and 
CB (blue bars) NK cells at days 7 and 21 of culture measured by multiplex bead-based 
immunoassay. Supernatants were collected 6 hr after restimulation with IL-12 and IL-
15. Results are presented as Mean ± SD. N=5 for PB and 4 for CB, p <0.05 (*) and p 
<0.01 (**). 
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6.2.3 Equivalent gene expression of IFN-! by control and pre-activated NK cells 
from PB and CB 
IFN-! gene expression was analysed by real-time PCR in comparison to reference 
genes (Fig 6.7). Equivalent relative expression of IFN-! was detected for control and 
pre-activated NK cells from PB (0.9703 ± 0.034 and 0.9937 ± 0.021 respectively) and 
CB (0.9155 ± 0.005 and 0.9088 ± 0.012 respectively). Interestingly, pre-activated CB 
NK cells exhibited significantly higher IFN-! gene expression than pre-activated PB 
NK cells (p = 0.0057).  
 
 
Figure 6.7 IFN-! gene expression by cytokine-induced memory-like NK cells. 
Real-time PCR analysis of IFN-! mRNA levels in control and pre-activated NK cells 
from PB (red symbols) and CB (blue symbols). Gene expression was normalised using 
three reference genes (ACTB, "2M and UBC). Results are presented as Mean ± SD. 
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It was recently shown that NK cells develop features of immunological memory under 
certain conditions including, exposure to infection, sensitisation with specific antigens 
such as haptens, or pre-activation with cytokines (Min-Oo et al., 2013). It has been 
shown that MCMV-induced-memory NK cells undergo secondary expansion as well as 
enhanced cytotoxicity and specificity to m175 viral proteins following re-exposure to 
antigen (Sun et al., 2009). Similarly, liver-restricted-memory NK cells have been shown 
to exhibit cytotoxicity and specificity to the sensitising antigen, but it remained to be 
determined whether these cells could undergo secondary expansion (O'Leary et al., 
2006, Paust et al., 2010). On the other hand, cytokine-induced memory-like NK cells 
have not been shown to exhibit any change in their cytotoxic function, rather, they tend 
to produce higher levels of IFN-! (Cooper et al., 2009). Although memory-like NK 
cells generated from different sources exhibited different properties in regards to their 
cytotoxic functions, they share a common feature of immunological memory, which is 
extended lifespan.  Hence, the aim of this chapter was to generate long-lived memory-
like NK cells from PB and CB NK cells using cytokines, following the published 
protocol of Romee and colleagues (Romee et al., 2012), and to address whether CB NK 
cells produce IFN-! in a similar manner to PB NK cells following cytokine stimulation. 
 
My results show that restimulation of pre-activated PB and CB NK cells with IL-12 and 
IL-15 results in a higher frequency of IFN-! producing cells than for control NK cell 
cultures. NK cells are known to be short-lived in vitro (5 to 7 days) (Cooper et al., 
2002) and NK cells require high doses of cytokines in order to maintain their viability 
in culture. Herein, NK cells were maintained in vitro with a very low dose of IL-15 for 
up to 3 weeks. The fact that NK cells are long-lived in culture following cytokine 
stimulation corresponds to one of the properties of memory NK cells. 
 
In addition, different patterns of intracellular IFN-! production were observed between 
control and pre-activated NK cells from PB and CB. It was evident that the vast 
majority of pre-activated NK cells produce IFN-!, whereas only a subset of control NK 
cells did. In control NK cell cultures, the main producers of IFN-! are the CD56bright 
population. This is in contrast to pre-activated NK cell cultures whereby all NK cells 
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produce IFN-!. In accordance with previous studies, cytokine pre-activation increases 
the frequency of IFN-! producing NK cells (Cooper et al., 2009, Romee et al., 2012). 
The finding that NK cells become IFN-! producing cells upon secondary stimulation 
indicates that NK cells preserve memory to previous cytokine exposure and exhibit a 
robust response when re-exposed to the same cytokine stimulation. However, this 
memory property is not specific to a single cytokine such as IL-12, IL-15 or IL-18 
which are not capable to induce similar properties alone, whereas pre-activation with 
combinations of IL-12+IL-18, IL-15+IL-18 or IL-15+IL-12 are sufficient to induce 
memory imprint of NK cells (Romee et al., 2012). Interestingly, it was shown that this 
pattern of IFN-! production is exhibited for both cells that have proliferated and non-
proliferated cells (Cooper et al., 2009). Hence, it is likely that this feature of memory-
like NK cells is passed onto successive generations of cells, although this was not 
investigated here.  
 
CB NK cells are considered to be naïve cells due to their immature phenotype and 
decreased cytotoxic function as compared to PB NK cells (Gaddy et al., 1995, Luevano 
et al., 2012a). Moreover, stimulation of CB NK cells with mitogens such as PMA and 
Ionomycin resulted in significantly less IFN-! production compared to PB NK cells. 
Nevertheless, it was possible to promote IFN-! production by CB NK cells by pre-
activation with cytokines. Hence, it could be that the exposure of CB NK cells to 
inflammatory cytokines induces intrinsic modification of CB NK cells, and that 
cytokine pre-activation modifies the cytokine receptor repertoire and the responsiveness 
to cytokine activation accordingly. In this context, it was shown that pre-activation of 
NK cells with IL-12 and IL-18 increased IL-2R" expression (Ni et al., 2012). As for 
cytokine-induced memory-like PB NK cells, mechanisms underlying these changes 
remain to be clarified. 
 
Although the vast majority of pre-activated NK cells were IFN-! producing cells, IFN-! 
secretion was variable among control and pre-activated NK cells, as well as between 
different sources of NK cells. I showed here that restimulation of pre-activated PB NK 
cells induces higher secretion of IFN-! than for control NK cells at day 7. However, 
IFN-! secretion by PB memory-like NK cells at day 21 was not consistent with 
intracellular IFN-! production, as control NK cells secreted higher IFN-! than pre-
activated NK cells. Control CB NK cells at day 7 secreted significantly less IFN-! than 
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pre-activated CB NK cells. By day 21, it appeared that control and pre-activated CB 
NK cells secreted similar amounts of IFN-!. In general, memory-like NK cells 
generated from CB NK cells secreted lower levels of IFN-! than those generated from 
PB NK cells. It is noteworthy that previous studies that aimed to generate memory-like 
NK cells using cytokines have detected intracellular expression of IFN-! in memory-
like NK cells, rather than IFN-! secretion (Cooper et al., 2009, Romee et al., 2012). 
Hence, my findings suggest that although pre-activated NK cells display higher 
intracellular IFN-!, it does not necessarily correlate with IFN-! secretion in vitro. It 
remains to be clarified whether these cells would behave similarly in vivo. Furthermore, 
there is the possibility that exposure to cytokines resulted in exhaustion of NK cells as 
control NK cells appeared to secrete higher levels of IFN-! than pre-activated NK cells. 
 
Finally, I investigated IFN-! mRNA levels to assess whether IFN-! gene expression 
differs between control and pre-activated groups of memory-like NK cells. In 
accordance with other reports, my results showed that there is no difference in IFN-! 
gene expression between the two groups, for both PB and CB NK cells. However, I 
showed here that CB NK cells in general express higher levels of IFN-! than PB NK 
cells. The fact that comparable IFN-! gene expression was seen in control and pre-
activated NK cells confirms that the higher production of IFN-! is not the result of an 
enhanced transcription of IFN-!. Rather, memory-like NK cells may experience post-
transcriptional or post-translational modifications to regulated IFN-! secretion, possibly 
occurring at other loci than the ifng locus (Romee et al., 2012, Stetson et al., 2003). 
 
To summarise, I generated long-lived NK cells in vitro using cytokines from PB and 
from CB NK cells for the first time. Cytokine pre-activated NK cells showed higher 
IFN-! production than the control NK cells upon restimulation with IL-12 and IL-15. 
However, this did not correlate with higher secretion of IFN-! or to higher IFN-! 
mRNA expression. Other aspects of cytokine-induced memory-like NK cells remain to 
be investigated to understand the underlying mechanisms of these interesting findings. 
! "#$%&'(!)!!
! 181 
Chapter 7: Conclusions and future directions 
7.3 Background of the current study  
NK cells are key players in the eradication of virally infected cells and transformed 
cells and have therefore been considered as a cell therapy option for cancers. Different 
groups have explored the use of cytokines to either expand NK cells or to enhance their 
cytotoxicity using NK cells from PB or CB. Unlike PB NK cells, freshly isolated CB 
NK cells are unable to mediate cytotoxic activities, however, they have been shown to 
be cytotoxic after cytokine stimulation. Studying the optimal activation conditions for 
different sources of NK cells will provide fundamental information for future NK cell-
based therapies. Hence, the aim of this study was to induce fully functional CB NK 
cells using cytokines and to perform comparative analysis of the mechanisms of 
activation between PB and CB NK cells. Herein, I was able to identify differential 
responsiveness of CB and PB NK cells to cytokine activation. 
 
7.4 Summary of key results 
Table 7.1 summarises my findings in regard to NK cell activation by cytokines. I 
observed that IL-2 promoted optimal effector functions of PB NK cells (upregulation of 
activating receptors, killing capacity and cytokine production), whereas CB NK cells 
did not respond similarly to IL-2 stimulation even when higher doses were used. 
Moreover, I found that IL-15 or IL-18 stimulation induced upregulation of activating 
receptors on both PB and CB NK cells. However, KIR and CD94/NKG2A expression 
was not altered by cytokine stimulation whereby cytokine-activated CB NK cells still 
exhibited low KIR expression and high CD94/NKG2A expression.  
 
All cytokine stimulation conditions used enhanced killing of K562 cells by PB NK cells 
after two days of stimulation with cytokine. However, the killing capacity of CB NK 
cells was the highest post-stimulation with IL-15 or IL-15+IL-2, whereas IL-18 
stimulation had no effect. After 5 days of stimulation, the killing capacity of CB NK 
cells was enhanced after IL-15+IL-2 stimulation, showing higher killing levels than PB 
NK cells. I confirmed that PB and CB NK cells have equivalent mRNA levels of 
! "#$%&'(!)!!
! 182 
perforin regardless of the cytokine stimulation used whereas the expression of 
granzyme B was variable among different cytokine stimulation strategies. In regard to 
cytokine production, PB NK cells secreted high amounts of IFN-! post-stimulation with 
IL-2, whereas CB NK cells secreted the highest levels of IFN-! and TNF-" after 
stimulation with the combination of IL-15+IL-18 (Table 7.1). 
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Table 7.1 Summary of NK cell activation study 
  






























Activating receptors +++ (*) + ++ +++ +++ +++ +++ +++ NI NI NI NI 
KIR expression  CB NK cells express less KIR than PB NK cells and cytokine stimulation has no impact on KIR expression 
CD94/NKG2A CB NK cells express higher levels of CD94/NKG2A than PB NK cells and cytokine stimulation has no impact on CD94/NKG2A expression 











+ ++ +++ +++ 
K562 killing at D2 +++ + +++ ++ +++ +++ ++ ! ++ ++ +++ + 






















IFN-! secretion (D2) ++ + + +++ ++ ++ + + + + ++ +++ 
IFN-! secretion (D5) +++ + NI NI ++ ++ NI NI + + ++ +++ 
TNF-" secretion (D2) + + ! ! ++ ++ ! +++ + + + +++ 
TNF-" secretion (D5) + + NI NI + + NI NI + + + ++ 
L-selectin expression +++ ! +++ +++ ++ ! +++ ++ NI NI NI NI 
CXCR3 expression ++  +++  +  ++  +++  +++  ++  ++  +++  +++  ++  +++  
CCR7 expression 
(3D12/358426 clones) +/+  !/+  !/+  +/+ +/+  +/+  !/+  !/+  +  ++  +  ++  
Migration in response 
to CXCL10/11 NI NI NI NI NI NI NI NI +++ +++ ++ ++ 
Migration in response 
to CCL19/21 NI NI NI NI NI NI NI NI +++ +++ ++ ++ 
(*) = +++ > ++ > + > !, (**) = NI (not identified), (***) = Gene expression evaluated as upregulated or downregulated compared to resting NK cells. 
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7.3 Caveats and weakness of the study 
Although this study presents differential findings in regards to activation of PB and CB 
NK cells, there is variability to consider between the two sources. PB samples were 
collected within the department and processed freshly after collection whereas CB 
samples were collected at different hospitals and transported to the Anthony Nolan 
Therapy Centre, Nottingham, UK. Thereafter, CB samples were dispatched to the 
Anthony Nolan Research Centre, London, UK. Therefore, the time between CB 
collection and processing may vary among samples leaving a time gap of 24 hrs to 48 
hrs between CB collections and processing that may affect CB viability. Hence, the 
time course could contribute to alteration of NK cell characteristics between the two 
sources including phenotype and effector functions (Naranbhai et al., 2011). 
One main weakness of the study was the inability to perform analysis on different 
subsets of NK cells; CD56bright and CD56dim after cytokine stimulation. This was due to 
the alteration of CD56 expression on NK cells post stimulation that becomes more 
homogeneous rendering difficult separation between the two subsets. Another 
limitation factor to consider in this study is sample number. The analysis was 
performed on 4 to 5 samples for each condition due to time constrains. Although 
significant findings were observed, sample size remains an important factor to detect 
genuine variation between PB and CB NK cells and to ensure reproducibility of each 
experiment. Hence, future analysis necessitates increasing of the sample size for all 
analysis performed. 
In addition, a cytokine dose-dependent responsiveness study is yet to be performed. In 
spite that CB NK cells showed maximal activation using lower doses of IL-15 (20 
ng/mL) and IL-12 (10 ng/mL), it is possible that lower doses may induce similar effects 
on CB NK cells. Therefore, future analysis may aim to optimise cytokine 
concentrations by performing activation study with lower doses of cytokines. Also, the 
IL-12, IL-15 and IL-18 concentration remained to be adjusted to an international unit 
(IU) instead of grams to provide more consistent biological activity of these cytokines. 
As for flow cytometric analysis, unstained cells were used as negative controls (except 
for signaling and intracellular IFN-! studies where isotype has been included). 
Therefore, suitable non-reactive isotype for each monoclonal antibody should have 
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been included in the phenotype study. Also, the inclusion of fluorescence minus one 
(FMO) control which include all fluorochromes except the one being tested, would 
offer the identification of the spread of any other fluorochromes into the channel of 
interest, and hence proper separation between negative and positive population could be 
achieved. 
 
In addition, the expression of cytotoxic mediators was assessed by real time PCR to 
measure mRNA levels of granzyme B and perforin. This was done to detect any change 
that could occur at the gene expression post cytokine stimulation and to perform 
comparison between cytokine-activated PB and CB NK cells. However, my results 
showed no significant findings that could be the result of transcription in order to 
assemble granzyme B and perforin proteins. Hence, mRNA levels may not be an actual 
indicative for NK cell cytotoxicity. Future analysis should be performed to assess the 
intracellular expression of granzyme B and perforin instead of gene expression to be 
able to detect possible variation between the two sources post cytokine stimulation as 
well as a comparison with resting NK cells.  
Cytokine secretion by activated NK cells was performed by Multiplex (bead-based 
immunoassay), which offered the detection of secretion of many cytokines in this study. 
However, those analyses were performed on the supernatant of cytokine activated NK 
cells that have been purified using negative selection. Despite that the purity of isolated 
NK cells was exceeding 90 %, there could be other possible contaminants produced by 
other cells remained after isolation. Future analysis are still required by using sorted 
CD56+ NK cells in similar experiments to confirm my findings.   
7.4 Physiological relevance of this study 
Human neonates have a naïve adaptive immune system and are more susceptible to 
infections than adults, in particular preterm infants (Berrington et al., 2011). In this 
context, infants are not able to develop TH1 responses against bacterial and viral 
infections. In contrast, T cell responses are shown to be skewed towards TH2 responses, 
which mediate a suppressive role, and hence limiting inflammation and tissue damages 
in infants (Zaghouani et al., 2009). It has been suggested recently that IL-8 plays a 
major role in neonatal immunity as increased IL-8 production was detected by neonatal 
CD4+ T cells as compared to adult CD4+ T cells after stimulation with PMA and 
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Ionomycin or anti-CD3+CD28 beads (Gibbons et al., 2014). In addition, IL-8 has been 
shown to co-stimulate the production of IFN-! from neonatal !" T cells (Gibbons et al., 
2009). 
IL-8 is a potent chemotactic factor of neutrophils mediating their migration towards 
infection sites where they exert their effector functions (Zlotnik and Yoshie, 2012). 
Herein, phenotypical and functional differences between adult PB and CB NK cells 
observed in this study may correlate with different physiological roles mediated by 
neonatal NK cells than those in adults. Similar to neonatal T cells, CB NK cells 
produced substantial amounts of IL-8 post cytokine stimulation as compared to adult 
NK cells, which may provide protection against neonatal infections by enhancing 
migration of neutrophils to infected sites to provide neutrophil-mediated anti-microbial 
response. Also, this finding highlights the necessity to further investigate the 
intracellular expression of IL-8 by CB NK cells to be able to quantify the percentage of 
IL-8-producing NK cells in CB and to gain insight to the role of neonatal NK cells in 
infants. 
7.5 Is interleukin-2 the “ideal “ cytokine to stimulate CB NK cells? 
It has been previously reported that CB NK cells require up to 10 times more IL-2 than 
PB NK cells for activation and expansion (Condiotti et al., 2001, Luevano et al., 
2012a). Herein, I showed that CB NK cells express less IL-2R# than PB NK cells. In 
addition, STAT5 phosphorylation following IL-2 stimulation was significantly reduced 
in CB NK cells compared to PB NK cells. IL-2R# together with IL-2R$/! mediates 
high affinity binding to IL-2, which promotes NK cell proliferation. In this context, 
CD56bright NK cells express high levels of IL-2R# and therefore have enhanced 
proliferative capacities in response to IL-2, as compared to CD56dim NK cells (Caligiuri 
et al., 1990, Carson et al., 1994, Cooper et al., 2001a). Accordingly, the reduced 
responsiveness of CB NK cells to IL-2 stimulation with respect to their expansion and 
cytotoxic functions could be a consequence of reduced high affinity binding to IL-2 
given that CB NK cells express less IL-2R# and exhibit reduced phosphorylation of 
STAT5.  
 
In addition, phosphorylation of STAT5 results in transcription of target genes such as 
IFN-!. Phosphorylated STAT5 dimers bind to the ifng locus enhancing the production 
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of IFN-! (Bream et al., 2004). I showed here that IL-2 activated CB NK cells secreted 
significantly less IFN-! than IL-2 activated PB NK cells. Yet, I did not observe 
differential IFN-! gene expression following IL-2 stimulation between PB and CB NK 
cells, although PB NK cells secreted higher levels of IFN-!.  
 
In the clinical context, IL-2 administration has been associated with toxicity, induction 
of AICD resulting in elimination of effector cells and expansion of Tregs (Ghiringhelli 
et al., 2005). In vitro studies showed that Tregs co-cultured with NK cells inhibit NK 
cell expansion by competing for IL-2 (Bachanova et al., 2014), as Tregs express IL-2R# 
(Yamaguchi and Sakaguchi, 2006). In contrast, parallel experiments have shown that 
the proliferation of IL-15 activated NK cells was not inhibited by Tregs as shown in 
(Bachanova et al., 2014). In the Bachanova study, successful expansion of donor NK 
cells along with systemic administration of IL-2 into AML patients was achieved by 
Treg cell depletion using an IL-2-diptheria fusion protein. Interestingly, NK cell 
persistence and expansion was associated with clearance of AML cells and high serum 
levels of IL-15 indicating that IL-2-diptheria fusion protein may indirectly enhance the 
production and presentation of endogenous IL-15 by DCs via the IL-15R#. This 
suggests that IL-15, but not IL-2, supplementation in NK cell-based therapies is 
essential for survival and persistence of adoptively transferred NK cells. Overall, I 
showed here that PB NK cells are optimally activated with IL-2, whereas IL-2 was not 
the ideal cytokine to activate CB NK cells. Thus, the use of IL-15 to activate CB NK 
cells should be taken into consideration for NK cell immunotherapy given that the in 
vitro effect of IL-2 on NK cells functions was not reflected in vivo. 
  
7.6 Cytokine combination  
The purpose of using combinations of cytokines in the present study was to assess 
whether certain cytokines have a synergistic effect on each other, as was indicated by 
several studies (de Rham et al., 2007, French et al., 2006a, Son et al., 2001, Strengell et 
al., 2003). The combinations that I studied were based on my initial findings regarding 
the phenotypes of cytokine-activated NK cells (Chapter 3). IL-15 was the most potent 
cytokine for inducing the expression of activating receptors on both PB and CB NK 
cells. However, IL-15 did not promote the expression of L-selectin on CB NK cells, a 
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receptor that is key in NK cell trafficking to LN. On the other hand, IL-12 or IL-18 
were shown to upregulate the expression of L-selectin. In addition, IL-18 is known to 
upregulate CCR7 expression. Since IL-12 has been shown to be toxic with documented 
clinical adverse effects, I focused on the combinations of IL-15+IL-2 and IL-15+IL-18.  
 
IL-15 is critical for NK cell development, homeostasis and activation. In this context, 
IL-15 may enhance the cytotoxicity of CB NK cells and promote their differentiation 
from CD34+ HSCs in a transplantation setting. The feasibility of using the combination 
of IL-15 with IL-2 to activate CB NK cells was shown here. First, IL-15+IL-2 induced 
the highest killing capacity by CB NK cells. Moreover, cytotoxicity of IL-15+IL-2 
stimulated CB NK cells exceeds PB NK cells at the different time points examined 
here. Second, IL-15+IL-2 promoted significant proliferative capacity of CB NK cells. 
Third, this combination was shown to induce chemotaxis of CB NK cells. Importantly, 
both IL-2 and IL-15 are FDA approved and have already been used in clinical trials, 
thereby making this combination attractive for further investigations. 
 
Similarly, the combination of IL-15+IL-18 was shown here to induce the production of 
inflammatory cytokines by CB NK cells, but also to enhance cytotoxicity upon 
prolonged stimulation. Nomura et al. showed previously that CB NK cells demonstrate 
selective responses to IL-18 stimulation (Nomura et al., 2001). I showed here that CB 
NK cells express less IL-18R than PB NK cells, which possibly explains their poor 
killing capacity when stimulated with IL-18 alone. In contrast, the use of IL-15+IL-18 
may deliver a synergistic effect by: (i) upregulating IL-18R expression, (ii) promoting 
IL-15-mediated NK cell survival and (iii) enhancing both cytotoxicity and cytokine 
production by NK cells. IL-18 has already been used in clinical trials and was shown to 
be less toxic than other cytokines as no maximum tolerated dose has been detected yet 
(Robertson et al., 2006, Tarhini et al., 2009). Although IL-18 alone induces limited anti-
tumour activity, its function can be exploited if used in combination with other 
cytokines. In this context, it has been shown recently that IL-18 in combination with 
IFN-#, IL-2, IL-12 or IL-15 promotes the production of CCL19 within tumour-
associated lymphoid tissues and this provides a rational for the use of IL-18 as a co-
stimulating agent in an immunotherapeutic context (Wong et al., 2013).  
 
In this study, I tested NK cell cytotoxicity in vitro using the K562 cell line. As the 
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cytotoxicity of cytokine-activated NK cells against primary AML cells would be an 
interesting approach to determine which conditions promote maximal activity of PB 
and CB NK cells, as NK cell activity correlates with the clearance of AML blasts after 
HSCT (Lion et al., 2012). In addition, the functionality of cytokine-activated NK cells 
in vivo remains to be investigated using an animal model. In this context, K562 or 
primary AML cells could be injected into irradiated mice along with cytokine-activated 
NK cells to further investigate their cytotoxicity. The ideal mouse model to study NK 
cell cytotoxicity in vivo is using NOD-scid-!c"/" mice as this strain lacks T cells, B 
cells and functional NK cells, exhibits enhanced engraftment of human lymphocytes 
and supports the growth of many transplantable human tumour cells (Shultz et al., 
2007). NOD-scid-!c"/" mice can be irradiated and intravenously injected with GFP-
labelled tumour cells as has been shown by Luevano and colleagues (Luevano et al., 
2014). Twenty four hours post-tumour injection, cytokine-activated NK cells can be 
injected into mice and their localisation into various tissues including liver, spleen, 
lungs and BM assessed 2 days later. Mice injected only with tumour cells can be used 
as a control in this experimental setting. This model can be helpful to assess 
cytotoxicity of NK cells in vivo as well the accumulation of NK cells in certain tissues 
after adoptive transfer. 
7.7 Do NK cell traffic to tumour sites after adoptive transfer? 
Successful approaches for adoptive transferring of cytokine-activated NK cells should 
offer effective recruitment of NK cells to inflammatory or tumour sites. In this context, 
the expression of CCR7 and/or CXCR3 mediates NK cell trafficking towards LN and 
tumour sites and hence the correct localisation to kill cancerous cells. Herein, I 
demonstrated upregulation of chemokine receptors involved in NK cell trafficking to 
LN and inflamed tissues as well as migration of PB and CB NK cells after IL-15+IL-2 
or IL-15+IL-18 activation in vitro. CXCR3 expression was upregulated on PB and CB 
NK cells after cytokine stimulation. In vivo, CXCR3+ NK cells are only able to infiltrate 
tumour tissues when CXCR3 ligand (CXCL10) is expressed. The upregulation of 
CXCL10 was shown to be IFN-!-dependent (Wendel et al., 2008). In this context, I 
showed here that NK cells secreted high concentrations of IFN-! after stimulation with 
cytokines, in particular IL-15+IL-18. Hence, it is possible that IFN-! production by IL-
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15+IL-18 activated NK cells could contribute to the upregulation of CXCL10 and 
enhanced NK cell trafficking to tumour sites or LN. 
 
Currently, the trafficking repertoire of adoptively transferred NK cells is not fully 
understood. A recent study has shown that adoptively transferred murine NK cells are 
efficiently recruited and accumulated within tumour sites (Gill et al., 2012). However, 
this study demonstrated that NK cells lost their capacity to attack tumour cells at day 5 
after transfer, and that they downregulated the expression of activating receptors, 
suggesting exhaustion of the transferred NK cells. Whilst it would be interesting to 
assess migration of cytokine-activated NK cells in vivo, this may be difficult as NK cell 
trafficking mechanisms vary between humans and mice (Martín-Fontecha et al., 2004).  
 
7.8 Memory-like NK cells 
It has been shown recently that cytokine stimulation induces memory-like properties in 
PB NK cells (Cooper et al., 2009, Ni et al., 2012, Romee et al., 2012). Hence, I tested 
the feasibility of generating memory-like NK cells from CB. My initial findings showed 
that CB NK cells respond to some cytokines even better than PB NK cells. I was able to 
generate memory-like NK cells from PB and CB NK cells with sustained ability to 
produce IFN-! after 21 days of culture after cytokine stimulation. This work is 
significant in the context of NK cell-based immunotherapy, as the ability to maintain 
NK cells in long-term culture offers a flexible source for multiple NK cell infusions 
from the same donor. Furthermore, the fact that these cells are a rich source of IFN-! 
could be utilised to treat viral infections post-transplantation. Indeed, Foley and 
colleagues showed this using different allogeneic transplantation cohorts: T cell-
deplete, T cell-replete from unrelated BM or PB donors and CBT. They showed that 
reconstituted NK cells have impaired IFN-! production particularly in T cell-depleted 
and CB cohorts suggesting that T cells play an important role in NK cell education 
(Foley et al., 2011). Hence, cytokine-induced memory-like NK cells may be infused in 
HSCT recipients to provide protection from post-transplantation infections. 
 
The cytotoxic capacity of cytokine-induced memory-like NK cells was not assessed 
here as it was shown firstly by Cooper and colleagues that the cytotoxic capacity of 
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memory-like NK cells was not enhanced in this protocol (Cooper et al., 2009). 
However, Ni et al. showed that the infusion of IL-12+IL-15+IL-18 pre-activated NK 
cells, but not naïve or IL-2 nor IL-15 stimulated NK cells, resulted in substantial 
reduction of tumour growth (Ni et al., 2012). Moreover, cytokine pre-activated 
memory-like NK cells have been shown to persist for up to 3 months following 
adoptive transfer. Interestingly, cytokine pre-activation results upregulates the 
expression of the IL-2R# by memory-like NK cells. As a result, the interaction between 
T helper cells and cytokine pre-activated NK cells within LN leads to robust expansion 
of memory-like NK cells, promoting their anti-tumour activity and priming of T cell 
specific responses (Ni et al., 2012, Leong et al., 2014). Given that cytokine pre-
activated NK cells undergo modification of cytokine receptor expression, further 
analysis of cytokine receptors, in particular IL-2R# and phosphorylation of STAT5 
components, should be carried out, especially because I showed in this study that CB 
NK cells express lower levels of IL-2R#. Also, further analysis of the chemokine 
receptor repertoire remains to be done as cytokine-induced memory-like NK cells were 
shown by Ni and colleagues to accumulate at tumour sites and produce IFN-!. In 
addition, in vitro and in vivo cytotoxic function of cytokine-induced memory-like NK 
cells against K562 or primary AML cells remains to be tested. Romee and colleagues 
have injected cytokine-induced memory-like NK cells into NOD-scid-!c"/" mice to 
study their expansion and accumulation within specific tissues (Leong et al., 2013). The 
expansion of transferred NK cells in this model was supported by low dose 
administration of IL-2. Hence, similar models could be utilised in future experiments to 
investigate expansion and cytotoxicity of cytokine-induced memory-like NK cells in 
vivo and importantly to provide comparative analysis of memory-like NK cells 
generated from the PB and CB sources.   
 
So far, the best-characterised model for memory-like NK cell properties has been for 
MCMV infection. Memory-like NK cells showed specific recall responses to m175 
MCMV derived proteins that are recognised by Ly49 on mouse NK cells (Sun et al., 
2009), whereas NKG2C+ NK cells expand in humans as a result of viral infections to 
mediate anti-viral protection (Gumá et al., 2006, Lopez-Vergès et al., 2011). In contrast 
to viral-induced memory-like NK cells, cytokine-induced memory-like NK cells do not 
confer specificity towards a particular antigen. Instead, cytokine-induced memory-like 
NK cells are a rich source of IFN-! and are readily responsive to restimulation. Thus, 
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their in vivo function can be studied in an HSCT context to investigate whether 
cytokine-induced memory NK cells mediate anti-viral protection, in particular to CMV 
infection, post-transplantation. Humanised mouse models have been developed by 
transplantation of HSCs into immunodeficient mice providing a tool to study human 
lymphocyte differentiation, reconstitution and also potential to investigate tumour 
growth and pathogenesis of infectious diseases (Legrand et al., 2009). Recently, the 
first humanised model of HCMV has been developed by transplantation of HSCs from 
CMV seropositive donors into NOD-scid-!c"/" mice, in which mice demonstrated 
evidence of HCMV in the liver, spleen and BM (Hakki et al., 2014). Such a model 
could be utilised by subsequent infusion of cytokine-induced memory-like NK cells to 
assess whether these cells confer IFN-!-mediated anti-viral protection. Currently, the 
infusion of cytokine-induced memory-like NK cells from a haploidentical donor is 
being tested in a phase I clinical trial to treat refractory AML by Romee and colleagues 
(clinicaltrial.gov, trial number; NCT01898793). It is possible that the cytokine-induced 
memory-like NK cells generated here from CB may offer a better option given that CB 
is a more readily available cell source.  
7.9 Cytokine dependence 
The expansion and cytotoxic function of ex vivo cytokine-activated NK cells following 
adoptive transfer needs to be supported by exogenous cytokine administration leading 
to the concept of cytokine addiction. Basically, NK cells exposed to high doses of 
cytokines ex vivo renders them susceptible to apoptosis when the cytokine doses are 
reduced in vivo. Berg and colleagues showed that IL-2 removal from the culture 
medium results in a sharp decline in the percentage of NK cells expressing NKG2D and 
TRAIL, while the expression of these markers was restored after subsequent addition of 
IL-2 to the culture in a dose-dependent manner (Berg et al., 2009). Miller and 
colleagues have reported similar findings, in which expansion of IL-2 or IL-15 
activated NK cells was reduced by 90 % 1 week after discontinuing cytokine 
administration. In this context, it was suggested by the same group that IL-15 might be 
better than IL-2 in promoting expansion of adoptively transferred NK cells (Miller, 
2013). In line with these findings, my results showed that in vitro proliferation of NK 
cells activated with IL-15 or its combination with IL-2 is superior to those expanded 
with IL-2 alone, especially for CB NK cells. Hence, similar mechanisms may take place 
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in vivo and survival of adoptively transferred NK cells could be supported with low 
doses of IL-15. IL-15 could be recycled by DCs and represented via IL-15R# to NK 
cells mediating their survival even after IL-15 withdrawal (Dubois et al., 2002). In 
addition, NK cells may utilise the expression of IL-15R# in immunotherapeutic settings 
without the involvement of DCs by enhancing IL-15 presentation in an autocrine 
manner. My results showed that resting CB NK cells express significantly higher IL-
15R# than PB NK cells. Thus, IL-15R# could be blocked using monoclonal antibodies 
to assess the role of this receptor in NK cell responsiveness to exogenous IL-15 by PB 
and CB NK cells in future comparative experiments, in particular NK cell expansion in 
response to IL-15 or IL-15 combinations.  
 
7.10 Therapeutic implications of CB NK cells 
NK cells are a promising therapeutic cellular source to treat cancers or to improve the 
outcomes after HSCT. Based on Ruggeri hypothesis, KIR ligand incompatibility 
between donor and recipient induces NK cell alloreactivity, whereby NK cells become 
more potent to attack leukemic cells (Ruggeri et al., 2005). Hence, allogeneic NK cells 
offer a promising source for cancer immunotherapy mediating GvL. CB is a potential 
source of NK cells as it has advantages over PB including immediate availability; more 
tolerance of HLA disparity, reduced intensity and severity of GvHD and possible GvL 
effect (Verneris et al., 2009). A study to evaluate the outcomes of KIR ligand 
incompatibility in CBT context showed that relapse rate was lower among KIR 
mismatched CB recipients (Miller et al., 2006). Béziat et al. have shown similar 
findings as relapse rates were lower after CBT and have shown that reconstituted CB 
NK cells have functional maturity, and importantly suggested that CB NK cells may 
mediate GvL post CBT (Béziat et al., 2009). However, the beneficial effect of KIR 
ligand incompatibility remains controversial although a Eurocord study showed 
favorable results in terms of leukaemia-free survival and relapse rates in CBT settings 
(Willemze et al., 2010). Given this, CB NK cells are possibly as potent as PB NK cells 
for allogeneic NK cell adoptive transfer. However, a challenge remains to consider, the 
expansion of CB NK cells with an activated phenotype for adoptive transfer to ensure 
efficacy of CB NK cells against cancerous cells.  
Several trials are underway to exploit the function of CB NK cells, primarily for 
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haematological malignancy treatment. CB NK cells are infused along with CBT to 
enhance GvL effect and reduce GvHD improving the outcomes of transplantation in 
leukaemia, lymphoma and multiple myeloma patients (clinicaltrial.gov, trial number; 
NCT01619761). In addition, CB NK cells can be expanded ex vivo with IL-2 and 
infused into multiple myeloma patients post chemotherapy and post-HSCT to kill 
residual myeloma cells (clinicaltrial.gov, trial number; NCT01729091). Another trial is 
aiming to treat refractory hematologic cancers by performing TBI followed by CBT and 
infusion of CB NK cells together with subcutaneous injections or systemic 
administration of IL-2 to support their expansion in vivo (clinicaltrial.gov, trial 
numbers; NCT00354172 and NCT00871689). Finally, a phase I clinical trial aims to 
activate mixed populations of CB NK cells and T cells with variety of cytokines to 
prevent tumour relapse after radical resection of the tumour in the context of 
hepatocellular carcinoma, renal cell carcinoma, lung cancer (clinicaltrial.gov, trial 
number; NCT01914263).  
Altogether, an NK cell therapy using CB as a cell source has potential in particular 
post-HSCT to prevent GvHD and improve GvL. Although the majority of trials and 
studies focuses on the use of CB NK cells to improve HSCT outcomes in 
haematological malignancies context, future studies may involve using of CB NK cells 
for the treatment of solid tumours. So far, anti-cancer effect of NK cells is mainly seen 
against AML blasts indicating the need to optimise NK cell-based therapy, via 
expansion or conditioning regimes to allow broader use of NK cells. Future implication 
of CB NK cells would certainly utilise cytokines to induce effector functions of CB NK 
cells as resting CB NK cells are poorly cytotoxic. 
7.11 Translation to the clinic 
In this study, I have shown that short periods of NK cell stimulation with cytokines 
promotes immediate cytotoxic functions by PB and CB NK cells and that the generation 
of memory-like NK cells provides a cellular source that can be maintained for 
prolonged periods in vitro. Theoretically, the application of either source would be 
dependent on the underlying condition as well as the accessibility of NK cell sources. 
NK cells upregulate L-selectin and CCR7 expression within short periods of stimulation 
with cytokines and might have the potency to home to LN. Indeed, it is known that 
prolonged stimulation of NK cells results in downregulation of L-selectin expression by 
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NK cells hence limiting their capability to home to LN (Romee et al., 2013). Also, it 
has been shown that CCR7 expression declines after 72 hours of uptake by trogocytosis 
(Somanchi et al., 2012), whereas the option of maintaining memory-like NK cells in 
prolonged cultures could be appealing for multiple infusions of NK cells into the same 
patient.  
 
As NK cells are the first lymphocyte population to reconstitute after HSCT it is 
believed that they play a key role in mediating GvL and reducing the incidence of 
GvHD. Many on-going trials are underway to treat AML and other haematological 
malignancies by promoting the GvL effect via NK cell infusion after HSCT 
(clinicaltrial.gov, trial numbers; NCT01220544, NCT00625729, NCT01853358). The 
aim of these trials is to potentiate donor NK cell-mediated killing of cancer cells by 
infusion of ex vivo expanded NK cells following HSCT. Such an approach delivers 
multiple functions of NK cells: (i) ex vivo cytokine-activated NK cells are more potent 
at targeting residual tumour cells after chemotherapy, (ii) infused NK cells reduce the 
incidence of GvHD by inhibition of donor alloreactive T cells (Olson et al., 2010), and 
(iii) reconstituted NK cells have the potency to become alloreactive according to the 
KIR-KIR ligand incompatibility hypothesis (Ruggeri et al., 2005). 
 
Although IL-2 has been used widely to activate NK cells in clinical trials, IL-15 has 
proven to be indispensible for NK cell functions in vivo. Currently, Miller and 
colleagues are assessing the systemic administration of IL-15 in conjunction with NK 
cell infusion from a haploidentical donor to treat refractory AML (clicaltrial.gov, 
NCT01385423). As I showed in this study, stimulation with IL-15+IL-2 or IL-15+IL-
18, promoted substantial cytotoxic functions of CB NK cells. Hence, my findings 
suggest that CB NK cells should be stimulated with IL-15+IL-2 or IL-15+IL-18 
combinations rather than IL-2 alone in order to be used as a cellular immunotherapeutic 
source to achieve optimal anti-tumour activity.  
 
In the present study, cells were stimulated and expanded in 96-well culture plates. Thus, 
protocols to optimise the product to GMP standards are still needed in order to make 
cytokine-activated NK cells suitable for clinical use. Recently, Koehl and colleagues 
described a protocol for clinical scale NK cell enrichment using GMP procedures 
(Koehl et al., 2013). This approach produces highly purified NK cell products whilst 
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maintaining cytotoxic function and importantly with minimal T cell contamination. 
This is performed using a fully closed system (bioreactors) and CliniMACS reagents 
designed to deplete CD3+ cells followed by enrichment of CD56+ cells. The purified 
NK cells can then be expanded using cytokines (Fig 7.1). Hence, this protocol seems to 
be applicable for CB units given that CB is readily available and is a rich source of NK 
cells that are responsive to cytokine stimulation. The cytotoxicity of isolated CB NK 
cells could be further enhanced using a combination of IL-15+IL-2 or IL-15+IL-18 
instead of using IL-2 alone. Thereafter, medium could be changed every three days and 
then the product infused into a recipient at different intervals or cryopreserved for 
future use. Expanded NK cells can be infused into HSCT recipients to kill residual 
tumour cells after transplantation or into solid tumours to promote an NK cell anti-
tumour effect. 
 
Figure 7.1 A model of adoptive transfer of ex vivo cytokine-activated NK cells 
into HSC recipients and solid tumour patients. NK cells can be enriched from a 
haploidentical donor or CB units and expanded with cytokines following GMP 
procedures. Expanded NK cells can be infused to treat different type of malignancies or 
stored for future use. Adapted from “Clinical grade purification and expansion of NK 
cell products for an optimized manufacturing protocol” by Koehl and colleagues (Koehl 
et al., 2013). 
 
In conclusion, differential activation of PB and CB NK cells using different cytokine 
combinations have been identified in the current study. PB NK cells showed optimum 
activation following stimulation with IL-2 whereas CB NK cells showed the least 
responsiveness to IL-2 stimulation among other cytokine conditionings. Less 
responsiveness of CB NK cells to IL-2 stimulation was associated with reduced 
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components. On the other hand, CB NK cells responded better to IL-15+IL-2 or IL-
15+IL-18 stimulation than IL-2 alone. The combination of IL-15+IL-2 promoted 
maximal cytotoxicity of CB NK cells whereas the combination of IL-15+IL-18 induced 
high levels of IFN-! and TNF-# secretion. Furthermore, the use of either combination 
enhanced PB and CB NK cells migration towards LN chemokines in vitro. In addition I 
was able to generate memory-like NK cells from PB and CB NK cells using cytokines 
with sustained IFN-! production for 21 days of culture, offering a future source of NK 
cells for immunotherapy. These findings provide the basis for the activation of NK cells 
derived from different sources using cytokines and could be considered in the future for 
NK cell-based immunotherapy. The data presented in this study stipulates the extension 
of this knowledge into animal models to gain a more complete understanding of 
cytokine-activated NK cell functionality in vivo. Overall, cytokine activation induces 
fully functional CB NK cells. Together with other advantages of CB including off-the-
shelf availability and less stringent HLA-matching, CB NK cells are potentially 
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